LEIDOS HOLDINGS, INC., 10-K filed on 2/14/2023
Annual Report
v3.22.4
Cover - USD ($)
12 Months Ended
Dec. 30, 2022
Feb. 07, 2023
Jul. 01, 2022
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 30, 2022    
Current Fiscal Year End Date --12-30    
Document Transition Report false    
Entity File Number 001-33072    
Entity Registrant Name Leidos Holdings, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 20-3562868    
Entity Address, Address Line One 1750 Presidents Street,    
Entity Address, City or Town Reston,    
Entity Address, State or Province VA    
Entity Address, Postal Zip Code 20190    
City Area Code 571    
Local Phone Number 526-6000    
Title of 12(b) Security Common stock, par value $.0001 per share    
Trading Symbol LDOS    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 13,863,703,025
Entity Common Stock, Shares Outstanding   136,937,673  
Documents Incorporated by Reference Portions of Leidos Holdings, Inc.'s definitive Proxy Statement for the 2022 Annual Meeting of Stockholders ("2023 Proxy Statement") are incorporated by reference in Part III of this Annual Report on Form 10-K.    
Amendment Flag false    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001336920    
v3.22.4
Audit Information
12 Months Ended
Dec. 30, 2022
Audit Information [Abstract]  
Auditor Name Deloitte & Touche LLP
Auditor Location McLean, Virginia
Auditor Firm ID 34
v3.22.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Assets:    
Cash and cash equivalents $ 516 $ 727
Receivables, net 2,350 2,189
Inventory, net 287 274
Other current assets 490 429
Total current assets 3,643 3,619
Property, plant and equipment, net 847 670
Intangible assets, net 952 1,177
Goodwill 6,696 6,744
Operating lease right-of-use assets, net 545 612
Other long-term assets 388 439
Total assets 13,071 13,261
Liabilities:    
Accounts payable and accrued liabilities 2,254 2,141
Accrued payroll and employee benefits 701 605
Short-term debt and current portion of long-term debt 992 483
Total current liabilities 3,947 3,229
Long-term debt, net of current portion 3,928 4,593
Operating lease liabilities 570 589
Deferred tax liabilities 40 239
Other long-term liabilities 233 267
Total liabilities 8,718 8,917
Commitments and contingencies (Note 21)
Stockholders’ equity:    
Preferred stock, $0.0001 par value, 10 million shares authorized and no shares issued and outstanding at December 30, 2022 and December 31, 2021 0 0
Common stock, $0.0001 par value, 500 million shares authorized, 137 million and 140 million shares issued and outstanding at December 30, 2022 and December 31, 2021, respectively 0 0
Additional paid-in capital 2,005 2,423
Retained earnings 2,367 1,880
Accumulated other comprehensive loss (73) (12)
Total Leidos stockholders’ equity 4,299 4,291
Non-controlling interest 54 53
Total stockholders' equity 4,353 4,344
Total liabilities and stockholders' equity $ 13,071 $ 13,261
v3.22.4
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 30, 2022
Dec. 31, 2021
Stockholders’ equity:    
Preferred stock, par value (usd per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (usd per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 137,000,000 140,000,000
Common stock, shares outstanding (in shares) 137,000,000 140,000,000
v3.22.4
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Income Statement [Abstract]      
Revenues $ 14,396 $ 13,737 $ 12,297
Cost of revenues 12,312 11,723 10,560
Selling, general and administrative expenses 950 860 770
Credit losses (recoveries), net 1 (9) (68)
Acquisition, integration and restructuring costs 17 27 39
Asset impairment charges 40 4 12
Equity earnings of non-consolidated subsidiaries (12) (20) (14)
Operating income 1,088 1,152 998
Non-operating expense:      
Interest expense, net (199) (184) (179)
Other expense, net (3) (1) (38)
Income before income taxes 886 967 781
Income tax expense (193) (208) (152)
Net income 693 759 629
Less: net income attributable to non-controlling interest 8 6 1
Net income attributable to Leidos common stockholders $ 685 $ 753 $ 628
Earnings per share:      
Basic (usd per share) $ 5.00 $ 5.34 $ 4.42
Diluted (usd per share) $ 4.96 $ 5.27 $ 4.36
v3.22.4
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Statement of Comprehensive Income [Abstract]      
Net income $ 693 $ 759 $ 629
Foreign currency translation adjustments (95) (8) 63
Unrecognized gain (loss) on derivative instruments 54 29 (37)
Pension adjustments (20) 13 (2)
Total other comprehensive (loss) income, net of taxes (61) 34 24
Comprehensive income 632 793 653
Less: comprehensive income attributable to non-controlling interest 8 6 1
Comprehensive income attributable to Leidos common stockholders $ 624 $ 787 $ 652
v3.22.4
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect, Period of Adoption, Adjusted Balance
Leidos stockholders' equity
Leidos stockholders' equity
Cumulative Effect, Period of Adoption, Adjustment
Leidos stockholders' equity
Cumulative Effect, Period of Adoption, Adjusted Balance
Shares of common stock
Shares of common stock
Cumulative Effect, Period of Adoption, Adjusted Balance
Additional paid-in capital
Additional paid-in capital
Cumulative Effect, Period of Adoption, Adjusted Balance
Retained earnings
Retained earnings
Cumulative Effect, Period of Adoption, Adjustment
Retained earnings
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated other comprehensive income (loss)
Accumulated other comprehensive income (loss)
Cumulative Effect, Period of Adoption, Adjusted Balance
Non-controlling interest
Non-controlling interest
Cumulative Effect, Period of Adoption, Adjusted Balance
Beginning balance (in shares) at Jan. 03, 2020             141,000,000 141,000,000                  
Beginning balance at Jan. 03, 2020 $ 3,417 $ (1) $ 3,416 $ 3,413 $ (1) $ 3,412     $ 2,587 $ 2,587 $ 896 $ (1) $ 895 $ (70) $ (70) $ 4 $ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net income 629     628             628         1  
Other comprehensive income (loss), net of taxes 24     24                   24      
Issuances of stock (in shares)             1,000,000                    
Issuances of stock 36     36         36                
Repurchases of stock and other (105)     (105)         (105)                
Dividends (195)     (195)             (195)            
Stock-based compensation 62     62         62                
Net capital contributions from non-controlling interest 4                             4  
Ending balance (in shares) at Jan. 01, 2021             142,000,000                    
Ending balance at Jan. 01, 2021 3,871     3,862         2,580   1,328     (46)   9  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net income 759     753             753         6  
Other comprehensive income (loss), net of taxes 34     34                   34      
Issuances of stock (in shares)             1,000,000                    
Issuances of stock 46     46         46                
Repurchases of stock and other (in shares)             (3,000,000)                    
Repurchases of stock and other (270)     (270)         (270)                
Dividends (201)     (201)             (201)            
Stock-based compensation 67     67         67                
Net capital contributions from non-controlling interest $ 38                             38  
Ending balance (in shares) at Dec. 31, 2021 140,000,000           140,000,000                    
Ending balance at Dec. 31, 2021 $ 4,344     4,291         2,423   1,880     (12)   53  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net income 693     685             685         8  
Other comprehensive income (loss), net of taxes (61)     (61)                   (61)      
Issuances of stock (in shares)             1,000,000                    
Issuances of stock 51     51         51                
Repurchases of stock and other (in shares)             (4,000,000)                    
Repurchases of stock and other (542)     (542)         (542)                
Dividends (198)     (198)             (198)            
Stock-based compensation 73     73         73                
Net capital distributions to non-controlling interest $ (7)                             (7)  
Ending balance (in shares) at Dec. 30, 2022 137,000,000           137,000,000                    
Ending balance at Dec. 30, 2022 $ 4,353     $ 4,299         $ 2,005   $ 2,367     $ (73)   $ 54  
v3.22.4
CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Statement of Stockholders' Equity [Abstract]      
Cash dividend per share (usd per share) $ 1.44 $ 1.40 $ 1.36
v3.22.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Cash flows from operations:      
Net income $ 693 $ 759 $ 629
Adjustments to reconcile net income to net cash provided by operations:      
Depreciation and amortization 333 325 282
Stock-based compensation 73 67 62
Loss on debt extinguishment 0 0 36
Asset impairment charges 40 4 12
Deferred income taxes (211) (26) (4)
Other 26 (7) 14
Change in assets and liabilities, net of effects of acquisitions and dispositions:      
Receivables (174) (5) (127)
Other current assets and other long-term assets 160 143 104
Accounts payable and accrued liabilities and other long-term liabilities (149) (212) 151
Accrued payroll and employee benefits 98 (32) 161
Income taxes receivable/payable 97 15 14
Net cash provided by operating activities 986 1,031 1,334
Cash flows from investing activities:      
Acquisitions of businesses, net of cash acquired (192) (622) (2,655)
Payments for property, equipment and software (129) (104) (183)
Proceeds from disposition of businesses 15 0 0
Net proceeds from sale of assets 6 0 12
Other (13) (4) 11
Net cash used in investing activities (313) (730) (2,815)
Cash flows from financing activities:      
Proceeds from debt issuance 380 380 7,225
Repayments of borrowings (545) (106) (5,456)
Payments for debt issuance and modification costs 0 0 (51)
Dividend payments (199) (199) (196)
Repurchases of stock and other (542) (270) (105)
Proceeds from issuances of stock 48 44 35
Net capital (distributions to) contributions from non-controlling interests (7) 38 4
Other 0 0 (5)
Net cash (used in) provided by financing activities (865) (113) 1,451
Net (decrease) increase in cash, cash equivalents and restricted cash (192) 188 (30)
Cash, cash equivalents and restricted cash at beginning of year 875 687 717
Cash, cash equivalents and restricted cash at end of year 683 875 687
Less: restricted cash at end of year 167 148 163
Cash and cash equivalents at end of year 516 727 524
Supplementary cash flow information:      
Cash paid for interest 195 182 161
Cash paid for income taxes, net of refunds 217 221 140
Non-cash investing activity:      
Property, plant and equipment additions 7 4 18
Finance lease obligations $ 1 $ 51 $ 12
v3.22.4
Nature of Operations and Basis of Presentation
12 Months Ended
Dec. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations and Basis of Presentation
Note 1—Nature of Operations and Basis of Presentation
Nature of Operations and Basis of Presentation
Leidos Holdings, Inc. ("Leidos"), a Delaware corporation, is a holding company whose direct 100%-owned subsidiary and principal operating company is Leidos, Inc. Leidos is a FORTUNE 500® technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil and health markets, both domestically and internationally. Leidos' customers include the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security, the Federal Aviation Administration, the Department of Veterans Affairs and many other U.S. civilian, state and local government agencies, foreign government agencies and commercial businesses. Unless indicated otherwise, references to "we," "us" and "our" refer collectively to Leidos Holdings, Inc. and its consolidated subsidiaries. We operate in three reportable segments: Defense Solutions, Civil and Health. Additionally, we separately present the unallocable costs associated with corporate functions as Corporate.
We have an 88% controlling interest in Mission Support Alliance, LLC ("MSA"), a joint venture with Centerra Group, LLC, which includes 41% purchased from Jacobs Group, LLC on January 26, 2018. MSA’s contract ended on January 24, 2021. We also have a 53% controlling interest in Hanford Mission Integration Solutions, LLC ("HMIS"), the legal entity for the follow-on contract to MSA's contract and a joint venture with Centerra Group, LLC and Parsons Government Services, Inc. We consolidate the financial results for MSA and HMIS into our consolidated financial statements.
The consolidated financial statements also include the balances of all voting interest entities in which Leidos has a controlling voting interest ("subsidiaries") and a variable interest entity ("VIE") in which Leidos is the primary beneficiary. The consolidated balances of the VIE are not material to the consolidated financial statements for the periods presented. Intercompany accounts and transactions between consolidated companies have been eliminated in consolidation.
Effective July 3, 2021, certain contracts were reassigned from the Defense Solutions reportable segment to the Civil reportable segment. Impact on prior year segment results were determined to be immaterial and have not been recast to reflect this change.
Certain amounts in the prior year financial statements have been reclassified to conform to the current year presentation. We combined "Capital distributions to non-controlling interests" and "Capital contributions from non-controlling interests" into "Net capital (distributions to) contributions from non-controlling interests", "Collections on promissory notes" and "Bad debt expense and recoveries" into "Other" on the consolidated statements of cash flows.
v3.22.4
Accounting Standards
12 Months Ended
Dec. 30, 2022
Accounting Changes and Error Corrections [Abstract]  
Accounting Standards
Note 2—Accounting Standards
Accounting Standards Updates Adopted
ASU 2021-08, Business Combinations (Topic 805)
In October 2021, the FASB issued ASU 2021-08, which amends how contract assets and liabilities acquired in a business combination are measured. Current guidance requires contract assets and liabilities to be measured at fair value in accordance with ASC 805, Business Combinations. The amendments in this Update remove the requirement to measure contract assets and liabilities at fair value and instead require that they be recognized in accordance with ASC 606, Revenue from Contracts with Customers.
We adopted the requirements of ASU 2021-08 using the prospective method effective the first day of fiscal 2022. For business combinations occurring after adoption, we measured contract assets and liabilities acquired in accordance ASC 606.
Accounting Standards Updates Issued But Not Yet Adopted
ASU 2020-04, ASU 2021-01, and ASU 2022-06 Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, which provides companies with optional expedients and exceptions to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. This update provides optional expedients for applying accounting guidance to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this update are effective for all entities as of March 2020 and can be adopted using a prospective approach no later than December 31, 2022.
In January 2021, the FASB issued ASU 2021-01 which amends the scope of ASU 2020-04. The amendments in this
update are elective and provide optional relief for entities with hedge accounting and contract modifications affected
by the discounting transition through December 31, 2022. In December 2022, the FASB issued ASU 2022-06 which extends the deadline for application of ASU 2021-01 through December 31, 2024. Under this relief, entities may continue to account for contract modifications as a continuation of the existing contract and the continuation of the hedge accounting arrangement. We are currently evaluating the impacts of the reference rate reform. Except for our new $380 million term loan entered into on May 6, 2022 (see "Note 13—Debt"), we currently use the one-month LIBOR for which the rate publication will cease in June 2023.
v3.22.4
Summary of Significant Accounting Policies
12 Months Ended
Dec. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 3—Summary of Significant Accounting Policies
Reporting Periods
Leidos' fiscal year ends on the Friday nearest the end of December. Fiscal 2022 ended December 30, 2022. Fiscal 2022, 2021 and 2020 each included 52 weeks.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, right-of-use ("ROU") assets and lease liabilities, fair value and impairment of intangible assets and goodwill, income taxes, pension benefits, stock-based compensation expense and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates.
Operating Cycle
Our operating cycle for long-term contracts may be greater than one year and is measured by the average time intervening between the inception and the completion of those contracts.
Business Combinations, Investments and Variable Interest Entities
Business Combinations
The accounting for business combinations requires management to make judgments and estimates related to the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities and contingencies assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with an acquisition. Estimating the fair value of acquired assets and assumed liabilities, including intangibles, requires judgments about expected future cash flows, weighted-average cost of capital, discount rates and expected long-term growth rates.
Investments
Investments in entities and corporate joint ventures where we have a non-controlling ownership interest but over which we have the ability to exercise significant influence, are accounted for under the equity method of accounting. We recognize our proportionate share of the entities' net income or loss and do not consolidate the entities' assets and liabilities.
Equity investments in entities over which we do not have the ability to exercise significant influence and whose securities do not have a readily determinable fair value are carried at cost or cost net of other-than-temporary impairments.
Variable Interest Entities
We occasionally form joint ventures and/or enter into arrangements with special purpose limited liability companies for the purpose of bidding and executing on specific projects. We analyze each such arrangement to determine whether it represents a VIE. If the arrangement is determined to be a VIE, we assess whether we are the primary beneficiary of the VIE and are consequently required to consolidate the VIE.
Divestitures
From time-to-time, we may dispose (or management may commit to plans to dispose) of strategic or non-strategic components of the business. Divestitures representing a strategic shift that has (or will have) a major effect in operations and financial results are classified as discontinued operations, whereas non-strategic divestitures remain in continuing operations.
Restructuring Expenses
Restructuring expenses are incurred in connection with programs aimed at reducing our costs. Restructuring costs may include one-time termination of benefits, costs to terminate contracts and other permanent exit costs to consolidate or close facilities directly related to the restructuring program.
One-time involuntary termination benefits are recognized as a liability at estimated fair value when the plan of termination has been communicated to employees and certain other criteria are met. Ongoing termination benefit arrangements are recognized as a liability at estimated fair value when it is probable that amounts will be paid and such amounts are reasonably estimable. Costs associated with exit or disposal activities, including the related one-time and ongoing involuntary termination benefits, are included as "Acquisition, integration and restructuring costs" on the consolidated statements of income.
Revenue Recognition
Our revenues from contracts with customers are from offerings including digital modernization, cyber operations, mission software systems, integrated systems and mission operations, primarily with the U.S. government and its agencies. We also serve various state and local governments, foreign governments and commercial customers.
We perform under various types of contracts, which include firm-fixed-price ("FFP"), time-and-materials ("T&M"), fixed-price-level-of-effort ("FP-LOE"), cost-plus-fixed-fee ("CPFF"), cost-plus-award-fee, cost-plus-incentive-fee and fixed-price-incentive-fee ("FP-IF") contracts.
To determine the proper revenue recognition, we first evaluate whether we have a duly approved and enforceable contract with a customer, in which the rights of the parties and payment terms are identified, and collectability is probable. We also evaluate whether two or more contracts should be combined and accounted for as a single contract, including the task orders issued under an indefinite delivery/indefinite quantity ("IDIQ") award. In addition, we assess contract modifications to determine whether changes to existing contracts should be accounted for as part of the original contract or as a separate contract. Contract modifications generally relate to changes in contract specifications and requirements and do not add distinct services, and therefore are accounted for as part of the original contract. If contract modifications add distinct goods or services and increase the contract value by an amount that reflects the standalone selling price, those modifications are accounted for as separate contracts.
Most of our contracts are comprised of multiple promises including the design and build of software-based systems, integration of hardware and software solutions, running and maintaining of IT infrastructure and procurement services. In all cases, we assess if the multiple promises should be accounted for as separate performance obligations or combined into a single performance obligation. We generally separate multiple promises in a contract as separate performance obligations if those promises are distinct, both individually and in the context of the contract. If multiple promises in a contract are highly interrelated or require significant integration or customization within a group, they are combined and accounted for as a single performance obligation.
Our contracts with the U.S. government often contain options to renew existing contracts for an additional period of time (generally a year at a time) under the same terms and conditions as the original contract, and generally do not provide the customer any material rights under the contract. We account for renewal options as separate contracts when they include distinct goods or services at standalone selling prices.
Contracts with the U.S. government are subject to the Federal Acquisition Regulation ("FAR") and priced on estimated or actual costs of providing the goods or services. The FAR provides guidance on types of costs that are allowable in establishing prices for goods and services provided to the U.S. government and its agencies. Each contract is competitively priced and bid separately. Pricing for non-U.S. government agencies and commercial customers is based on specific negotiations with each customer. In circumstances where the standalone selling price is not directly observable, we estimate the standalone selling price using the expected cost-plus margin approach. Any taxes collected or imposed when determining the transaction price are excluded.
Certain cost-plus and fixed-price contracts contain award fees, incentive fees or other provisions that may either increase or decrease the transaction price. These variable amounts generally are awarded upon achievement of certain performance metrics, program milestones or cost targets and can be based upon customer discretion. We estimate variable consideration at the most probable amount that we expect to be entitled to, based on the assessment of the contractual variable fee criteria, complexity of work and related risks, extent of customer discretion, amount of variable consideration received historically and the potential of significant reversal of revenue.
We allocate the transaction price of a contract to its performance obligations in the proportion of its respective standalone selling prices. The standalone selling price of the performance obligations is generally based on an expected cost-plus margin approach, in accordance with the FAR. For certain product sales, prices from other standalone sales are used. Substantially all of our contracts do not contain a significant financing component, which would require an adjustment to the transaction price of the contract.
We recognize revenue on our service-based contracts primarily over time as there is continuous transfer of control to the customer over the duration of the contract as the promised services are performed. For U.S. government contracts, continuous transfer of control to the customer is evidenced by clauses in the contract that allow the customer to unilaterally terminate the contract for convenience, pay for costs incurred plus a reasonable profit and take control of any work-in-process. Similarly, for non-U.S. government contracts, the customer typically controls the work-in-process as evidenced by rights to payment for work performed to date plus a reasonable profit to deliver products or services for which we do not have an alternate use. Anticipated losses on service-based contracts are recognized when incurred (generally on a straight-line basis) over the contract term. In certain product sales, where the products have an alternate use, revenue is recognized at a point in time when the customer takes control of the asset usually denoted by possession, transfer of legal title and acceptance by the customer.
On FFP contracts requiring system integration and cost-plus contracts with variable consideration, revenue is recognized over time generally using a method that measures the extent of progress towards completion of a performance obligation, principally using a cost-input method (referred to as the cost-to-cost method). Under the cost-to-cost method, revenue is recognized based on the proportion of total costs incurred to estimated total costs-at-completion ("EAC"). A performance obligation's EAC includes all direct costs such as materials, labor, subcontract costs, overhead and a ratable portion of general and administrative costs. In addition, an EAC of a performance obligation includes future losses estimated to be incurred on onerous contracts, as and when known. On certain other contracts, principally T&M, FP-LOE and CPFF, revenue is generally recognized using the right-to-invoice practical expedient as we are contractually able to invoice the customer based on the control transferred to the customer. Additionally, on maintenance (generally FFP) performance obligations, revenue is recognized over time using a straight-line method as the control of the services is provided to the customer evenly over the period of performance.
For certain performance obligations where we are not primarily responsible for fulfilling the promise to provide the goods or service to the customer, do not have inventory risk and do not have discretion in establishing the price for the goods or service, we recognize revenue on a net basis.
Contract Costs
Contract costs generally include direct costs such as labor, materials, subcontract costs and indirect costs identifiable with or allocable to a specific contract. Costs are expensed as incurred unless they qualify for deferral and capitalization. Contract costs incurred for U.S. government contracts, including indirect costs, are subject to audit and adjustment by the Defense Contract Audit Agency ("DCAA") (see "Note 21—Commitments and Contingencies").
Pre-contract Costs
Costs incurred on projects as pre-contract costs are deferred as assets when we have been requested by the customer to begin work under a new arrangement prior to contract execution and it is probable that we will recover the costs through the issuance of a contract. Pre-contract costs are amortized over the contract period of performance or a specified period of performance.
Transition Costs
Under certain service contracts, costs are incurred, usually at the beginning of the contract performance, to transition the services, employees and equipment to or from the customer, a prior contract or prior contractor. These costs are generally capitalized as deferred assets and amortized on a straight-line basis over the anticipated term of the contract or a specified period of performance, including unexercised option periods that are reasonably certain of being exercised.
Project Assets
Purchases of project assets are capitalized for specific contracts where we maintain ownership of the asset over the life of the contract and the benefit is received over a period of time. Project assets include enterprise software licenses, dedicated hardware, maintenance agreements and significant material purchases and other costs incurred on contracts. Project assets are amortized from the balance sheet using the straight-line method over the estimated useful life of the asset or over the expected term of the period of performance, whichever is shorter.
Changes in Estimates on Contracts
Changes in estimates related to contracts accounted for using the cost-to-cost method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes, with the exception of contracts acquired through a business combination, where the adjustment is made for the period commencing from the date of acquisition.
Changes in estimates on contracts for the periods presented were as follows:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions, except for per share amounts)
Favorable impact
$146 $149 $137 
Unfavorable impact
(113)(102)(61)
Net favorable impact to income before income taxes
$33 $47 $76 
Impact on diluted EPS attributable to Leidos common stockholders
$0.17 $0.25 $0.39 
The impact on diluted earnings per share ("EPS") attributable to Leidos common stockholders is calculated using our statutory tax rate.
Revenue Recognized from Prior Obligations
During fiscal 2022, 2021 and 2020, revenue recognized from performance obligations satisfied in previous periods was $9 million, $26 million and $40 million, respectively. The changes primarily relate to revisions of variable consideration, including award and incentive fees, and revisions to estimates at completion resulting from changes in contract scope, mitigation of contract risks or due to true-ups of contract estimates at the end of contract performance.
Selling, General and Administrative Expenses
We classify indirect costs incurred within or allocated to our U.S. government customers as overhead (included in "Cost of revenues") or general and administrative expenses in the same manner as such costs are defined in our disclosure statements under U.S. government Cost Accounting Standards.
Selling, general and administrative expenses include general and administrative, bid and proposal, company-funded research and development expenses, and legal fees and settlements.
We conduct research and development activities under customer-funded contracts and with company-funded research and development funds. Company-funded research and development expense was $116 million, $109 million and $73 million for fiscal 2022, 2021 and 2020, respectively. Expenses for research and development activities performed under customer contracts are charged directly to cost of revenues for those contracts.
Income Taxes
We account for income taxes under the asset and liability method in accordance with the accounting standard for income taxes. The asset and liability method requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities. Under this method, changes in tax rates and laws are recognized in income in the period such changes are enacted.
We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations. If we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount or would no longer be able to realize our deferred income tax assets in the future as currently recorded, we would make an adjustment to the valuation allowance which would decrease or increase the provision for income taxes.
The provision for federal, state, foreign and local income taxes is calculated on income before income taxes based on current tax law and includes the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Such provision differs from the amounts currently payable because certain items of income and expense are recognized in different reporting periods for financial reporting purposes than for income tax purposes.
We record liabilities for uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. We recognize interest and penalties related to uncertain tax positions in our income tax expense.
Cash and Cash Equivalents
Our cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less. Outstanding payments are included within "Cash and cash equivalents" and "Accounts payable and accrued liabilities" correspondingly on the consolidated balance sheets. At December 30, 2022, and December 31, 2021, $158 million and $138 million, respectively, of outstanding payments were included within "Cash and cash equivalents."
Restricted Cash
We have restricted cash balances, primarily representing advances from customers that are restricted as to use for certain expenditures related to that customer's contract. Restricted cash balances are included as "Other current assets" on the consolidated balance sheets. Our restricted cash balances were $167 million and $148 million at December 30, 2022, and December 31, 2021, respectively.
Receivables
Receivables include amounts billed and currently due from customers, amounts billable where the right to consideration is unconditional and amounts unbilled. Amounts billable and unbilled amounts are recognized at estimated realizable value and consist of costs and fees, substantially all of which are expected to be billed and collected generally within one year. Unbilled amounts also include rate variances that are billable upon negotiation of final indirect rates with the Defense Contract Management Agency.
Cost-reimbursable and T&M contracts are generally billed as costs are incurred. FFP contracts are billed either based on milestones, which are the achievement of specific events as defined in the contract, or based on progress payments, which are interim payments up to a designated amount of costs incurred as work progresses. On certain contracts, the customer withholds a certain percentage of the contract price (retainage). These withheld amounts are included within unbilled receivables and are billed upon contract completion or the occurrence of a specified event, and when negotiation of final indirect rates with the U.S. government is complete. Based on our historical experience, the write-offs of retention balances have not been significant.
When events or conditions indicate that amounts outstanding from customers may become uncollectible, an allowance is estimated and recorded.
Amounts billed and collected on contracts but not yet recorded as revenue because we have not performed our obligation under the arrangement with a customer are deferred and included within "Accounts payable and accrued liabilities" or "Other long-term liabilities" on the consolidated balance sheets.
Concentration of Credit Risk
Financial instruments that potentially subject us to concentrations of credit risk primarily consist of accounts receivable and derivatives. Since our receivables are primarily with the U.S. government, we do not have exposure to a material credit risk. We manage our credit risk related to derivatives through the use of multiple counterparties with high credit standards.
Inventories
Inventories are valued at the lower of cost or estimated net realizable value. Generally, raw material inventory is valued using the average cost method. Work-in-process inventory may include material costs, labor and allocable overhead costs. The majority of finished goods inventory consists of technology and security products, inspection systems, baggage scanning equipment and small glide munitions. Inventory is evaluated against historical or planned usage to determine appropriate provisions for obsolete inventory.
Goodwill
Goodwill represents the excess of the fair value of consideration transferred, plus the fair value of any non-controlling interests in the acquiree, over the fair value of the net assets acquired and liabilities assumed as of the acquisition date. Goodwill is not amortized, but instead is tested annually for impairment at the reporting unit level and tested more frequently if events or circumstances indicate that the carrying value of the reporting unit may not be recoverable. Our policy is to perform our annual goodwill impairment evaluation as of the first day of the fourth quarter of our fiscal year. During both fiscal 2022 and 2021, we had seven reporting units for the purpose of testing goodwill for impairment.
Goodwill is evaluated for impairment either under a qualitative assessment option or a quantitative approach, which depends on the facts and circumstances of a reporting unit, consideration of the excess of a reporting unit's fair value over its carrying amount in previous assessments and changes in business environment.
When performing a qualitative assessment, we consider factors including, but not limited to, current macroeconomic conditions, industry and market conditions, cost factors, financial performance and other events relevant to the entity or reporting unit under evaluation to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If we determine that it is more likely than not that a reporting unit's fair value is less than its carrying value, a quantitative goodwill impairment test is performed.
When performing a quantitative goodwill impairment test, the reporting unit carrying value is compared to its fair value. Goodwill is deemed impaired if, and the impairment loss is recognized for the amount by which, the reporting unit carrying value exceeds its fair value.
We estimate the fair value of each reporting unit using Level 3 inputs when a quantitative analysis is performed. These analyses rely on significant judgements and assumptions about expected future cash flows, weighted-average cost of capital, discount rates, expected long-term growth rates, operating margins and on the selection of guideline public companies.
Intangible Assets
Acquired intangible assets with finite lives and internally developed software are amortized using the method that best reflects how their economic benefits are utilized or, if a pattern of economic benefits cannot be reliably determined, on a straight-line basis over their estimated useful lives. Program intangible assets are amortized over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows. Backlog and trade name intangible assets are amortized on a straight-line basis over their estimated useful lives. Customer relationships and software and technology intangible assets are amortized either on a straight-line basis over their estimated useful lives or over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows, as deemed appropriate.
Intangible assets with finite lives are amortized over the following periods:
 Estimated useful lives (in years)
Backlog
1
Customer relationships
8-10
Programs
4-13
Software and technology
3-15
Trade names3
Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
Intangible assets with indefinite lives are not amortized but are assessed for impairment at the beginning of the fourth quarter and whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
Property, Plant and Equipment
Purchases of property, plant and equipment, including purchases of software and software licenses, as well as costs associated with major renewals and improvements are capitalized. Maintenance, repairs and minor renewals and improvements are expensed as incurred.
Construction in Progress ("CIP") is used to accumulate all costs for projects that are not yet complete. CIP balances are transferred to the appropriate asset account when the asset is capitalized and ready for its intended use.
When assets are sold or otherwise disposed of, the cost and related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is recognized. Depreciation is recognized using the methods and estimated useful lives as follows:
 Depreciation methodEstimated useful lives (in years)
Computers and other equipmentStraight-line or declining-balance
2-15
Buildings Straight-line
Not to exceed 40
Building improvements and leasehold improvements
Straight-lineShorter of useful life of asset or remaining lease term
Vehicles and transportation equipmentStraight-line
2-15
Office furniture and fixturesStraight-line or declining-balance
6-9
We evaluate our long-lived assets for potential impairment whenever there is evidence that events or changes in circumstances indicate that the carrying value may not be recoverable and the carrying value of the asset exceeds its estimated fair value.
Leases
Lessee
We have facilities and equipment lease arrangements. An arrangement is determined to be a lease at inception if it conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.
ROU assets and lease liabilities are recorded on the consolidated balance sheet at lease commencement date based on the present value of the future minimum lease payments over the lease term. We generally do not know the discount rate implicit in our leases; therefore, the discount rate used is our incremental borrowing rate which is determined based on the rate of interest that we would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term. An ROU asset is initially measured by the present value of the remaining lease payments, plus initial direct costs and prepaid lease payments, less any lease incentives received before commencement. The remaining lease cost is allocated over the remaining lease term on a straight-line basis unless another systematic or rational basis is more representative of the pattern in which the underlying asset is expected to be used.
Certain facility leases contain options to renew or extend the terms of the lease which are included in the determination of the ROU assets and lease liabilities when it is reasonably certain that we will exercise the option. Leases may also include variable lease payments such as an escalation clause based on consumer price index rates, maintenance costs and utilities. Variable lease payments that depend on an index or a rate are included in the determination of ROU assets and lease liabilities using the index or rate at the lease commencement date, whereas variable lease payments that do not depend on an index or rate are recorded as lease expense in the period incurred. At December 30, 2022, certain of the Company's equipment leases include residual value guarantees.
We use the practical expedient to not separate non-lease components from lease components and instead account for both components as a single lease. The practical expedient is applied to all material classes of leased assets except for aircraft, for which we account for the lease component and non-lease component separately.
The related lease payments on short-term facilities and equipment leases are recognized as expense on a straight-line basis over the lease term.
ROU assets are evaluated for impairment in a manner consistent with the treatment of other long-lived assets. ROU assets are assessed for potential impairment whenever there is evidence that events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and the carrying amount of the asset exceeds its estimated fair value. This includes an establishment of a plan of abandonment, which occurs when we have committed to a plan to abandon the lease before the end of its previously estimated useful life and there is no expectation that we will re-enter or re-purpose the space.
Lessor
We are a lessor on certain equipment sales-type and operating lease arrangements with our customers. To be considered lease revenue, the contract must contain a specified asset, we must not have a substantive substitution right, the customer must have the right to direct the use of the specified asset during the period of use and the customer must have the right to obtain substantially all of the economic benefit of the specified asset.
Certain arrangements may contain variable payments that depend on an index or rate and are measured using the index or rate on the commencement date. Variable payments that are not included in the net investments are recorded as revenue as incurred. Arrangements may also contain options to renew or extend the performance period. Option periods are included in the lease term if we determine that it is reasonably certain the customer will exercise an option.
We have arrangements that contain both lease and non-lease components. We account for them as one unit of account if the timing and pattern of transfer is identical for both the lease and the non-lease components and the lease component would be classified as an operating lease if accounted for separately. If both criteria are met and the predominant component is a lease, then the entire arrangement will be accounted for in accordance with ASC 842. If we account for an arrangement both as a lease and non-lease component, then the allocation of consideration for each component will be based on the relative standalone sales price.
Fair Value Measurements
The accounting standard for fair value measurements establishes a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: observable inputs such as quoted prices in active markets (Level 1); inputs other than quoted prices in active markets for identical assets or liabilities that are observable either directly or indirectly or quoted prices that are not active (Level 2); and unobservable inputs in which there is little or no market data (e.g., discounted cash flow and other similar pricing models), which requires us to develop our own assumptions about the assumptions that market participants would use in pricing the asset or liability (Level 3).
The accounting guidance for fair value measurements requires that we maximize the use of observable inputs and minimize the use of unobservable inputs in determining fair value. The accounting guidance provides for the irrevocable option to elect, on a contract-by-contract basis, to measure certain financial assets and liabilities at fair value at inception of the contract and record any subsequent changes in fair value in earnings. We have not made fair value option elections on any of our financial assets and liabilities.
The fair value of financial instruments is determined based on quoted market prices, if available, or management's best estimate (see "Financial Instruments" below).
Management evaluates its investments for other-than-temporary impairment at each balance sheet date. When testing long-term investments for recovery of carrying value, the fair value of long-term investments is determined using various valuation techniques and factors, such as market prices of comparable companies (Level 2 input), discounted cash flow models (Level 3 input). If management determines that an other-than-temporary decline in the fair value of an investment has occurred, an impairment loss is recognized to reduce the investment to its estimated fair value.
Our non-financial instruments measured at fair value on a non-recurring basis include goodwill, indefinite-lived intangible assets and long-lived tangible assets. The valuation methods used to determine fair value require a significant degree of management judgment to determine the key assumptions. As such, we generally classify non-financial instruments as either Level 2 or Level 3 fair value measurements.
Financial Instruments
We are exposed to certain market risks which are inherent in certain transactions entered into during the normal course of business. These transactions include sales or purchase contracts denominated in foreign currencies and exposure to changing interest rates. We manage our risk to changes in interest rates and foreign currency exchange rates through the use of derivative instruments.
For fixed rate borrowings, we use variable interest rate swaps, effectively converting fixed rate borrowings to variable rate borrowings. These swaps are designated as fair value hedges. The fair value of these interest rate swaps is determined based on observed values for underlying interest rates on the LIBOR yield curve (Level 2).
For variable rate borrowings, we use fixed interest rate swaps, effectively converting a portion of the variable interest rate payments to fixed interest rate payments. These swaps are designated as cash flow hedges. The fair value of these interest rate swaps is determined based on observed values for the underlying interest rates (Level 2).
We enter into foreign currency forward contracts in order to mitigate fluctuations in our earnings and cash flows due to changes in foreign currency exchange rates. The foreign currency forward contracts are not designated as hedges and hedge accounting does not apply. We do not hold derivative instruments for trading or speculative purposes.
Our defined benefit plan assets consist of investments in pooled funds that contain investments with values based on quoted market prices, but for which the pools are not valued on a daily quoted market basis (Level 2).
Stock-Based Compensation
We account for stock-based compensation at the grant date based on the fair value of the award and recognize expense over the requisite service period, which is generally the vesting period, net of an estimated forfeiture rate.
The fair value of restricted stock awards and performance-based stock awards is based on the closing price of Leidos common stock on the date of grant. The fair value of performance-based stock awards with market conditions is based on using a Monte Carlo simulation.
The fair value of stock option awards granted is based on using the Black-Scholes-Merton option pricing model. The estimation of stock option fair value requires management to make estimates and judgments about, among other things, employee exercise behavior, forfeiture rates and the expected volatility of Leidos common stock over the expected option term. These judgments directly affect the amount of compensation expense that will ultimately be recognized.
Foreign Currency
The financial statements of consolidated international subsidiaries, for which the functional currency is not the U.S. dollar, are translated into U.S. dollars using the exchange rate at each balance sheet date for assets and liabilities and a weighted average exchange rate over the reporting period for revenues, expenses, gains and losses. Translation adjustments are recorded as accumulated other comprehensive loss in stockholders' equity. Gains and losses due to movements in foreign currency exchange rates are recognized as "Other expense, net" on the consolidated statements of income.
v3.22.4
Revenues
12 Months Ended
Dec. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenues
Note 4—Revenues
Remaining Performance Obligations
Remaining performance obligations ("RPO") represent the expected value of exercised contracts, both funded and unfunded, less revenue recognized to date. RPO does not include unexercised option periods and future potential task orders expected to be awarded under IDIQ contracts, General Services Administration Schedule or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.
As of December 30, 2022, we had $15.4 billion of RPO and expect to recognize approximately 57% and 74% over the next 12 months and 24 months, respectively, with the remaining to be recognized thereafter.
Disaggregation of Revenues
We disaggregate revenues by customer-type, contract-type and geographic location for each of our reportable segments. These categories represent how the nature, timing and uncertainty of revenues and cash flows are affected.
Disaggregated revenues by customer-type were as follows:
Year Ended December 30, 2022
Defense SolutionsCivilHealthTotal
(in millions)
DoD and U.S. Intelligence Community
$6,027 $84 $999 $7,110 
Other U.S. government agencies(1)
1,004 2,660 1,576 5,240 
Commercial and non-U.S. customers1,211 618 108 1,937 
Total$8,242 $3,362 $2,683 $14,287 
Year Ended December 31, 2021
Defense SolutionsCivilHealthTotal
(in millions)
DoD and U.S. Intelligence Community
$5,939 $54 $756 $6,749 
Other U.S. government agencies(1)
964 2,447 1,681 5,092 
Commercial and non-U.S. customers1,126 543 107 1,776 
Total$8,029 $3,044 $2,544 $13,617 
Year Ended January 1, 2021
Defense SolutionsCivilHealthTotal
(in millions)
DoD and U.S. Intelligence Community$5,407 $59 $519 $5,985 
Other U.S. government agencies(1)
995 2,418 1,329 4,742 
Commercial and non-U.S. customers937 426 107 1,470 
Total$7,339 $2,903 $1,955 $12,197 
(1) Includes federal government agencies other than the DoD and U.S. Intelligence Community, as well as state and local government agencies.
The majority of our revenues are generated from U.S. government contracts, either as a prime contractor or as a subcontractor to other contractors. Revenues from the U.S. government can be adversely impacted by spending caps or changes in budgetary priorities of the U.S. government, as well as delays in program start dates or the award of a contract.
Disaggregated revenues by contract-type were as follows:
Year Ended December 30, 2022
Defense SolutionsCivilHealthTotal
(in millions)
Cost-reimbursement and fixed-price-incentive-fee
$4,620 $1,781 $712 $7,113 
Firm-fixed-price
2,642 1,077 1,683 5,402 
Time-and-materials and fixed-price-level-of-effort
980 504 288 1,772 
Total$8,242 $3,362 $2,683 $14,287 
Year Ended December 31, 2021
Defense SolutionsCivilHealthTotal
(in millions)
Cost-reimbursement and fixed-price-incentive-fee
$4,792 $1,576 $508 $6,876 
Firm-fixed-price
2,290 1,020 1,661 4,971 
Time-and-materials and fixed-price-level-of-effort
947 448 375 1,770 
Total$8,029 $3,044 $2,544 $13,617 
Year Ended January 1, 2021
Defense SolutionsCivilHealthTotal
(in millions)
Cost-reimbursement and fixed-price-incentive-fee
$4,504 $1,411 $280 $6,195 
Firm-fixed-price
2,067 1,061 1,303 4,431 
Time-and-materials and fixed-price-level-of-effort
768 431 372 1,571 
Total$7,339 $2,903 $1,955 $12,197 
Cost-reimbursement and FP-IF contracts are generally lower risk and have lower profits. T&M and FP-LOE contracts are also lower risk, but profits may vary depending on actual labor costs compared to negotiated contract billing rates. FFP contracts offer the potential for higher profits while increasing the exposure to risk of cost overruns.
Disaggregated revenues by geographic location were as follows:
Year Ended December 30, 2022
Defense SolutionsCivilHealthTotal
(in millions)
United States
$7,212 $3,203 $2,683 $13,098 
International
1,030 159  1,189 
Total$8,242 $3,362 $2,683 $14,287 
Year Ended December 31, 2021
Defense SolutionsCivilHealthTotal
(in millions)
United States
$7,045 $2,880 $2,544 $12,469 
International
984 164 — 1,148 
Total$8,029 $3,044 $2,544 $13,617 
Year Ended January 1, 2021
Defense SolutionsCivilHealthTotal
(in millions)
United States
$6,501 $2,738 $1,955 $11,194 
International
838 165 — 1,003 
Total$7,339 $2,903 $1,955 $12,197 
Our international business operations, primarily located in Australia and the U.K., are subject to additional and different risks than our U.S. business. Failure to comply with U.S. government laws and regulations applicable to international business, such as the Foreign Corrupt Practices Act or U.S. export control regulations, could have an adverse impact on our business with the U.S. government.
In some countries, there is an increased chance for economic, legal or political changes that may adversely affect the performance of our services, sales of products or repatriation of profits. International transactions can also involve increased financial and legal risks arising from foreign exchange variability, imposition of tariffs or additional taxes and restrictive trade policies and delays or failure to collect amounts due to differing legal systems.
Revenues by contract-type, customer-type and geographic location exclude lease income of $109 million, $120 million and $100 million for fiscal 2022, 2021 and 2020, respectively (see "Note 10—Leases").
Contract Assets and Liabilities
Performance obligations are satisfied either over time as work progresses or at a point in time. Firm-fixed-price contracts are typically billed to the customer using milestone payments while cost-reimbursable and time and materials contracts are typically billed to the customer on a monthly or bi-weekly basis as indicated by the negotiated billing terms and conditions of the contract. As a result, the timing of revenue recognition, customer billings and cash collections for each contract results in a net contract asset or liability at the end of each reporting period.
Contract assets consist of unbilled receivables, which is the amount of revenue recognized that exceeds the amount billed to the customer, where right to payment is not solely subject to the passage of time. Unbilled receivables exclude amounts billable where the right to consideration is unconditional. Contract liabilities consist of deferred revenue, which represents cash advances received prior to performance for programs and billings in excess of revenue recognized.
The components of contract assets and contract liabilities consisted of the following:
Balance sheet line itemDecember 30,
2022
December 31,
2021
(in millions)
Contract assets - current:
Unbilled receivablesReceivables, net$1,010 $1,022 
Contract liabilities - current:
Deferred revenue(1)
Accounts payable and accrued liabilities
$380 $364 
Contract liabilities - non-current:
Deferred revenue(1)
Other long-term liabilities$29 $24 
(1) Certain contracts record revenue on a net contract basis, and therefore, the respective deferred revenue balance will not fully convert to revenue.
Revenue recognized during fiscal 2022 and 2021 of $270 million and $340 million, respectively, was included as a contract liability at December 31, 2021, and January 1, 2021, respectively.
There were no impairment losses recognized on contract assets during fiscal 2022, 2021 and 2020.
v3.22.4
Acquisitions and Divestitures
12 Months Ended
Dec. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisitions and Divestitures
Note 5—Acquisitions and Divestitures
Acquisitions
We may acquire businesses as part of our growth strategy to provide new or enhance existing capabilities and offerings to customers. During fiscal 2022, we completed the acquisition of Cobham Aviation Services Australia’s Special Mission business ("Cobham Special Mission"). During fiscal 2021, we completed the acquisitions of Gibbs & Cox, 1901 Group, LLC ("1901 Group"), and an immaterial strategic acquisition. During fiscal 2020, we completed the acquisitions of L3Harris Technologies' security detection and automation businesses (the "SD&A Businesses") and Dynetics, Inc. ("Dynetics").
Cobham Special Mission Acquisition
On October 30, 2022 (the "Agreement Date"), we completed the acquisition of Cobham Special Mission for a preliminary purchase consideration of $295 million Australian dollars, net of $10 million of Australian dollars acquired, approximately $190 million United States dollars, net of $6 million of cash acquired, which is subject to working capital adjustments. Cobham Special Mission provides airborne border surveillance and search and rescue services to the Australian Federal Government.
The preliminary goodwill recognized of $26 million represents intellectual capital and the acquired assembled workforce, neither of which qualify for recognition as a separate intangible asset. None of the goodwill recognized is tax deductible.
In connection with this acquisition, we acquired preliminary fair value of property, plant and equipment of $147 million at the Agreement Date. The following table summarizes the preliminary fair value of intangible assets acquired at the Agreement Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Programs7$21 
Technology94
Total7$25 
As of December 30, 2022, we had not finalized the determination of fair values allocated to assets and liabilities, including, but not limited to, property, plant and equipment, intangible assets, accounts receivables, accounts payable and accrued liabilities and other long-term liabilities.
For fiscal 2022, $21 million of revenues related to the Cobham Special Mission acquisition were recognized within the Defense Solutions reportable segment.
Gibbs & Cox Acquisition
On May 7, 2021 (the "Purchase Date"), we completed the acquisition of Gibbs & Cox for purchase consideration of approximately $375 million, net of $1 million of cash acquired. Gibbs & Cox is an independent engineering and design firm specializing in naval architecture, marine engineering, management support and engineering consulting.
The final goodwill recognized of $276 million represents intellectual capital and the acquired assembled workforce, neither of which qualify for recognition as a separate intangible asset. All of the goodwill recognized is tax deductible.
The following table summarizes the fair value of intangible assets acquired at the Purchase Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Programs12$89 
For fiscal 2022 and fiscal 2021, $114 million and $98 million, respectively, of revenues related to the Gibbs & Cox acquisition were recognized within the Defense Solutions reportable segment.
1901 Group Acquisition
On January 14, 2021 (the "Closing Date"), we completed the acquisition of 1901 Group for purchase consideration of $212 million, net of $2 million of cash acquired.
As of December 31, 2021, we had completed the determination of fair values of the acquired assets and liabilities assumed. The final goodwill recognized of $123 million represents intellectual capital and the acquired assembled workforce, none of which qualify for recognition as separate intangible assets. Of the goodwill recognized, $118 million is tax deductible.
The following table summarizes the fair value of intangible assets acquired at the Closing Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Technology8$43 
Programs1037 
Backlog1
Total8$86 
For fiscal 2022 and fiscal 2021, $40 million and $47 million, respectively, of revenues related to the 1901 Group acquisition were recognized within the Defense Solutions reportable segment.
Strategic Business Acquisition
On September 21, 2021, we completed an immaterial strategic business acquisition for purchase consideration of approximately $36 million. In connection with the transaction, the Company recognized an $8 million program intangible asset and goodwill of $25 million.
SD&A Businesses Acquisition
On May 4, 2020 (the "Transaction Date"), we completed the acquisition of the SD&A Businesses. The SD&A Businesses were acquired for cash consideration of $1,019 million, net of $27 million of cash acquired. The purchase consideration includes the initial cash payment of $1,015 million plus a $31 million payment for contractual net working capital acquired. The SD&A Businesses provide airport and critical infrastructure screening products, automated tray return systems and other industrial automation products. The addition of the SD&A Businesses will expand the scope and scale of our global security detection and automation offerings.
The final fair values of the assets acquired and liabilities assumed at the Transaction Date were as follows (in millions):
Current assets$287 
Intangible assets355 
Other assets67 
Current liabilities(140)
Long-term liabilities(97)
Total identifiable net assets acquired472 
Goodwill574 
Purchase price$1,046 
As of May 4, 2021, we had completed the determination of fair values of the acquired assets and liabilities assumed. The goodwill represents intellectual capital and the acquired assembled workforce. Of the goodwill recognized, $432 million is deductible for tax purposes.
The following table summarizes the final fair value of intangible assets acquired at the Transaction Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Programs13$141 
Customer relationships1049 
Technology 1073 
In-process research and development ("IPR&D")(1)
— 92 
Total11$355 
(1) IPR&D assets are indefinite-lived at the acquisition date until placed into service, at which time such assets will be reclassified to a finite-lived amortizable intangible asset.
For fiscal 2022, fiscal 2021 and fiscal 2020, $330 million, $291 million and $243 million, respectively, of revenues related to the SD&A Businesses were recognized within the Civil reportable segment.
Dynetics Acquisition
On January 31, 2020 (the "Acquisition Date"), we completed our acquisition of Dynetics, an industry-leading applied research and national security solutions company. The addition of Dynetics will accelerate opportunities within our innovation engine that researches and develops new technologies and solutions to address the most challenging needs of our customers. All of the issued and outstanding shares of common stock of Dynetics were purchased for $1.64 billion, net of cash acquired.
The final fair values of the assets acquired and liabilities assumed at the Acquisition Date were as follows (in millions):
Current assets$241 
Intangible assets528 
Other assets205 
Current liabilities(79)
Long-term liabilities(24)
Total identifiable net assets acquired871 
Goodwill789 
Purchase price$1,660 
As of January 31, 2021, we had completed the determination of fair values of the acquired assets and liabilities assumed. The goodwill represents intellectual capital and the acquired assembled workforce. All of the goodwill recognized is deductible for tax purposes.
The following table summarizes the final fair value of intangible assets acquired at the Acquisition Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Programs13$485 
Backlog 132 
Technology 1111 
Total12$528 
For fiscal 2022, fiscal 2021 and fiscal 2020, $950 million, $1,065 million and $937 million, respectively, of revenues related to Dynetics were recognized within the Defense Solutions reportable segment.
Acquisition and Integration Costs
The following expenses were incurred related to the acquisitions of Dynetics, the SD&A Businesses, 1901 Group, Gibbs & Cox, Cobham Special Mission and our strategic business acquisition:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Acquisition costs$ $$23 
Integration costs16 20 12 
Total acquisition and integration costs$16 $24 $35 
These acquisition and integration costs have been primarily recorded within Corporate and presented in "Acquisition, integration and restructuring costs" on the consolidated statement of income.
Divestitures
Aviation & Missile Solutions LLC ("AMS")
On November 22, 2021, our Defense Solutions reportable segment signed a definitive agreement to dispose of its AMS business in order to focus on leading-edge and technologically advanced services, solutions and products. The divestiture was completed on April 29, 2022. The net sales price was $15 million and net assets of $19 million were divested. The loss was recorded in "Other expense, net" on the consolidated statements of income. This disposition did not meet the criteria to be classified as a discontinued operation in the financial statements.
v3.22.4
Receivables
12 Months Ended
Dec. 30, 2022
Receivables [Abstract]  
Receivables
Note 6—Receivables
The components of receivables, net consisted of the following:
 December 30,
2022
December 31,
2021
 (in millions)
Billed and billable receivables$1,368 $1,194 
Unbilled receivables1,010 1,022 
Allowance for credit losses(28)(27)
$2,350 $2,189 
Sale of Accounts Receivable
We have entered into purchase agreements with a financial institution which provide us the election to sell accounts receivable at a discount. The receivables sold are typically collectable from our customers within 30 days of the sale date. During fiscal 2022, 2021 and 2020, we sold $209 million, $693 million and $1,866 million, respectively, of accounts receivable under the agreements and received proceeds of $209 million, $693 million and $1,864 million, respectively. These activities are classified as operating activities in the consolidated statements of cash flows.
These transfers have been recognized as a sale, as the receivables had been legally isolated from Leidos, the financial institution had the right to pledge or exchange the assets received and we did not maintain effective control over the transferred accounts receivable. As of December 30, 2022, and December 31, 2021, all sold receivables had been remitted to the financial institution.
v3.22.4
Inventory
12 Months Ended
Dec. 30, 2022
Inventory Disclosure [Abstract]  
Inventory
Note 7—Inventory
The components of inventory, net consisted of the following:
 December 30,
2022
December 31,
2021
 (in millions)
Raw materials$180 $154 
Work in process34 27 
Finished goods73 93 
$287 $274 
v3.22.4
Goodwill and Intangible Assets
12 Months Ended
Dec. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Note 8—Goodwill and Intangible Assets
Goodwill
The following table presents changes in the carrying amount of goodwill by reportable segment:
Defense SolutionsCivilHealthTotal
 (in millions)
Goodwill at January 1, 2021(1)
$3,300 $2,047 $966 $6,313 
Acquisitions of businesses425 — 430 
Divestiture of a business(1)— — (1)
Goodwill re-allocation(17)17 — — 
Foreign currency translation adjustments(26)28 — 
Goodwill at December 31, 2021(1)
3,681 2,097 966 6,744 
Acquisitions of businesses26 — — 26 
Divestiture of a business(6)— — (6)
Foreign currency translation adjustments(37)(31)— (68)
Goodwill at December 30, 2022(1)
$3,664 $2,066 $966 $6,696 
(1) Carrying amount includes accumulated impairment losses of $369 million and $117 million within the Health and Civil segments, respectively.
In the fourth quarter of fiscal 2022, we performed a qualitative analysis for certain reporting units which determined that it was more likely than not that the fair values of these reporting units were in excess of the individual reporting units' carrying values. We performed a quantitative analysis for certain reporting units and concluded that these reporting units were not impaired as their fair values exceeded their carrying values. The quantitative analysis for the Security Enterprise Solutions reporting unit, which holds goodwill of $899 million as of December 30, 2022, showed that fair value exceeded carrying value by 13%. Operations of the reporting unit rely heavily on the sales and servicing of security and detection products, which have been negatively impacted by COVID-19. The forecasts utilized to estimate the fair value of the Security Enterprise Solutions reporting unit assume continued global operations in all of our existing markets and a gradual improvement in the global aviation security product and related service sales, reaching pre-COVID-19 levels by fiscal 2025. In the event that there are significant unfavorable changes to the forecasted cash flows of the reporting unit (including if the impact of COVID-19 on passenger travel levels is more prolonged or severe than what is incorporated into our forecast), terminal growth rates or the cost of capital used in the fair value estimates, we may be required to record a material impairment of goodwill or intangible assets at a future date.
In the fourth quarter of fiscal 2021, we performed a qualitative analysis for certain reporting units which determined that it was more likely than not that the fair values of these reporting units were in excess of the individual reporting units' carrying values. For reporting units whose composition was affected by a reorganization, or those for which an indication of impairment exists, a quantitative assessment was performed. The quantitative analysis for the Security Enterprise Solutions reporting unit within the Civil reportable segment, which holds goodwill in the amount of $926 million as of December 31, 2021, showed that the fair value of the reporting unit exceeded the carrying value.
In the fourth quarter of fiscal 2020, we performed a qualitative analysis for all reporting units and determined that it was more likely than not that the fair values of the reporting units were in excess of the individual reporting units carrying values, and as a result, a quantitative step one analysis was not necessary.
As a result, no goodwill impairments were identified as part of the annual goodwill impairment evaluation for the periods mentioned above.
Intangible Assets
Intangible assets, net consisted of the following:
 December 30, 2022December 31, 2021
 Gross
carrying
value
Accumulated
amortization
Net
carrying
value
Gross
carrying
value
Accumulated
amortization
Net
carrying
value
 (in millions)
Finite-lived intangible assets:   
Programs$1,721 $(1,016)$705 $1,722 $(830)$892 
Software and technology225 (136)89 230 (121)109 
Customer relationships87 (25)62 97 (18)79 
Backlog   38 (37)
Trade names1 (1) (1)— 
Total finite-lived intangible assets2,034 (1,178)856 2,088 (1,007)1,081 
Indefinite-lived intangible assets:      
In-process research and development (1)
92  92 92 — 92 
Trade names4  4 — 
Total indefinite-lived intangible assets96  96 96 — 96 
Total intangible assets$2,130 $(1,178)$952 $2,184 $(1,007)$1,177 
(1) IPR&D assets are indefinite-lived at the acquisition date until placed into service, at which time such assets will be reclassified to a finite-lived amortizable intangible asset.
Amortization expense related to intangible assets was $230 million, $228 million and $198 million for fiscal 2022, 2021 and 2020, respectively.
The estimated annual amortization expense related to finite-lived intangible assets as of December 30, 2022, is as follows:
Fiscal Year Ending 
 (in millions)
2023$208 
2024153 
2025124 
202699 
202771 
2028 and thereafter201 
 $856 
Actual amortization expense in future periods could differ from these estimates as a result of future acquisitions, divestitures, impairments, the outcome and timing of completion of in-process research and development projects and other factors.
In the fourth quarter of fiscal 2022, we evaluated indefinite-lived intangibles for impairment and concluded that no impairment was necessary.
v3.22.4
Property Plant and Equipment
12 Months Ended
Dec. 30, 2022
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Note 9—Property, Plant and Equipment
Property, plant and equipment, net consisted of the following:
 December 30,
2022
December 31,
2021
 (in millions)
Computers and other equipment$399 $373 
Leasehold improvements404 367 
Vehicles and transportation equipment210 99 
Buildings and improvements138 140 
Office furniture and fixtures64 65 
Land17 18 
Construction in progress147 78 
 1,379 1,140 
Less: accumulated depreciation and amortization(532)(470)
 $847 $670 
Depreciation expense was $103 million, $97 million and $84 million for fiscal 2022, 2021 and 2020, respectively.
v3.22.4
Leases
12 Months Ended
Dec. 30, 2022
Leases [Abstract]  
Leases
Note 10—Leases
Lessee
ROU assets and lease liabilities consisted of the following:
Balance sheet line itemDecember 30,
2022
December 31,
2021
(in millions)
ROU assets:
Finance leasesProperty, plant and equipment, net$43 $51 
Operating leasesOperating lease right-of-use assets, net545 612 
$588 $663 
Current lease liabilities:
Finance leasesShort-term debt and current portion of long-term debt$6 $
Operating leasesAccounts payable and accrued liabilities130 140 
$136 $149 
Non-current lease liabilities:
Finance leasesLong-term debt, net of current portion$38 $43 
Operating leasesOperating lease liabilities570 589 
$608 $632 
During fiscal 2022, we reduced our leased space by exiting and consolidating underutilized buildings as part of an ongoing facility rationalization effort. We used discounted cash flow models to estimate the fair values of the affected assets and as a result, we recorded impairments of ROU and other assets in the amount of $37 million. The impairment charges were allocated across our reportable segments and to Corporate.
During fiscal 2020, we made a decision to vacate one of our facilities. The carrying amount was determined to be less than the expected recovery from sublease income and as a result, we recorded an impairment charge of $11 million, which was recorded within our Health reportable segment.
Total lease cost for the periods presented consisted of the following:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Finance lease cost:
Amortization of ROU assets$9 $11 $
Interest on lease liabilities
1 — 
10 12 
Operating lease cost(1)
161 172 169 
Variable lease cost42 90 103 
Short-term lease cost3 
Less: Sublease income(6)(8)(11)
Total lease cost$210 $270 $278 
(1) Includes ROU lease expense of $134 million, $150 million and $145 million for fiscal 2022, 2021 and 2020, respectively.
Lease costs and sublease income are included in "Cost of revenues" and "Selling, general and administrative expenses" within the consolidated statements of income.
Lease terms and discount rates related to leases were as follows:
December 30,
2022
December 31,
2021
January 1,
2021
Weighted-average remaining lease term (in years):
Finance leases8.28.42.9
Operating leases7.56.87.3
Weighted-average discount rate:
Finance leases2.6 %2.5 %2.7 %
Operating leases3.3 %3.2 %3.5 %
Other information related to leases was as follows:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Cash paid for amounts included in measurement of lease liabilities:
Operating cash related to finance leases$1 $$— 
Operating cash related to operating leases168 174 164 
Financing cash flows related to finance leases9 11 
ROU assets obtained in exchange for lease liabilities:
Finance lease liabilities$1 $51 $12 
Operating lease liabilities122 161 314 
The change in operating ROU assets and lease liabilities are presented within cash flows from operations on the consolidated statements of cash flows.
Future minimum lease commitments of our finance and operating leases on an undiscounted basis, reconciled to the respective lease liability at December 30, 2022, were as follows:
Fiscal Year EndingFinance lease commitmentsOperating lease commitments
(in millions)
2023$$152 
2024143 
2025103 
202679 
202757 
2028 and thereafter21 266 
Total undiscounted cash flows49 800 
Less: imputed interest(5)(100)
Lease liability as of December 30, 2022$44 $700 
Lessor
As of December 30, 2022 and December 31, 2021, we had a total net investment in sales-type leases, which relates to lease payment receivables, of $103 million and $93 million, respectively. The current and non-current portions of net investment in sales-type leases are included within "Other current assets" and "Other long-term assets", respectively, on the consolidated balance sheets.
The components of lease income were as follows:
Year Ended
Income statement line itemDecember 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Sales-type leases:
Selling price at lease commencementRevenues$65 $80 $61 
Cost of underlying assetCost of revenues(52)(60)(47)
Operating income 13 20 14 
Interest income on lease receivablesRevenues9 
22 28 22 
Operating lease incomeRevenues35 32 31 
Total lease income$57 $60 $53 
As of December 30, 2022, undiscounted cash flows for sales-type and operating leases for the next five years are as follows:
Fiscal Year EndingSales-type leasesOperating leases
(in millions)
2023$42 $26 
202431 27 
202520 29 
202611 — 
2027— 
2028 and thereafter— 
Total undiscounted cash flows$114 $82 
Present value of lease payments as lease receivables103 
Difference between undiscounted cash flows and discounted cash flows$11 
Leases
Note 10—Leases
Lessee
ROU assets and lease liabilities consisted of the following:
Balance sheet line itemDecember 30,
2022
December 31,
2021
(in millions)
ROU assets:
Finance leasesProperty, plant and equipment, net$43 $51 
Operating leasesOperating lease right-of-use assets, net545 612 
$588 $663 
Current lease liabilities:
Finance leasesShort-term debt and current portion of long-term debt$6 $
Operating leasesAccounts payable and accrued liabilities130 140 
$136 $149 
Non-current lease liabilities:
Finance leasesLong-term debt, net of current portion$38 $43 
Operating leasesOperating lease liabilities570 589 
$608 $632 
During fiscal 2022, we reduced our leased space by exiting and consolidating underutilized buildings as part of an ongoing facility rationalization effort. We used discounted cash flow models to estimate the fair values of the affected assets and as a result, we recorded impairments of ROU and other assets in the amount of $37 million. The impairment charges were allocated across our reportable segments and to Corporate.
During fiscal 2020, we made a decision to vacate one of our facilities. The carrying amount was determined to be less than the expected recovery from sublease income and as a result, we recorded an impairment charge of $11 million, which was recorded within our Health reportable segment.
Total lease cost for the periods presented consisted of the following:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Finance lease cost:
Amortization of ROU assets$9 $11 $
Interest on lease liabilities
1 — 
10 12 
Operating lease cost(1)
161 172 169 
Variable lease cost42 90 103 
Short-term lease cost3 
Less: Sublease income(6)(8)(11)
Total lease cost$210 $270 $278 
(1) Includes ROU lease expense of $134 million, $150 million and $145 million for fiscal 2022, 2021 and 2020, respectively.
Lease costs and sublease income are included in "Cost of revenues" and "Selling, general and administrative expenses" within the consolidated statements of income.
Lease terms and discount rates related to leases were as follows:
December 30,
2022
December 31,
2021
January 1,
2021
Weighted-average remaining lease term (in years):
Finance leases8.28.42.9
Operating leases7.56.87.3
Weighted-average discount rate:
Finance leases2.6 %2.5 %2.7 %
Operating leases3.3 %3.2 %3.5 %
Other information related to leases was as follows:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Cash paid for amounts included in measurement of lease liabilities:
Operating cash related to finance leases$1 $$— 
Operating cash related to operating leases168 174 164 
Financing cash flows related to finance leases9 11 
ROU assets obtained in exchange for lease liabilities:
Finance lease liabilities$1 $51 $12 
Operating lease liabilities122 161 314 
The change in operating ROU assets and lease liabilities are presented within cash flows from operations on the consolidated statements of cash flows.
Future minimum lease commitments of our finance and operating leases on an undiscounted basis, reconciled to the respective lease liability at December 30, 2022, were as follows:
Fiscal Year EndingFinance lease commitmentsOperating lease commitments
(in millions)
2023$$152 
2024143 
2025103 
202679 
202757 
2028 and thereafter21 266 
Total undiscounted cash flows49 800 
Less: imputed interest(5)(100)
Lease liability as of December 30, 2022$44 $700 
Lessor
As of December 30, 2022 and December 31, 2021, we had a total net investment in sales-type leases, which relates to lease payment receivables, of $103 million and $93 million, respectively. The current and non-current portions of net investment in sales-type leases are included within "Other current assets" and "Other long-term assets", respectively, on the consolidated balance sheets.
The components of lease income were as follows:
Year Ended
Income statement line itemDecember 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Sales-type leases:
Selling price at lease commencementRevenues$65 $80 $61 
Cost of underlying assetCost of revenues(52)(60)(47)
Operating income 13 20 14 
Interest income on lease receivablesRevenues9 
22 28 22 
Operating lease incomeRevenues35 32 31 
Total lease income$57 $60 $53 
As of December 30, 2022, undiscounted cash flows for sales-type and operating leases for the next five years are as follows:
Fiscal Year EndingSales-type leasesOperating leases
(in millions)
2023$42 $26 
202431 27 
202520 29 
202611 — 
2027— 
2028 and thereafter— 
Total undiscounted cash flows$114 $82 
Present value of lease payments as lease receivables103 
Difference between undiscounted cash flows and discounted cash flows$11 
Leases
Note 10—Leases
Lessee
ROU assets and lease liabilities consisted of the following:
Balance sheet line itemDecember 30,
2022
December 31,
2021
(in millions)
ROU assets:
Finance leasesProperty, plant and equipment, net$43 $51 
Operating leasesOperating lease right-of-use assets, net545 612 
$588 $663 
Current lease liabilities:
Finance leasesShort-term debt and current portion of long-term debt$6 $
Operating leasesAccounts payable and accrued liabilities130 140 
$136 $149 
Non-current lease liabilities:
Finance leasesLong-term debt, net of current portion$38 $43 
Operating leasesOperating lease liabilities570 589 
$608 $632 
During fiscal 2022, we reduced our leased space by exiting and consolidating underutilized buildings as part of an ongoing facility rationalization effort. We used discounted cash flow models to estimate the fair values of the affected assets and as a result, we recorded impairments of ROU and other assets in the amount of $37 million. The impairment charges were allocated across our reportable segments and to Corporate.
During fiscal 2020, we made a decision to vacate one of our facilities. The carrying amount was determined to be less than the expected recovery from sublease income and as a result, we recorded an impairment charge of $11 million, which was recorded within our Health reportable segment.
Total lease cost for the periods presented consisted of the following:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Finance lease cost:
Amortization of ROU assets$9 $11 $
Interest on lease liabilities
1 — 
10 12 
Operating lease cost(1)
161 172 169 
Variable lease cost42 90 103 
Short-term lease cost3 
Less: Sublease income(6)(8)(11)
Total lease cost$210 $270 $278 
(1) Includes ROU lease expense of $134 million, $150 million and $145 million for fiscal 2022, 2021 and 2020, respectively.
Lease costs and sublease income are included in "Cost of revenues" and "Selling, general and administrative expenses" within the consolidated statements of income.
Lease terms and discount rates related to leases were as follows:
December 30,
2022
December 31,
2021
January 1,
2021
Weighted-average remaining lease term (in years):
Finance leases8.28.42.9
Operating leases7.56.87.3
Weighted-average discount rate:
Finance leases2.6 %2.5 %2.7 %
Operating leases3.3 %3.2 %3.5 %
Other information related to leases was as follows:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Cash paid for amounts included in measurement of lease liabilities:
Operating cash related to finance leases$1 $$— 
Operating cash related to operating leases168 174 164 
Financing cash flows related to finance leases9 11 
ROU assets obtained in exchange for lease liabilities:
Finance lease liabilities$1 $51 $12 
Operating lease liabilities122 161 314 
The change in operating ROU assets and lease liabilities are presented within cash flows from operations on the consolidated statements of cash flows.
Future minimum lease commitments of our finance and operating leases on an undiscounted basis, reconciled to the respective lease liability at December 30, 2022, were as follows:
Fiscal Year EndingFinance lease commitmentsOperating lease commitments
(in millions)
2023$$152 
2024143 
2025103 
202679 
202757 
2028 and thereafter21 266 
Total undiscounted cash flows49 800 
Less: imputed interest(5)(100)
Lease liability as of December 30, 2022$44 $700 
Lessor
As of December 30, 2022 and December 31, 2021, we had a total net investment in sales-type leases, which relates to lease payment receivables, of $103 million and $93 million, respectively. The current and non-current portions of net investment in sales-type leases are included within "Other current assets" and "Other long-term assets", respectively, on the consolidated balance sheets.
The components of lease income were as follows:
Year Ended
Income statement line itemDecember 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Sales-type leases:
Selling price at lease commencementRevenues$65 $80 $61 
Cost of underlying assetCost of revenues(52)(60)(47)
Operating income 13 20 14 
Interest income on lease receivablesRevenues9 
22 28 22 
Operating lease incomeRevenues35 32 31 
Total lease income$57 $60 $53 
As of December 30, 2022, undiscounted cash flows for sales-type and operating leases for the next five years are as follows:
Fiscal Year EndingSales-type leasesOperating leases
(in millions)
2023$42 $26 
202431 27 
202520 29 
202611 — 
2027— 
2028 and thereafter— 
Total undiscounted cash flows$114 $82 
Present value of lease payments as lease receivables103 
Difference between undiscounted cash flows and discounted cash flows$11 
Leases
Note 10—Leases
Lessee
ROU assets and lease liabilities consisted of the following:
Balance sheet line itemDecember 30,
2022
December 31,
2021
(in millions)
ROU assets:
Finance leasesProperty, plant and equipment, net$43 $51 
Operating leasesOperating lease right-of-use assets, net545 612 
$588 $663 
Current lease liabilities:
Finance leasesShort-term debt and current portion of long-term debt$6 $
Operating leasesAccounts payable and accrued liabilities130 140 
$136 $149 
Non-current lease liabilities:
Finance leasesLong-term debt, net of current portion$38 $43 
Operating leasesOperating lease liabilities570 589 
$608 $632 
During fiscal 2022, we reduced our leased space by exiting and consolidating underutilized buildings as part of an ongoing facility rationalization effort. We used discounted cash flow models to estimate the fair values of the affected assets and as a result, we recorded impairments of ROU and other assets in the amount of $37 million. The impairment charges were allocated across our reportable segments and to Corporate.
During fiscal 2020, we made a decision to vacate one of our facilities. The carrying amount was determined to be less than the expected recovery from sublease income and as a result, we recorded an impairment charge of $11 million, which was recorded within our Health reportable segment.
Total lease cost for the periods presented consisted of the following:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Finance lease cost:
Amortization of ROU assets$9 $11 $
Interest on lease liabilities
1 — 
10 12 
Operating lease cost(1)
161 172 169 
Variable lease cost42 90 103 
Short-term lease cost3 
Less: Sublease income(6)(8)(11)
Total lease cost$210 $270 $278 
(1) Includes ROU lease expense of $134 million, $150 million and $145 million for fiscal 2022, 2021 and 2020, respectively.
Lease costs and sublease income are included in "Cost of revenues" and "Selling, general and administrative expenses" within the consolidated statements of income.
Lease terms and discount rates related to leases were as follows:
December 30,
2022
December 31,
2021
January 1,
2021
Weighted-average remaining lease term (in years):
Finance leases8.28.42.9
Operating leases7.56.87.3
Weighted-average discount rate:
Finance leases2.6 %2.5 %2.7 %
Operating leases3.3 %3.2 %3.5 %
Other information related to leases was as follows:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Cash paid for amounts included in measurement of lease liabilities:
Operating cash related to finance leases$1 $$— 
Operating cash related to operating leases168 174 164 
Financing cash flows related to finance leases9 11 
ROU assets obtained in exchange for lease liabilities:
Finance lease liabilities$1 $51 $12 
Operating lease liabilities122 161 314 
The change in operating ROU assets and lease liabilities are presented within cash flows from operations on the consolidated statements of cash flows.
Future minimum lease commitments of our finance and operating leases on an undiscounted basis, reconciled to the respective lease liability at December 30, 2022, were as follows:
Fiscal Year EndingFinance lease commitmentsOperating lease commitments
(in millions)
2023$$152 
2024143 
2025103 
202679 
202757 
2028 and thereafter21 266 
Total undiscounted cash flows49 800 
Less: imputed interest(5)(100)
Lease liability as of December 30, 2022$44 $700 
Lessor
As of December 30, 2022 and December 31, 2021, we had a total net investment in sales-type leases, which relates to lease payment receivables, of $103 million and $93 million, respectively. The current and non-current portions of net investment in sales-type leases are included within "Other current assets" and "Other long-term assets", respectively, on the consolidated balance sheets.
The components of lease income were as follows:
Year Ended
Income statement line itemDecember 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Sales-type leases:
Selling price at lease commencementRevenues$65 $80 $61 
Cost of underlying assetCost of revenues(52)(60)(47)
Operating income 13 20 14 
Interest income on lease receivablesRevenues9 
22 28 22 
Operating lease incomeRevenues35 32 31 
Total lease income$57 $60 $53 
As of December 30, 2022, undiscounted cash flows for sales-type and operating leases for the next five years are as follows:
Fiscal Year EndingSales-type leasesOperating leases
(in millions)
2023$42 $26 
202431 27 
202520 29 
202611 — 
2027— 
2028 and thereafter— 
Total undiscounted cash flows$114 $82 
Present value of lease payments as lease receivables103 
Difference between undiscounted cash flows and discounted cash flows$11 
v3.22.4
Fair Value Measurements
12 Months Ended
Dec. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Note 11—Fair Value Measurements
Financial instruments measured on a recurring basis at fair value consisted of the following:
December 30, 2022December 31, 2021
Carrying valueFair valueCarrying valueFair value
(in millions)
Financial assets:
Derivatives$20 $20 $— $— 
Financial liabilities:
Derivatives$ $ $53 $53 
As of December 30, 2022, our derivatives primarily consisted of the cash flow interest rate swaps on $1.0 billion of the variable rate senior unsecured term loan (see "Note 12—Derivative Instruments"). The fair value of the cash flow interest rate swaps is determined based on observed values for underlying interest rates on the LIBOR yield curve (Level 2 inputs).
Financial instruments measured on a recurring basis at fair value also include our defined benefit plan assets (Level 2 inputs). See "Note 19—Retirement Plans" for further details on these investments.
The carrying amounts of our financial instruments, other than derivatives, which include cash equivalents, accounts receivable, accounts payable and accrued expenses, are reasonable estimates of their related fair values. The carrying value of our notes receivable of $12 million and $15 million as of December 30, 2022 and December 31, 2021, respectively, approximates fair value as the stated interest rates within the agreements are consistent with the current market rates used in notes with similar terms in the market (Level 2 inputs).
As of December 30, 2022 and December 31, 2021, the fair value of debt was $4.6 billion and $5.4 billion, respectively, and the carrying amount was $4.9 billion and $5.1 billion, respectively (see "Note 13—Debt"). The fair value of debt is determined based on current interest rates available for debt with terms and maturities similar to our existing debt arrangements (Level 2 inputs).
On October 30, 2022, May 7, 2021, and January 14, 2021, non-financial instruments measured at fair value on a non-recurring basis were recorded in connection with the acquisitions of Cobham Special Mission, Gibbs & Cox and 1901 Group, respectively. The fair values of the assets acquired and liabilities assumed were determined using Level 3 inputs. See "Note 5—Acquisitions and Divestitures" for further details on these acquisitions. As of December 30, 2022 and December 31, 2021, we did not have any assets or liabilities measured at fair value on a non-recurring basis.
v3.22.4
Derivative Instruments
12 Months Ended
Dec. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments
Note 12—Derivative Instruments
The fair value of the interest rate swaps was as follows:
Balance sheet line itemDecember 30,
2022
December 31,
2021
(in millions)
Asset derivatives:
Cash flow interest rate swapsOther long-term assets$20 $— 
Liability derivatives:
Cash flow interest rate swapsOther long-term liabilities$ $53 
The cash flows associated with the interest rate swaps are classified as operating activities in the consolidated statements of cash flows.
During fiscal 2022, we entered into a foreign currency forward contract to offset foreign currency fluctuations of the $310 million Australian dollar preliminary purchase price for the Cobham Special Mission acquisition against the U.S. dollar. We realized a loss of $18 million resulting from the settlement of the foreign currency forward contract. The loss was recorded within Corporate and presented in "Other expense, net" on the consolidated statements of income and the settlement associated with the foreign currency forward contract was classified as investing activities in the consolidated statements of cash flows.
Cash Flow Hedges
We have interest rate swap agreements to hedge the cash flows of $1.0 billion of the variable rate senior unsecured term loan (the "Variable Rate Loan"). These interest rate swap agreements have a maturity date of August 2025 and a fixed interest rate of 3.00%. The objective of these instruments is to reduce variability in the forecasted interest payments of the Variable Rate Loan, which are based on the LIBOR rate. Under the terms of the interest rate swap agreements, we receive monthly variable interest payments based on the one-month LIBOR rate and pay interest at a fixed rate.
The interest rate swap transactions were accounted for as cash flow hedges. The gain/loss on the swap is reported as a component of other comprehensive income (loss) and is reclassified into earnings when the interest payments on the underlying hedged items impact earnings. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.
The effect of the cash flow hedges on other comprehensive income (loss) and earnings for the periods presented was as follows:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Total interest expense, net presented in the consolidated statements of income in which the effects of cash flow hedges are recorded
$199 $184 $179 
Amount recognized in other comprehensive income (loss)59 18 (61)
Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net11 19 14 
We expect to reclassify net gains of $14 million from accumulated other comprehensive loss into earnings during the next 12 months.
v3.22.4
Debt
12 Months Ended
Dec. 30, 2022
Debt Disclosure [Abstract]  
Debt
Note 13—Debt
Debt consisted of the following:
 Stated
interest rate
Effective
interest rate
December 30, 2022December 31, 2021
 (in millions)
Short-term debt and current portion of long-term debt:
Senior unsecured term loans:
$380 million term loan, due May 2022
1.54 %1.64 %$ $380 
$380 million term loan, due May 2023
5.42 %5.51 %320 — 
Current portion of long-term debt672 103 
Total short-term debt and current portion of long-term debt$992 $483 
Long-term debt:
Senior unsecured term loan:
$1,925 million term loan, due January 2025
5.77 %6.09 %$1,211 $1,306 
Senior unsecured notes:    
$500 million notes, due May 2023
2.95 %3.17 %500 500 
$500 million notes, due May 2025
3.63 %3.76 %500 500 
$750 million notes, due May 2030
4.38 %4.50 %750 750 
$1,000 million notes, due February 2031
2.30 %2.38 %1,000 1,000 
$250 million notes, due July 2032
7.13 %7.43 %250 250 
$300 million notes, due July 2033
5.50 %5.88 %161 161 
$300 million notes, due December 2040
5.95 %6.03 %218 218 
Notes payable and finance leases due on various dates through fiscal 2032
1.84%-4.51%
Various44 54 
Less: unamortized debt discounts and deferred debt issuance costs(34)(43)
Total long-term debt  4,600 4,696 
Less: current portion  (672)(103)
Total long-term debt, net of current portion
  $3,928 $4,593 
Term Loans and Revolving Credit Facility
On May 6, 2022, we entered into a 364-day term loan credit agreement ("Term Loan Agreement") with certain financial institutions, which provided for a senior unsecured term loan facility in an aggregate principal amount of $380 million. The proceeds of the Term Loan Agreement were used to repay the $380 million senior unsecured term loan entered into on May 7, 2021.
Borrowings under the Term Loan Agreement bear interest at a rate based on the Secured Overnight Financing Rate plus 1.10%, or an alternate base rate at our option.
The financial covenants in the Term Loan Agreement require that we maintain, as of the last day of each fiscal quarter, a ratio of adjusted consolidated total debt to consolidated EBITDA of not more than 3.75 to 1.00, subject to increases to 4.50 to 1.00 following a material acquisition, and a ratio of EBITDA to consolidated interest expense of not less than 3.50 to 1.00.
On May 7, 2021, we entered into a credit agreement with certain financial institutions, which provided for a senior unsecured term loan facility in an aggregate principal amount of $380 million with maturity 364 days after the credit agreement date. The proceeds were used to fund the acquisition of Gibbs & Cox. The term loan was repaid on May 6, 2022.
We have a Credit Agreement (the "Credit Agreement") with certain financial institutions, which provided for a senior unsecured term loan facility in an aggregate principal amount of $1.9 billion (the "Term Loan Facility") and a $750 million senior unsecured revolving facility (the "Revolving Facility" and, together with the Term Loan Facility, the "Credit Facilities"). The Credit Facilities are scheduled to mature in January 2025, with the Revolving Facility subject to two additional one year extensions. As of December 30, 2022, and December 31, 2021, there were no borrowings outstanding under the Revolving Facility.
Borrowings under the Credit Agreement bear interest at a rate determined, at our option, based on either an alternate base rate or a LIBOR rate plus, in each case, an applicable margin that varies depending on our credit rating. The applicable margin range for LIBOR-denominated borrowings is from 1.13% to 1.75%. Based on our current ratings, the applicable margin for LIBOR-denominated borrowings is 1.38%.
The financial covenants in the Credit Agreement require that we maintain, as of the last day of each fiscal quarter, a ratio of adjusted consolidated total debt to consolidated EBITDA of not more than 3.75 to 1.00, subject to two increases to 4.50 to 1.00 following a material acquisition, and a ratio of EBITDA to consolidated interest expense of not less than 3.50 to 1.00.
Commercial Paper
On July 12, 2021, we established a commercial paper program in which the Company may issue short-term unsecured commercial paper notes ("Commercial Paper Notes") not to exceed $750 million. The proceeds will be used for general corporate purposes, including working capital, capital expenditures, acquisitions and share repurchases.
The Commercial Paper Notes will be issued in minimum denominations of $0.25 million and will have maturities of up to 397 days from the date of issuance. The Commercial Paper Notes will bear either a stated or floating interest rate, if interest bearing, or will be sold at a discount from the face amount. As of December 30, 2022, and December 31, 2021, we did not have any Commercial Paper Notes outstanding.
Principal Payments and Debt Issuance Costs
We made principal payments on our debt of $545 million, $106 million and $731 million during fiscal 2022, 2021 and 2020, respectively. This activity included required principal payments on our term loans of $476 million, $96 million and $72 million during fiscal 2022, 2021 and 2020, respectively. During fiscal 2020, we made $4,925 million of principal repayments for outstanding debt and retired the $450 million senior notes.
Principal payments are made quarterly on our Term Loan Facility, with the majority of the principal due at maturity. Interest on the Term Loan Facility is payable on a periodic basis, which must be at least quarterly. Principal on the Term Loan Agreement is due at maturity and interest is paid monthly. Interest on the senior fixed rate unsecured notes is payable on a semi-annual basis with principal payments due at maturity.
Amortization of debt discount and deferred financing costs was $11 million for both fiscal 2022 and 2021, and $16 million for fiscal 2020.
The Credit Facilities, the Term Loan Agreement, Commercial Paper Notes, senior unsecured term loans and notes are fully and unconditionally guaranteed and contain certain customary restrictive covenants, including among other things, restrictions on our ability to create liens and enter into sale and leaseback transactions under certain circumstances. We were in compliance with all covenants as of December 30, 2022.
Future minimum payments of debt are as follows:
Fiscal Year Ending
 (in millions)
2023$996 
2024197 
20251,353 
2026
2027
2028 and thereafter2,399 
Total principal payments4,954 
Less: unamortized debt discount and issuance costs(34)
Total short-term and long-term debt$4,920 
v3.22.4
Accumulated Other Comprehensive Income (Loss)
12 Months Ended
Dec. 30, 2022
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss)
Note 14—Accumulated Other Comprehensive Income (Loss)
Changes in the components of Accumulated Other Comprehensive Income (Loss) ("AOCI") were as follows:
Foreign currency translation adjustmentsUnrecognized gain (loss) on derivative instrumentsPension adjustmentsTotal AOCI
(in millions)
Balance at January 3, 2020$(33)$(33)$(4)$(70)
Other comprehensive income (loss)70 (61)(3)
Taxes(7)10 
Reclassification from AOCI— 14 — 14 
Balance at January 1, 202130 (70)(6)(46)
Other comprehensive income (loss)(3)18 17 32 
Taxes(5)(8)(4)(17)
Reclassification from AOCI— 19 — 19 
Balance at December 31, 202122 (41)(12)
Other comprehensive income (loss)(108)59 (27)(76)
Taxes13 (16)
Reclassification from AOCI— 11 — 11 
Balance at December 30, 2022$(73)$13 $(13)$(73)
Reclassifications for unrecognized gain (loss) on derivative instruments are associated with outstanding debt and are recorded in "Interest expense, net" on the consolidated statements of income. See "Note 12—Derivative Instruments" for more information on our interest rate swap agreements.
v3.22.4
Composition of Certain Financial Statement Captions
12 Months Ended
Dec. 30, 2022
Disclosure Schedule Of Certain Financial Statement Captions [Abstract]  
Composition of Certain Financial Statement Captions
Note 15—Composition of Certain Financial Statement Captions
 Balance Sheets
December 30,
2022
December 31,
2021
 (in millions)
Other current assets:  
Restricted cash$167 $148 
Transition costs and project assets(1)
132 110 
Other(2)
191 171 
 $490 $429 
Other long-term assets:
Transition costs and project assets(1)
$74 $121 
Equity method investments(3)
18 25 
Other(2)
296 293 
$388 $439 
Accounts payable and accrued liabilities:  
Accrued liabilities(4)
$772 $747 
Accounts payable733 692 
Deferred revenue380 364 
Other(2)(4)
369 338 
 $2,254 $2,141 
Accrued payroll and employee benefits:  
Accrued vacation$356 $351 
Salaries, bonuses and amounts withheld from employees’ compensation345 254 
 $701 $605 
(1) During the year ended December 30, 2022, and December 31, 2021, $489 million and $428 million, respectively, of amortization was recognized related to transition costs and project assets.
(2) Balance represents items that are not individually significant to disclose separately.
(3) Balances are net of $19 million and $16 million of dividends received during fiscal 2022 and fiscal 2021, respectively, that were recorded in cash flows provided by operating activities of continuing operations on the consolidated statements of cash flows.
(4) Certain accounts in accrued liabilities were reclassified in the prior year to other to conform to current year presentation.


Year Ended
 Statements of Income
December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Other expense, net:
Loss on debt extinguishment$ $— $(36)
Loss on sale of businesses (3)— 
Loss on foreign currencies(3)(1)(4)
Other income, net 
$(3)$(1)$(38)
v3.22.4
Earnings Per Share ("EPS")
12 Months Ended
Dec. 30, 2022
Earnings Per Share [Abstract]  
Earnings Per Share ("EPS")
Note 16—Earnings Per Share ("EPS")
Basic EPS is computed by dividing net income attributable to Leidos common stockholders by the basic weighted average number of shares outstanding. Diluted EPS is calculated to give effect to all potentially dilutive common shares that were outstanding during the reporting period. The dilutive effect of outstanding equity-based compensation awards is reflected in diluted EPS by application of the treasury stock method, only in periods in which such effect would have been dilutive for the period.
We issue unvested stock awards that have forfeitable rights to dividends or dividend equivalents. These stock awards are dilutive common share equivalents subject to the treasury stock method.
The weighted average number of shares used to compute basic and diluted EPS attributable to Leidos stockholders were:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Basic weighted average number of shares outstanding137 141 142 
Dilutive common share equivalents—stock options and other stock awards
1 
Diluted weighted average number of shares outstanding138 143 144 
Anti-dilutive stock-based awards are excluded from the weighted average number of shares outstanding used to compute diluted EPS. The total outstanding stock options and vesting stock awards that were anti-dilutive were 1 million for both fiscal 2022 and 2021. There were no significant anti-diluted equity awards for fiscal 2020.
Share Repurchases
During fiscal 2021 and 2020, we made open market repurchases of our common stock for an aggregate purchase price of $237 million and $67 million, respectively. There were no open market share repurchases in fiscal 2022.
In fiscal 2022, we entered into Accelerated Share Repurchase agreement with a financial institution to repurchase shares of our outstanding common stock. We paid $500 million to the financial institution and received 4.8 million shares.
The repurchases were recorded to "Additional paid-in capital" in the consolidated balance sheets. All shares delivered were immediately retired.
v3.22.4
Stock-Based Compensation
12 Months Ended
Dec. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
Note 17—Stock-Based Compensation
Plan Summaries
As of December 30, 2022, we had stock-based compensation awards outstanding under the following plans: the 2017 Omnibus Incentive Plan, the 2006 Equity Incentive Plan, as amended, and the 2006 Employee Stock Purchase Plan, as amended ("ESPP"). We issue new shares upon the vesting of stock units or exercising of stock options under these plans.
The 2017 Omnibus Incentive Plan provides Leidos and its affiliates' employees, directors and consultants the opportunity to receive various types of stock-based compensation awards, such as stock options, restricted stock units and performance-based awards, as well as cash awards. We grant service-based awards that generally vest or become exercisable 25% a year over four years or cliff vest in three years. As of December 30, 2022, 3.5 million shares of Leidos' stock were reserved for future issuance under the 2017 Omnibus Incentive Plan and the 2006 Equity Incentive Plan.
We offer eligible employees the opportunity to defer restricted stock units into an equity-based deferred equity compensation plan, the Key Executive Stock Deferral Plan ("KESDP"). Prior to 2013, we offered an additional opportunity for deferrals into the Management Stock Compensation Plan ("MSCP"). Benefits from these plans are payable in shares of Leidos' stock that are held in a trust for the purpose of funding shares to the plans' participants. Restricted stock units deferred under the KESDP are counted against the total shares available for future issuance under the 2017 Omnibus Incentive Plan. All awards under the MSCP are fully vested and the plan does not provide for a maximum number of shares available for future issuance.
Our ESPP allows eligible employees to purchase shares of Leidos' stock at a discount of up to 15% of the fair market value on the date of purchase. During fiscal 2022, 2021 and 2020, the discount was 10% of the fair market value on the date of purchase. During fiscal 2022, 2021 and 2020, $45 million, $39 million and $32 million, respectively, was received from ESPP plan participants for the issuance of Leidos' stock. A total of 2.9 million shares remain available for future issuance under the ESPP.
Stock-based compensation and related tax benefits recognized under all plans were as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Total stock-based compensation expense
$73 $67 $62 
Tax benefits recognized from stock-based compensation
16 17 15 
Stock Options
Stock options are granted with exercise prices equal to the fair market value of Leidos' common stock on the date of grant and for terms not greater than ten years. Stock options have a term of seven years and a vesting period of four years, except for stock options granted to our outside directors, which have a vesting period of the earlier of one year from grant date or the next annual meeting of stockholders following grant date.
The fair value of the stock option awards is estimated on the date of grant using the Black-Scholes-Merton option-pricing model. The fair value of the stock option awards to employees are expensed on a straight-line basis over the vesting period of four years, except for stock options granted to our outside directors, which is recognized over the vesting period of one year or less.
During fiscal 2022, 2021 and 2020, we used a blended approach to measure expected volatility that is based on our weighted average historical and implied volatilities.
The risk-free rate is derived using the yield curve of a zero-coupon U.S. Treasury bond with a maturity equal to the expected term of the stock option on the grant date. To determine the expected term, we use the midpoint scenario with a one-year grant date filter assumption for outstanding options and we use historical data to estimate forfeitures. The weighted average grant-date fair value and assumptions used to determine fair value of stock options granted for the periods presented were as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
Weighted average grant-date fair value$24.67$20.23$19.64
Expected term (in years)4.74.64.5
Expected volatility29.5 %29.6 %25.0 %
Risk-free interest rate1.6 %0.7 %0.6 %
Dividend yield1.6 %1.3 %1.3 %
Stock option activity for each of the periods presented was as follows:
Shares of
stock under
stock options
Weighted
average
exercise price
Weighted
average
remaining
contractual
term
Aggregate
intrinsic value
 (in millions) (in years)(in millions)
Outstanding at January 3, 20202.4 $46.04 3.8$128 
Options granted0.3 106.73 
Options forfeited or expired(0.1)66.84 
Options exercised(0.4)35.94 29 
Outstanding at January 1, 20212.2 $56.01 3.5$108 
Options granted0.3 90.25 
Options forfeited or expired— 85.42 
Options exercised(0.4)38.79 27 
Outstanding at December 31, 20212.1 $65.18 3.5$54 
Options granted0.3 105.01 
Options forfeited or expired— 92.10 
Options exercised(0.6)39.26 41 
Outstanding at December 30, 20221.8 $81.45 3.9$42 
Exercisable at December 30, 20221.0 $69.70 2.8$34 
Vested and expected to vest in the future as of December 30, 2022
1.7 $81.24 3.9$42 
As of December 30, 2022, there was $6 million of unrecognized compensation cost, net of estimated forfeitures, related to stock options, which is expected to be recognized over a weighted-average period of 2.1 years. Tax benefits from stock options exercised for fiscal 2022, 2021 and 2020 were $9 million, $6 million and $7 million, respectively.
Restricted Stock Units and Awards
Compensation expense is measured at the grant date fair value and generally recognized over the vesting period of either three to four years based upon required service conditions and in some cases revenue or EPS-based performance conditions.
Restricted stock units and awards activity for each of the periods presented was as follows:
Shares of stock
under stock
awards
Weighted
average grant-
date fair value
(in millions) 
Unvested stock awards at January 3, 20201.4 $60.91 
Awards granted0.5 106.38 
Awards forfeited(0.1)79.61 
Awards vested(0.5)56.36 
Unvested stock awards at January 1, 20211.3 $79.05 
Awards granted0.7 91.09 
Awards forfeited(0.1)89.56 
Awards vested(0.5)71.60 
Unvested stock awards at December 31, 20211.4 $88.89 
Awards granted0.5 104.78 
Awards forfeited(0.1)99.38 
Awards vested(0.5)74.20 
Unvested stock awards at December 30, 20221.3 $98.52 
As of December 30, 2022, there was $52 million of unrecognized compensation cost, net of estimated forfeitures, related to restricted stock units, which is expected to be recognized over a weighted average period of 2.0 years. The fair value of restricted stock units that vested in fiscal 2022, 2021 and 2020 was $52 million, $48 million and $58 million, respectively. In addition, the fair value of dividend equivalents with respect to restricted stock units that vested in fiscal 2022, 2021 and 2020 was immaterial.
Performance-Based Stock Awards
Performance-based stock awards vest and the stock is issued at the end of a three-year period based upon the achievement of specific performance criteria, with the number of shares ultimately awarded, if any, ranging up to 150% of the specified target awards. If performance is below the threshold level of performance, no shares will be issued.
For awards granted during fiscal 2022, 2021 and 2020, the target number of shares of stock granted under the awards will vest and the stock will be issued at the end of a three-year period based on a three-year cycle performance period and the actual number of shares to be issued will be based upon the achievement of the three-year cycle's performance criteria. Also, during fiscal 2022, 2021 and 2020, we granted performance-based awards with market conditions. These market conditions grants represent the target number of shares and the actual number of shares to be awarded upon vesting may be higher or lower depending upon the achievement of the relevant market conditions. The target number of shares granted under the market conditions grants will vest and the stock will be issued at the end of a three-year period based on the attainment of certain total shareholder return performance measures and the employee's continued service through the vest date.
Performance-based stock award activity for each of the periods presented was as follows:
Expected number
of shares of stock
to be issued under
performance-based
stock awards
Weighted
average grant-
date fair value
 (in millions) 
Unvested at January 3, 20200.6 $63.66 
Awards granted0.2 103.34 
Awards forfeited(0.1)72.96 
Awards vested(0.2)58.61 
Unvested at January 1, 20210.5 $80.20 
Awards granted0.2 86.88 
Awards forfeited— 89.65 
Awards vested(0.2)65.30 
Unvested at December 31, 20210.5 $88.72 
Awards granted0.2 114.98 
Awards forfeited— 103.06 
Awards vested(0.2)67.79 
Unvested at December 30, 20220.5 $106.70 
The weighted average grant date fair value for performance-based stock, excluding those with a market condition, during fiscal 2022, 2021 and 2020 was $105.07, $89.26 and $106.80, respectively. The weighted average grant date fair value for performance-based stock with market conditions that were granted during fiscal 2022, 2021 and 2020 was $129.42, $88.21 and $127.92, respectively, and was calculated using the Monte Carlo simulation.
The Monte Carlo simulation assumptions used for the periods presented were as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
Expected volatility33.18 %32.86 %23.99 %
Risk free rate of return1.61 %0.29 %0.50 %
Weighted average grant date stock price$107.67 $90.85 $105.12 
As of December 30, 2022, there was $21 million of unrecognized compensation cost, net of estimated forfeitures, which is expected to be recognized over a weighted average period of 1.7 years. The fair value of performance-based stock awards that vested in fiscal 2022, 2021 and 2020 was $17 million, $19 million, and $25 million, respectively.
v3.22.4
Income Taxes
12 Months Ended
Dec. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes
Note 18—Income Taxes
The provision for income taxes for the periods presented included the following:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Current:   
Federal$290 $156 $90 
State80 49 37 
Foreign33 29 28 
Deferred:  
Federal(169)(20)13 
State(36)(3)(11)
Foreign(5)(3)(5)
Total$193 $208 $152 
A reconciliation of the provision for income taxes to the amount computed by applying the statutory federal income tax rate to income before income taxes for the periods presented was as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Amount computed at the statutory federal income tax rate$186 $203 $164 
State income taxes, net of federal tax benefit36 34 20 
Research and development credits(31)(23)(26)
Excess tax benefits from stock-based compensation(13)(11)(15)
Change in valuation allowance for deferred tax assets3 (5)
Impact of foreign operations2 11 
Dividends paid to employee stock ownership plan(2)(2)(2)
Change in accruals for uncertain tax positions(1)
Other13 (3)
Total$193 $208 $152 
Effective income tax rate21.8 %21.5 %19.5 %
The effective tax rates for both fiscal 2022 and fiscal 2021 were favorably impacted primarily by federal research tax credits and excess tax benefits related to employee stock-based payment transactions.
The effective tax rate for fiscal 2020 was favorably impacted primarily by federal research tax credits and excess tax benefits related to employee stock-based payment transactions, partially offset by taxes related to foreign operations.
Deferred income taxes are recorded for differences in the basis of assets and liabilities for financial reporting purposes and tax reporting purposes. Deferred tax assets (liabilities) were comprised of the following:
 December 30,
2022
December 31,
2021
 (in millions)
Capitalized research and development$228 $— 
Operating lease liabilities190 187 
Accrued vacation and bonuses87 91 
Reserves40 47 
Deferred compensation32 39 
Credits and net operating losses carryovers32 26 
Vesting stock awards27 24 
Deferred revenue 16 
Accumulated other comprehensive loss2 — 
Other13 
Total deferred tax assets651 439 
Valuation allowance(24)(21)
Deferred tax assets, net of valuation allowance$627 $418 
Purchased intangible assets$(415)$(413)
Operating lease right-of-use assets(140)(158)
Property, plant and equipment(75)(63)
Accumulated other comprehensive income (1)
Deferred revenue(4)— 
Other(5)(9)
Total deferred tax liabilities(639)(644)
Net deferred tax liabilities$(12)$(226)
At December 30, 2022, we had state net operating losses of $62 million and state tax credits of $2 million. Both will begin to expire in fiscal 2023; however, we expect to utilize $45 million and $2 million of these state net operating losses and state tax credits, respectively. We had foreign tax credits of $18 million that will begin to expire in fiscal 2030. We expect to utilize $7 million of these foreign tax credits. We also had foreign net operating losses of $35 million, which do not expire. We expect to utilize $2 million of these foreign net operating losses.
Our valuation allowance for deferred tax assets was $24 million and $21 million as of December 30, 2022 and December 31, 2021, respectively.
Income tax balance sheet items are included in the accompanying consolidated balance sheets as follows:
 December 30,
2022
December 31,
2021
 (in millions)
Other current assets:
Prepaid income taxes and tax refunds receivable$11 $
Other long-term assets:
Deferred tax assets$28 $13 
Accounts payable and accrued liabilities:
Income taxes payable$135 $29 
Deferred tax liabilities$40 $239 
Other long-term liabilities:
Unrecognized tax benefits$92 $
Unrecognized tax benefits are primarily related to certain recurring deductions customary for our industry. The changes in the unrecognized tax benefits were as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Unrecognized tax benefits at beginning of year$2 $$
Additions for tax positions related to current year91 — — 
Additions for tax positions related to prior years 
Reductions for tax positions related to prior years (2)— 
Settlements with taxing authorities (3)— 
Lapse of statute of limitations(1)(1)— 
Unrecognized tax benefits at end of year$92 $$
Unrecognized tax benefits that, if recognized, would affect the effective income tax rate
$ $$
At December 30, 2022, and December 31, 2021, the balance of unrecognized tax benefits included liabilities for uncertain tax positions of $92 million and $2 million, respectively, which were classified as other long-term liabilities on the consolidated balance sheets. At January 1, 2021, the balance of unrecognized tax benefits included liabilities for uncertain tax positions of $6 million, $4 million of which were classified as other long-term liabilities on the consolidated balance sheets.
Beginning in 2022, the Tax Cuts and Jobs Act of 2017 (“TCJA”) eliminated the option to currently deduct certain research and development costs for tax purposes and requires taxpayers to capitalize and amortize research costs over five years. Based upon our interpretation of the law as currently enacted, we recorded the estimated fiscal 2022 impact, resulting in increases of $130 million to both our income taxes payable and net deferred tax assets. Our unrecognized tax benefits also increased by $91 million with a corresponding increase to net deferred tax assets. The actual impact will depend on the amount of research and development costs the Company will incur, whether Congress modifies or repeals this provision and whether new guidance and interpretive rules are issued by the U.S. Treasury, among other factors.
We file income tax returns in the United States and various state and foreign jurisdictions. For the year ended December 30, 2022, we are participating in the Internal Revenue Service (“IRS”) Compliance Assurance Process ("CAP"), a real-time audit of our consolidated federal corporate income tax return. The IRS has examined our consolidated federal income tax returns through the year ended January 3, 2020. For the years ended January 1, 2021 and December 31, 2021, we were selected to participate in the phase of CAP reserved for taxpayers whose risk of noncompliance does not warrant use of IRS resources. We believe that participation in CAP should reduce tax-related uncertainties, if any. Additionally, with a few exceptions, as of December 30, 2022, we are no longer subject to state, local, or foreign examinations by the tax authorities for fiscal years ended on or before December 28, 2018.
During the next 12 months, we expect our balance of unrecognized tax benefits to decrease by $20 million related to capitalized research and development costs. While we believe we have adequate accruals for uncertain tax positions, the tax authorities may determine that we owe taxes in excess of recorded accruals or the recorded accruals may be in excess of the final settlement amounts agreed to by tax authorities.
v3.22.4
Retirement Plans
12 Months Ended
Dec. 30, 2022
Retirement Benefits [Abstract]  
Retirement Plans
Note 19—Retirement Plans
Defined Contribution Plans
We sponsor various defined contribution plans in which most employees are eligible to participate. These plans allow eligible participants to contribute a portion of their income through payroll deductions and Leidos may also make discretionary contributions. Company contributions were $145 million, $131 million and $120 million for fiscal 2022, 2021 and 2020, respectively.
Deferred Compensation Plans
We maintain three deferred compensation plans, the Keystaff Deferral Plan ("KDP"), the KESDP and the MSCP (the "Plans"), for the benefit of certain management or highly compensated employees or members of the Board of Directors. The Plans allow eligible participants to elect to defer a portion of their salary, and all or a portion of certain bonuses, including restricted stock unit awards. Directors may also elect to defer their cash compensation in addition to their restricted stock unit awards. Deferred balances in the Plans are paid in lump sum or installments upon retirement, termination or the elected specified date.
We do not make any contributions to the KDP but maintain participant accounts for deferred amounts and investments. We maintain a rabbi trust for the purpose of funding benefit payments to the KDP participants. Participants may allocate deferred salary and cash bonus amounts into a variety of designated investment options, with gains and losses based on the elected investment option performance with the participant assuming all risks related to future returns of their contributions.
Under the KESDP, eligible participants may elect to defer in share units all or a portion of certain cash bonuses and restricted stock unit awards granted under the previous 2006 Equity Incentive Plan and the current 2017 Omnibus Incentive Plan (see "Note 17—Stock-Based Compensation"). Under the MSCP, restricted stock share units are fully vested and no further deferrals into the plan are made. We do not make any contributions to the accounts of KESDP or MSCP participants. Benefits from the KESDP and MSCP are payable in shares of Leidos common stock held in a rabbi trust for the purpose of funding benefit payments to KESDP and MSCP participants.
Defined Benefit Plans
We sponsor two frozen defined benefit pension plans ("the Plans"), one in the United Kingdom ("UK") for former employees on an expired customer contract and another assumed as a result of the Gibbs & Cox acquisition.
On May 20, 2022, the trustee of our UK defined benefit pension plan (the “Plan”) invested the assets of the Plan in a bulk purchase annuity policy to fully insure the benefits payable to the members of the Plan. As the buy-in transaction insured the defined benefit obligation, we do not anticipate material future contributions.
The bulk purchase annuity policy is structured to enable the Plan to move to a full buy-out, at which time the insurer would become directly responsible for all pension payments and we would be relieved of our obligations under the Plan. At this future date, a settlement loss will be recognized for an amount equal to any unamortized loss associated with the Plan recorded within AOCI and any remaining net plan assets of the Plan will be remitted to the Company. As of December 30, 2022, the unamortized loss within AOCI related to the Plan was $20 million and the Plan had net assets of $7 million.
The projected benefit obligation of the Plans as of December 30, 2022 and December 31, 2021, was $101 million and $160 million, respectively. The decrease in the projected benefit obligation was primarily due to assumption changes and an actuarial gain.
The fair value of the Plans assets as of December 30, 2022, and December 31, 2021, was $101 million and $189 million, respectively. The decrease was primarily driven by assumption changes to reflect the fair value of the annuity contract and return on plan assets. The UK Plan funding status was overfunded $7 million and $37 million as of December 30, 2022, and December 31, 2021, respectively. The Gibbs & Cox defined benefit pension plan funding status was underfunded $7 million and $8 million as of December 30, 2022, and December 31, 2021, respectively. The fair value of Plans assets has been included within "Other long-term liabilities" on the consolidated balance sheets.
Other
We also sponsor multiemployer defined benefit pension plans and a defined contribution plan (a 401(k) plan) (the "Sponsored Plans") for employees working on two U.S. government contracts. As part of the contractual agreements, the customers reimburse Leidos for contributions made to these Sponsored Plans as these costs are allowable under government contract cost accounting requirements. If we were to cease being the contractor as a result of a recompetition process, the defined benefit pension plans and related plan assets and liabilities would transfer to the new contractor. If the contract expires or is terminated with no transfer of the pension plan to a successor contractor, any amount by which the plan liabilities exceed plan assets, as of that date, will be reimbursed by the U.S. government customer. Since we are not responsible for the current or future funded status of the pension plans, no assets or liabilities arising from their funded status are recorded in the consolidated financial statements and no amounts associated with these pension plans are included in the defined benefit plan disclosures above.
v3.22.4
Business Segments
12 Months Ended
Dec. 30, 2022
Segment Reporting [Abstract]  
Business Segments
Note 20—Business Segments
Our operations and reportable segments are organized around the customers and markets we serve. We define our reportable segments based on the way the chief operating decision maker ("CODM"), currently the Chairman and Chief Executive Officer, manages the operations for purposes of allocating resources and assessing performance.
Our business is aligned into three reportable segments (Defense Solutions, Civil and Health). Additionally, we separately present the unallocable costs associated with corporate functions as Corporate.
Effective July 3, 2021, certain contracts were reassigned from the Defense Solutions reportable segment to the Civil reportable segment. Impact on prior year segment results were determined to be immaterial and have not been recast to reflect this change.
Defense Solutions provides leading-edge and technologically advanced services, solutions and products to a broad customer base. Our ever-changing technologies and innovations cover a wide spectrum of markets with primary areas of concentration in digital modernization, mission systems and integration, Command, Control, Computers, Communications, Intelligence, Surveillance and Reconnaissance ("C4ISR") technologies and services, maritime solutions, transformative software, analytics, intelligence analysis, mission support and logistics services, weapons systems and space systems and solutions. We are dedicated to delivering cost-effective solutions backed by innovation-generating research and development to meet the evolving missions of our customers. We provide a diverse portfolio of national security solutions and systems for air, land, sea, space and cyberspace for the U.S. Intelligence Community, the DoD, the Space Development Agency, the National Aeronautics and Space Administration, Defense Information Systems Agency, military services, government agencies of U.S. allies abroad and other federal and commercial customers in the national security industry. We are heavily engaged in the top defense Research Development Test and Evaluation priorities that are driven by critical evolving threat-driven needs. Our solutions deliver innovative technology, large-scale systems, command and control platforms, data analytics, logistics and cybersecurity solutions, as well as intelligence analysis and operations support to critical missions around the world.
Our Civil business is focused on modernizing infrastructure, systems and security for government and commercial customers both domestically and internationally. By applying leading science, innovative technologies and business acumen, our talented employees help customers achieve their missions and take on the connected world with data-driven insights, improved efficiencies and technological advantages in the areas of digital modernization, energy infrastructure, integrated missions, transportation applications and security detection.
Our Health business focuses on delivering effective and affordable solutions to federal and commercial customers that are responsible for the health and well-being of people worldwide, including service members and veterans. Our solutions enable customers to deliver on the health mission of providing high-quality, cost-effective care, and are accomplished through the integration of information technology, engineering, life sciences, health services, clinical insights and health policy. The capabilities we provide predominantly fall in four major areas of activity: health information management services, managed health services, digital modernization and life sciences research and development.
Corporate includes the operations of various corporate activities, certain corporate expense items that are not reimbursed by our U.S. government customers and certain other expense items excluded from a reportable segment's performance.
The following table summarizes business segment information for the periods presented:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Revenues:  
Defense Solutions$8,244 $8,032 $7,341 
Civil3,464 3,157 2,994 
Health2,688 2,548 1,962 
Total revenues$14,396 $13,737 $12,297 
Operating income (loss):  
Defense Solutions$541 $569 $506 
Civil234 248 280 
Health421 442 235 
Corporate(108)(107)(23)
Total operating income$1,088 $1,152 $998 
Amortization of intangible assets:  
Defense Solutions$130 $121 $92 
Civil70 73 66 
Health30 34 40 
Total amortization of intangible assets$230 $228 $198 
The income statement performance measures used to evaluate segment performance are revenues and operating income. As a result, "Interest expense, net," "Other expense, net," and "Income tax expense," as reported in the consolidated financial statements are not allocated to our segments. Under U.S. government Cost Accounting Standards, indirect costs including depreciation expense are collected in indirect cost pools, which are then collectively allocated out to the reportable segments based on a representative causal or beneficial relationship of the costs in the pool to the costs in the base. While depreciation expense is a component of the allocated costs, the allocation process precludes depreciation expense from being specifically identified by the individual reportable segments. For this reason, depreciation expense by reportable segment has not been reported above.
Asset information by segment is not a key measure of performance used by the CODM.
We generated approximately 86% of our total revenues in fiscal 2022, and 87% in fiscal 2021 and 2020 from contracts with the U.S. government, either as a prime contractor or a subcontractor to other contractors engaged in work for the U.S. government. Revenues under contracts with the DoD and U.S. Intelligence Community, including subcontracts under which the DoD or the U.S. Intelligence Community is the ultimate purchaser, represented approximately 44% of our total revenues for fiscal 2022, 44% for fiscal 2021 and 49% for fiscal 2020.
Approximately 8% of our revenues and tangible long-lived assets are generated by or owned by entities outside of the United States. As such, additional financial information by geographic location is not presented.
v3.22.4
Commitments and Contingencies
12 Months Ended
Dec. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 21—Commitments and Contingencies
Legal Proceedings
We are involved in various claims and lawsuits arising in the normal conduct of our business, none of which, in the opinion of management, based upon current information, will likely have a material adverse effect on our financial position, results of operations or cash flows.
Contingencies
VirnetX, Inc. ("VirnetX")
On April 10, 2018, a jury trial concluded in an additional patent infringement case brought by VirnetX against Apple, referred to as the Apple II case, in which the jury returned a verdict against Apple for infringement and awarded VirnetX damages in the amount of over $502 million. On April 11, 2018, in a second phase of the Apple II trial, the jury found Apple's infringement to be willful. On August 30, 2018, the federal trial court in the Eastern District of Texas entered a final judgment and rulings on post-trial motions in the Apple II case. The court affirmed the jury’s verdict of over $502 million and granted VirnetX’s motions for supplemental damages, a sunset royalty and royalty rate of $1.20 per infringing device, along with pre-judgment and post-judgment interest and costs. The court denied VirnetX’s motions for enhanced damages, attorneys’ fees and an injunction. The court also denied Apple’s motions for judgment as a matter of law and for a new trial. An additional sum of over $93 million for costs and pre-judgment interest was subsequently agreed upon pursuant to a court order, bringing the total award to VirnetX in the Apple II case to over $595 million. Apple filed an appeal of the judgment in the Apple II case with the U.S. Court of Appeals for the Federal Circuit, and on November 22, 2019, the Federal Circuit affirmed in part, reversed in part and remanded the Apple II case back to the District Court. The Federal Circuit affirmed that Apple infringed two of the patents at issue in the case, and ruled that Apple is precluded from making certain patent invalidity arguments. However, the Federal Circuit reversed the judgment that Apple infringed two other patents at issue, vacated the prior damages awarded in the Apple II case, and remanded the Apple II case back to the District Court for further proceedings regarding damages. On April 23, 2020, the District Court ordered a new trial on damages in the Apple II case, which was delayed by the coronavirus pandemic and started on October 26, 2020. On October 30, 2020, the jury awarded VirnetX $503 million in damages and specified a royalty rate of $0.84 per infringing device. In January 2021, the District Court entered final judgment affirming the jury award and the parties separately agreed on additional costs and interest of over $75 million, subject to Apple's appeal. On February 4, 2021, Apple filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit in the Apple II case.
Under our agreements with VirnetX, Leidos would receive 25% of the proceeds obtained by VirnetX after reduction for attorneys' fees and costs. However, the verdict in the Apple II case remains subject to the ongoing and potential future proceedings and appeals. In addition, the patents at issue in these cases are subject to U.S. Patent and Trademark Office post-grant inter partes review and/or reexamination proceedings and related appeals, which may result in all or part of these patents being invalidated or the claims of the patents being limited. Thus, no assurances can be given when or if we will receive any proceeds in connection with these jury awards. In addition, if Leidos receives any proceeds, we are required to pay a royalty to the customer who paid for the development of the technology.
Government Investigations and Reviews
We are routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect to our role as a contractor to federal, state and local government customers and in connection with performing services in countries outside of the United States. Adverse findings could have a material effect on our business, financial position, results of operations and cash flows due to our reliance on government contracts.
Defense Contract Audit Agency
As of December 30, 2022, active indirect cost audits by the DCAA remain open for fiscal 2021 and subsequent fiscal years. Although we have recorded contract revenues based upon an estimate of costs that we believe will be approved upon final audit or review, we cannot predict the outcome of any ongoing or future audits or reviews and adjustments and, if future adjustments exceed estimates, our profitability may be adversely affected. As of December 30, 2022, we believe we have adequately reserved for potential adjustments from audits or reviews of contract costs.
Other Government Investigations and Reviews
Through its internal processes, the Company discovered, in late 2021, activities by its employees, third party representatives and subcontractors, raising concerns related to a portion of our business that conducts international operations. The Company is conducting an internal investigation, overseen by an independent committee of the Board of Directors, with the assistance of external legal counsel, to determine whether the identified conduct may have violated the Company’s Code of Conduct and potentially applicable laws, including the U.S. Foreign Corrupt Practices Act ("FCPA"). The Company has voluntarily self-reported this investigation to the Department of Justice and the Securities and Exchange Commission and is cooperating with both agencies. Because the investigation is ongoing, the Company cannot anticipate the timing, outcome or possible impact of the investigation, although violations of the FCPA and other applicable laws may result in criminal and civil sanctions, including monetary penalties, and reputational damage. In September 2022, the Company received a Federal Grand Jury Subpoena related to the criminal investigation by the U.S. Attorney’s Office for the Southern District of California, in conjunction with the U.S. Department of Justice’s Fraud Section. The subpoena requests documents relating to the conduct that is the subject of the Company’s internal investigation. The Company is in the process of responding to the subpoena.
In August 2022, the Company received a Federal Grand Jury Subpoena in connection with a criminal investigation being conducted by the U.S. Department of Justice Antitrust Division (“DOJ”). The subpoena requests that the Company produce a broad range of documents related to three U.S. Government procurements associated with the Company’s Intelligence Group in 2021 and 2022. We intend to fully cooperate with the investigation, and we are conducting our own internal investigation with the assistance of outside counsel. It is not possible at this time to determine whether we will incur, or to reasonably estimate the amount of, any fines, penalties, or further liabilities in connection with the investigation pursuant to which the subpoena was issued.
Commitments
We have outstanding letters of credit of $72 million as of December 30, 2022, principally related to performance guarantees on contracts. We also have outstanding surety bonds with a notional amount of $100 million as of December 30, 2022, principally related to performance and subcontractor payment bonds on contracts. The value of the surety bonds may vary due to changes in the underlying project status and/or contractual modifications. We also have future lease commitments of $74 million for the use of certain aircraft.
As of December 30, 2022, the future expirations of the outstanding letters of credit, surety bonds and future lease commitments were as follows:
Fiscal year ending
(in millions)
2023$60 
2024104 
202537 
202619 
202722 
2028 and thereafter
$246 
v3.22.4
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 30, 2022
Accounting Policies [Abstract]  
Accounting Standards Updates Adopted and Updates Issued But Not Yet Adopted
Accounting Standards Updates Adopted
ASU 2021-08, Business Combinations (Topic 805)
In October 2021, the FASB issued ASU 2021-08, which amends how contract assets and liabilities acquired in a business combination are measured. Current guidance requires contract assets and liabilities to be measured at fair value in accordance with ASC 805, Business Combinations. The amendments in this Update remove the requirement to measure contract assets and liabilities at fair value and instead require that they be recognized in accordance with ASC 606, Revenue from Contracts with Customers.
We adopted the requirements of ASU 2021-08 using the prospective method effective the first day of fiscal 2022. For business combinations occurring after adoption, we measured contract assets and liabilities acquired in accordance ASC 606.
Accounting Standards Updates Issued But Not Yet Adopted
ASU 2020-04, ASU 2021-01, and ASU 2022-06 Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, which provides companies with optional expedients and exceptions to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. This update provides optional expedients for applying accounting guidance to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this update are effective for all entities as of March 2020 and can be adopted using a prospective approach no later than December 31, 2022.
In January 2021, the FASB issued ASU 2021-01 which amends the scope of ASU 2020-04. The amendments in this
update are elective and provide optional relief for entities with hedge accounting and contract modifications affected
by the discounting transition through December 31, 2022. In December 2022, the FASB issued ASU 2022-06 which extends the deadline for application of ASU 2021-01 through December 31, 2024. Under this relief, entities may continue to account for contract modifications as a continuation of the existing contract and the continuation of the hedge accounting arrangement. We are currently evaluating the impacts of the reference rate reform. Except for our new $380 million term loan entered into on May 6, 2022 (see "Note 13—Debt"), we currently use the one-month LIBOR for which the rate publication will cease in June 2023.
Reporting Periods
Reporting Periods
Leidos' fiscal year ends on the Friday nearest the end of December. Fiscal 2022 ended December 30, 2022. Fiscal 2022, 2021 and 2020 each included 52 weeks.
Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, right-of-use ("ROU") assets and lease liabilities, fair value and impairment of intangible assets and goodwill, income taxes, pension benefits, stock-based compensation expense and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates.
Operating Cycle Operating CycleOur operating cycle for long-term contracts may be greater than one year and is measured by the average time intervening between the inception and the completion of those contracts.
Business Combinations Business CombinationsThe accounting for business combinations requires management to make judgments and estimates related to the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities and contingencies assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with an acquisition. Estimating the fair value of acquired assets and assumed liabilities, including intangibles, requires judgments about expected future cash flows, weighted-average cost of capital, discount rates and expected long-term growth rates.
Investments
Investments
Investments in entities and corporate joint ventures where we have a non-controlling ownership interest but over which we have the ability to exercise significant influence, are accounted for under the equity method of accounting. We recognize our proportionate share of the entities' net income or loss and do not consolidate the entities' assets and liabilities.
Equity investments in entities over which we do not have the ability to exercise significant influence and whose securities do not have a readily determinable fair value are carried at cost or cost net of other-than-temporary impairments.
Variable Interest Entities
Variable Interest Entities
We occasionally form joint ventures and/or enter into arrangements with special purpose limited liability companies for the purpose of bidding and executing on specific projects. We analyze each such arrangement to determine whether it represents a VIE. If the arrangement is determined to be a VIE, we assess whether we are the primary beneficiary of the VIE and are consequently required to consolidate the VIE.
Divestitures DivestituresFrom time-to-time, we may dispose (or management may commit to plans to dispose) of strategic or non-strategic components of the business. Divestitures representing a strategic shift that has (or will have) a major effect in operations and financial results are classified as discontinued operations, whereas non-strategic divestitures remain in continuing operations.
Restructuring Expenses
Restructuring Expenses
Restructuring expenses are incurred in connection with programs aimed at reducing our costs. Restructuring costs may include one-time termination of benefits, costs to terminate contracts and other permanent exit costs to consolidate or close facilities directly related to the restructuring program.
One-time involuntary termination benefits are recognized as a liability at estimated fair value when the plan of termination has been communicated to employees and certain other criteria are met. Ongoing termination benefit arrangements are recognized as a liability at estimated fair value when it is probable that amounts will be paid and such amounts are reasonably estimable. Costs associated with exit or disposal activities, including the related one-time and ongoing involuntary termination benefits, are included as "Acquisition, integration and restructuring costs" on the consolidated statements of income.
Revenue Recognition
Revenue Recognition
Our revenues from contracts with customers are from offerings including digital modernization, cyber operations, mission software systems, integrated systems and mission operations, primarily with the U.S. government and its agencies. We also serve various state and local governments, foreign governments and commercial customers.
We perform under various types of contracts, which include firm-fixed-price ("FFP"), time-and-materials ("T&M"), fixed-price-level-of-effort ("FP-LOE"), cost-plus-fixed-fee ("CPFF"), cost-plus-award-fee, cost-plus-incentive-fee and fixed-price-incentive-fee ("FP-IF") contracts.
To determine the proper revenue recognition, we first evaluate whether we have a duly approved and enforceable contract with a customer, in which the rights of the parties and payment terms are identified, and collectability is probable. We also evaluate whether two or more contracts should be combined and accounted for as a single contract, including the task orders issued under an indefinite delivery/indefinite quantity ("IDIQ") award. In addition, we assess contract modifications to determine whether changes to existing contracts should be accounted for as part of the original contract or as a separate contract. Contract modifications generally relate to changes in contract specifications and requirements and do not add distinct services, and therefore are accounted for as part of the original contract. If contract modifications add distinct goods or services and increase the contract value by an amount that reflects the standalone selling price, those modifications are accounted for as separate contracts.
Most of our contracts are comprised of multiple promises including the design and build of software-based systems, integration of hardware and software solutions, running and maintaining of IT infrastructure and procurement services. In all cases, we assess if the multiple promises should be accounted for as separate performance obligations or combined into a single performance obligation. We generally separate multiple promises in a contract as separate performance obligations if those promises are distinct, both individually and in the context of the contract. If multiple promises in a contract are highly interrelated or require significant integration or customization within a group, they are combined and accounted for as a single performance obligation.
Our contracts with the U.S. government often contain options to renew existing contracts for an additional period of time (generally a year at a time) under the same terms and conditions as the original contract, and generally do not provide the customer any material rights under the contract. We account for renewal options as separate contracts when they include distinct goods or services at standalone selling prices.
Contracts with the U.S. government are subject to the Federal Acquisition Regulation ("FAR") and priced on estimated or actual costs of providing the goods or services. The FAR provides guidance on types of costs that are allowable in establishing prices for goods and services provided to the U.S. government and its agencies. Each contract is competitively priced and bid separately. Pricing for non-U.S. government agencies and commercial customers is based on specific negotiations with each customer. In circumstances where the standalone selling price is not directly observable, we estimate the standalone selling price using the expected cost-plus margin approach. Any taxes collected or imposed when determining the transaction price are excluded.
Certain cost-plus and fixed-price contracts contain award fees, incentive fees or other provisions that may either increase or decrease the transaction price. These variable amounts generally are awarded upon achievement of certain performance metrics, program milestones or cost targets and can be based upon customer discretion. We estimate variable consideration at the most probable amount that we expect to be entitled to, based on the assessment of the contractual variable fee criteria, complexity of work and related risks, extent of customer discretion, amount of variable consideration received historically and the potential of significant reversal of revenue.
We allocate the transaction price of a contract to its performance obligations in the proportion of its respective standalone selling prices. The standalone selling price of the performance obligations is generally based on an expected cost-plus margin approach, in accordance with the FAR. For certain product sales, prices from other standalone sales are used. Substantially all of our contracts do not contain a significant financing component, which would require an adjustment to the transaction price of the contract.
We recognize revenue on our service-based contracts primarily over time as there is continuous transfer of control to the customer over the duration of the contract as the promised services are performed. For U.S. government contracts, continuous transfer of control to the customer is evidenced by clauses in the contract that allow the customer to unilaterally terminate the contract for convenience, pay for costs incurred plus a reasonable profit and take control of any work-in-process. Similarly, for non-U.S. government contracts, the customer typically controls the work-in-process as evidenced by rights to payment for work performed to date plus a reasonable profit to deliver products or services for which we do not have an alternate use. Anticipated losses on service-based contracts are recognized when incurred (generally on a straight-line basis) over the contract term. In certain product sales, where the products have an alternate use, revenue is recognized at a point in time when the customer takes control of the asset usually denoted by possession, transfer of legal title and acceptance by the customer.
On FFP contracts requiring system integration and cost-plus contracts with variable consideration, revenue is recognized over time generally using a method that measures the extent of progress towards completion of a performance obligation, principally using a cost-input method (referred to as the cost-to-cost method). Under the cost-to-cost method, revenue is recognized based on the proportion of total costs incurred to estimated total costs-at-completion ("EAC"). A performance obligation's EAC includes all direct costs such as materials, labor, subcontract costs, overhead and a ratable portion of general and administrative costs. In addition, an EAC of a performance obligation includes future losses estimated to be incurred on onerous contracts, as and when known. On certain other contracts, principally T&M, FP-LOE and CPFF, revenue is generally recognized using the right-to-invoice practical expedient as we are contractually able to invoice the customer based on the control transferred to the customer. Additionally, on maintenance (generally FFP) performance obligations, revenue is recognized over time using a straight-line method as the control of the services is provided to the customer evenly over the period of performance.
For certain performance obligations where we are not primarily responsible for fulfilling the promise to provide the goods or service to the customer, do not have inventory risk and do not have discretion in establishing the price for the goods or service, we recognize revenue on a net basis.
Contract Costs
Contract costs generally include direct costs such as labor, materials, subcontract costs and indirect costs identifiable with or allocable to a specific contract. Costs are expensed as incurred unless they qualify for deferral and capitalization. Contract costs incurred for U.S. government contracts, including indirect costs, are subject to audit and adjustment by the Defense Contract Audit Agency ("DCAA") (see "Note 21—Commitments and Contingencies").
Pre-contract Costs
Costs incurred on projects as pre-contract costs are deferred as assets when we have been requested by the customer to begin work under a new arrangement prior to contract execution and it is probable that we will recover the costs through the issuance of a contract. Pre-contract costs are amortized over the contract period of performance or a specified period of performance.
Transition Costs
Under certain service contracts, costs are incurred, usually at the beginning of the contract performance, to transition the services, employees and equipment to or from the customer, a prior contract or prior contractor. These costs are generally capitalized as deferred assets and amortized on a straight-line basis over the anticipated term of the contract or a specified period of performance, including unexercised option periods that are reasonably certain of being exercised.
Project Assets
Purchases of project assets are capitalized for specific contracts where we maintain ownership of the asset over the life of the contract and the benefit is received over a period of time. Project assets include enterprise software licenses, dedicated hardware, maintenance agreements and significant material purchases and other costs incurred on contracts. Project assets are amortized from the balance sheet using the straight-line method over the estimated useful life of the asset or over the expected term of the period of performance, whichever is shorter.
Changes in Estimates on Contracts
Changes in Estimates on Contracts
Changes in estimates related to contracts accounted for using the cost-to-cost method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes, with the exception of contracts acquired through a business combination, where the adjustment is made for the period commencing from the date of acquisition.
The impact on diluted earnings per share ("EPS") attributable to Leidos common stockholders is calculated using our statutory tax rate.The changes primarily relate to revisions of variable consideration, including award and incentive fees, and revisions to estimates at completion resulting from changes in contract scope, mitigation of contract risks or due to true-ups of contract estimates at the end of contract performance.
Selling, General and Administrative Expenses
Selling, General and Administrative Expenses
We classify indirect costs incurred within or allocated to our U.S. government customers as overhead (included in "Cost of revenues") or general and administrative expenses in the same manner as such costs are defined in our disclosure statements under U.S. government Cost Accounting Standards.
Selling, general and administrative expenses include general and administrative, bid and proposal, company-funded research and development expenses, and legal fees and settlements.
We conduct research and development activities under customer-funded contracts and with company-funded research and development funds. Company-funded research and development expense was $116 million, $109 million and $73 million for fiscal 2022, 2021 and 2020, respectively. Expenses for research and development activities performed under customer contracts are charged directly to cost of revenues for those contracts.
Income Taxes
Income Taxes
We account for income taxes under the asset and liability method in accordance with the accounting standard for income taxes. The asset and liability method requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities. Under this method, changes in tax rates and laws are recognized in income in the period such changes are enacted.
We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations. If we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount or would no longer be able to realize our deferred income tax assets in the future as currently recorded, we would make an adjustment to the valuation allowance which would decrease or increase the provision for income taxes.
The provision for federal, state, foreign and local income taxes is calculated on income before income taxes based on current tax law and includes the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Such provision differs from the amounts currently payable because certain items of income and expense are recognized in different reporting periods for financial reporting purposes than for income tax purposes.
We record liabilities for uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. We recognize interest and penalties related to uncertain tax positions in our income tax expense.
Cash and Cash Equivalents Cash and Cash EquivalentsOur cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less. Outstanding payments are included within "Cash and cash equivalents" and "Accounts payable and accrued liabilities" correspondingly on the consolidated balance sheets.
Restricted Cash
Restricted Cash
We have restricted cash balances, primarily representing advances from customers that are restricted as to use for certain expenditures related to that customer's contract. Restricted cash balances are included as "Other current assets" on the consolidated balance sheets. Our restricted cash balances were $167 million and $148 million at December 30, 2022, and December 31, 2021, respectively.
Receivables
Receivables
Receivables include amounts billed and currently due from customers, amounts billable where the right to consideration is unconditional and amounts unbilled. Amounts billable and unbilled amounts are recognized at estimated realizable value and consist of costs and fees, substantially all of which are expected to be billed and collected generally within one year. Unbilled amounts also include rate variances that are billable upon negotiation of final indirect rates with the Defense Contract Management Agency.
Cost-reimbursable and T&M contracts are generally billed as costs are incurred. FFP contracts are billed either based on milestones, which are the achievement of specific events as defined in the contract, or based on progress payments, which are interim payments up to a designated amount of costs incurred as work progresses. On certain contracts, the customer withholds a certain percentage of the contract price (retainage). These withheld amounts are included within unbilled receivables and are billed upon contract completion or the occurrence of a specified event, and when negotiation of final indirect rates with the U.S. government is complete. Based on our historical experience, the write-offs of retention balances have not been significant.
When events or conditions indicate that amounts outstanding from customers may become uncollectible, an allowance is estimated and recorded.
Amounts billed and collected on contracts but not yet recorded as revenue because we have not performed our obligation under the arrangement with a customer are deferred and included within "Accounts payable and accrued liabilities" or "Other long-term liabilities" on the consolidated balance sheets.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially subject us to concentrations of credit risk primarily consist of accounts receivable and derivatives. Since our receivables are primarily with the U.S. government, we do not have exposure to a material credit risk. We manage our credit risk related to derivatives through the use of multiple counterparties with high credit standards.
Inventories
Inventories
Inventories are valued at the lower of cost or estimated net realizable value. Generally, raw material inventory is valued using the average cost method. Work-in-process inventory may include material costs, labor and allocable overhead costs. The majority of finished goods inventory consists of technology and security products, inspection systems, baggage scanning equipment and small glide munitions. Inventory is evaluated against historical or planned usage to determine appropriate provisions for obsolete inventory.
Goodwill
Goodwill
Goodwill represents the excess of the fair value of consideration transferred, plus the fair value of any non-controlling interests in the acquiree, over the fair value of the net assets acquired and liabilities assumed as of the acquisition date. Goodwill is not amortized, but instead is tested annually for impairment at the reporting unit level and tested more frequently if events or circumstances indicate that the carrying value of the reporting unit may not be recoverable. Our policy is to perform our annual goodwill impairment evaluation as of the first day of the fourth quarter of our fiscal year. During both fiscal 2022 and 2021, we had seven reporting units for the purpose of testing goodwill for impairment.
Goodwill is evaluated for impairment either under a qualitative assessment option or a quantitative approach, which depends on the facts and circumstances of a reporting unit, consideration of the excess of a reporting unit's fair value over its carrying amount in previous assessments and changes in business environment.
When performing a qualitative assessment, we consider factors including, but not limited to, current macroeconomic conditions, industry and market conditions, cost factors, financial performance and other events relevant to the entity or reporting unit under evaluation to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If we determine that it is more likely than not that a reporting unit's fair value is less than its carrying value, a quantitative goodwill impairment test is performed.
When performing a quantitative goodwill impairment test, the reporting unit carrying value is compared to its fair value. Goodwill is deemed impaired if, and the impairment loss is recognized for the amount by which, the reporting unit carrying value exceeds its fair value.
We estimate the fair value of each reporting unit using Level 3 inputs when a quantitative analysis is performed. These analyses rely on significant judgements and assumptions about expected future cash flows, weighted-average cost of capital, discount rates, expected long-term growth rates, operating margins and on the selection of guideline public companies.
Intangible Assets
Intangible Assets
Acquired intangible assets with finite lives and internally developed software are amortized using the method that best reflects how their economic benefits are utilized or, if a pattern of economic benefits cannot be reliably determined, on a straight-line basis over their estimated useful lives. Program intangible assets are amortized over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows. Backlog and trade name intangible assets are amortized on a straight-line basis over their estimated useful lives. Customer relationships and software and technology intangible assets are amortized either on a straight-line basis over their estimated useful lives or over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows, as deemed appropriate.
Intangible assets with finite lives are amortized over the following periods:
 Estimated useful lives (in years)
Backlog
1
Customer relationships
8-10
Programs
4-13
Software and technology
3-15
Trade names3
Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
Intangible assets with indefinite lives are not amortized but are assessed for impairment at the beginning of the fourth quarter and whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
Property, Plant and Equipment
Property, Plant and Equipment
Purchases of property, plant and equipment, including purchases of software and software licenses, as well as costs associated with major renewals and improvements are capitalized. Maintenance, repairs and minor renewals and improvements are expensed as incurred.
Construction in Progress ("CIP") is used to accumulate all costs for projects that are not yet complete. CIP balances are transferred to the appropriate asset account when the asset is capitalized and ready for its intended use.
When assets are sold or otherwise disposed of, the cost and related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is recognized. Depreciation is recognized using the methods and estimated useful lives as follows:
 Depreciation methodEstimated useful lives (in years)
Computers and other equipmentStraight-line or declining-balance
2-15
Buildings Straight-line
Not to exceed 40
Building improvements and leasehold improvements
Straight-lineShorter of useful life of asset or remaining lease term
Vehicles and transportation equipmentStraight-line
2-15
Office furniture and fixturesStraight-line or declining-balance
6-9
We evaluate our long-lived assets for potential impairment whenever there is evidence that events or changes in circumstances indicate that the carrying value may not be recoverable and the carrying value of the asset exceeds its estimated fair value.
Leases, Lessee
Lessee
We have facilities and equipment lease arrangements. An arrangement is determined to be a lease at inception if it conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities represent the obligation to make lease payments arising from the lease.
ROU assets and lease liabilities are recorded on the consolidated balance sheet at lease commencement date based on the present value of the future minimum lease payments over the lease term. We generally do not know the discount rate implicit in our leases; therefore, the discount rate used is our incremental borrowing rate which is determined based on the rate of interest that we would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term. An ROU asset is initially measured by the present value of the remaining lease payments, plus initial direct costs and prepaid lease payments, less any lease incentives received before commencement. The remaining lease cost is allocated over the remaining lease term on a straight-line basis unless another systematic or rational basis is more representative of the pattern in which the underlying asset is expected to be used.
Certain facility leases contain options to renew or extend the terms of the lease which are included in the determination of the ROU assets and lease liabilities when it is reasonably certain that we will exercise the option. Leases may also include variable lease payments such as an escalation clause based on consumer price index rates, maintenance costs and utilities. Variable lease payments that depend on an index or a rate are included in the determination of ROU assets and lease liabilities using the index or rate at the lease commencement date, whereas variable lease payments that do not depend on an index or rate are recorded as lease expense in the period incurred. At December 30, 2022, certain of the Company's equipment leases include residual value guarantees.
We use the practical expedient to not separate non-lease components from lease components and instead account for both components as a single lease. The practical expedient is applied to all material classes of leased assets except for aircraft, for which we account for the lease component and non-lease component separately.
The related lease payments on short-term facilities and equipment leases are recognized as expense on a straight-line basis over the lease term.
ROU assets are evaluated for impairment in a manner consistent with the treatment of other long-lived assets. ROU assets are assessed for potential impairment whenever there is evidence that events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and the carrying amount of the asset exceeds its estimated fair value. This includes an establishment of a plan of abandonment, which occurs when we have committed to a plan to abandon the lease before the end of its previously estimated useful life and there is no expectation that we will re-enter or re-purpose the space.
Leases, Lessor
Lessor
We are a lessor on certain equipment sales-type and operating lease arrangements with our customers. To be considered lease revenue, the contract must contain a specified asset, we must not have a substantive substitution right, the customer must have the right to direct the use of the specified asset during the period of use and the customer must have the right to obtain substantially all of the economic benefit of the specified asset.
Certain arrangements may contain variable payments that depend on an index or rate and are measured using the index or rate on the commencement date. Variable payments that are not included in the net investments are recorded as revenue as incurred. Arrangements may also contain options to renew or extend the performance period. Option periods are included in the lease term if we determine that it is reasonably certain the customer will exercise an option.
We have arrangements that contain both lease and non-lease components. We account for them as one unit of account if the timing and pattern of transfer is identical for both the lease and the non-lease components and the lease component would be classified as an operating lease if accounted for separately. If both criteria are met and the predominant component is a lease, then the entire arrangement will be accounted for in accordance with ASC 842. If we account for an arrangement both as a lease and non-lease component, then the allocation of consideration for each component will be based on the relative standalone sales price.
Fair Value Measurements
Fair Value Measurements
The accounting standard for fair value measurements establishes a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: observable inputs such as quoted prices in active markets (Level 1); inputs other than quoted prices in active markets for identical assets or liabilities that are observable either directly or indirectly or quoted prices that are not active (Level 2); and unobservable inputs in which there is little or no market data (e.g., discounted cash flow and other similar pricing models), which requires us to develop our own assumptions about the assumptions that market participants would use in pricing the asset or liability (Level 3).
The accounting guidance for fair value measurements requires that we maximize the use of observable inputs and minimize the use of unobservable inputs in determining fair value. The accounting guidance provides for the irrevocable option to elect, on a contract-by-contract basis, to measure certain financial assets and liabilities at fair value at inception of the contract and record any subsequent changes in fair value in earnings. We have not made fair value option elections on any of our financial assets and liabilities.
The fair value of financial instruments is determined based on quoted market prices, if available, or management's best estimate (see "Financial Instruments" below).
Management evaluates its investments for other-than-temporary impairment at each balance sheet date. When testing long-term investments for recovery of carrying value, the fair value of long-term investments is determined using various valuation techniques and factors, such as market prices of comparable companies (Level 2 input), discounted cash flow models (Level 3 input). If management determines that an other-than-temporary decline in the fair value of an investment has occurred, an impairment loss is recognized to reduce the investment to its estimated fair value. Our non-financial instruments measured at fair value on a non-recurring basis include goodwill, indefinite-lived intangible assets and long-lived tangible assets. The valuation methods used to determine fair value require a significant degree of management judgment to determine the key assumptions. As such, we generally classify non-financial instruments as either Level 2 or Level 3 fair value measurements.
Financial Instruments
Financial Instruments
We are exposed to certain market risks which are inherent in certain transactions entered into during the normal course of business. These transactions include sales or purchase contracts denominated in foreign currencies and exposure to changing interest rates. We manage our risk to changes in interest rates and foreign currency exchange rates through the use of derivative instruments.
For fixed rate borrowings, we use variable interest rate swaps, effectively converting fixed rate borrowings to variable rate borrowings. These swaps are designated as fair value hedges. The fair value of these interest rate swaps is determined based on observed values for underlying interest rates on the LIBOR yield curve (Level 2).
For variable rate borrowings, we use fixed interest rate swaps, effectively converting a portion of the variable interest rate payments to fixed interest rate payments. These swaps are designated as cash flow hedges. The fair value of these interest rate swaps is determined based on observed values for the underlying interest rates (Level 2).
We enter into foreign currency forward contracts in order to mitigate fluctuations in our earnings and cash flows due to changes in foreign currency exchange rates. The foreign currency forward contracts are not designated as hedges and hedge accounting does not apply. We do not hold derivative instruments for trading or speculative purposes.
Our defined benefit plan assets consist of investments in pooled funds that contain investments with values based on quoted market prices, but for which the pools are not valued on a daily quoted market basis (Level 2).
Stock-Based Compensation
Stock-Based Compensation
We account for stock-based compensation at the grant date based on the fair value of the award and recognize expense over the requisite service period, which is generally the vesting period, net of an estimated forfeiture rate.
The fair value of restricted stock awards and performance-based stock awards is based on the closing price of Leidos common stock on the date of grant. The fair value of performance-based stock awards with market conditions is based on using a Monte Carlo simulation.
The fair value of stock option awards granted is based on using the Black-Scholes-Merton option pricing model. The estimation of stock option fair value requires management to make estimates and judgments about, among other things, employee exercise behavior, forfeiture rates and the expected volatility of Leidos common stock over the expected option term. These judgments directly affect the amount of compensation expense that will ultimately be recognized.
Foreign Currency
Foreign Currency
The financial statements of consolidated international subsidiaries, for which the functional currency is not the U.S. dollar, are translated into U.S. dollars using the exchange rate at each balance sheet date for assets and liabilities and a weighted average exchange rate over the reporting period for revenues, expenses, gains and losses. Translation adjustments are recorded as accumulated other comprehensive loss in stockholders' equity. Gains and losses due to movements in foreign currency exchange rates are recognized as "Other expense, net" on the consolidated statements of income.
v3.22.4
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 30, 2022
Accounting Policies [Abstract]  
Schedule of Changes in Estimates on Contracts for the Periods Presented Changes in estimates on contracts for the periods presented were as follows:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions, except for per share amounts)
Favorable impact
$146 $149 $137 
Unfavorable impact
(113)(102)(61)
Net favorable impact to income before income taxes
$33 $47 $76 
Impact on diluted EPS attributable to Leidos common stockholders
$0.17 $0.25 $0.39 
Schedule of Finite-Lived Intangible Assets Intangible assets with finite lives are amortized over the following periods:
 Estimated useful lives (in years)
Backlog
1
Customer relationships
8-10
Programs
4-13
Software and technology
3-15
Trade names3
Schedule of Depreciation Using Estimated Useful Lives Depreciation is recognized using the methods and estimated useful lives as follows:
 Depreciation methodEstimated useful lives (in years)
Computers and other equipmentStraight-line or declining-balance
2-15
Buildings Straight-line
Not to exceed 40
Building improvements and leasehold improvements
Straight-lineShorter of useful life of asset or remaining lease term
Vehicles and transportation equipmentStraight-line
2-15
Office furniture and fixturesStraight-line or declining-balance
6-9
Property, plant and equipment, net consisted of the following:
 December 30,
2022
December 31,
2021
 (in millions)
Computers and other equipment$399 $373 
Leasehold improvements404 367 
Vehicles and transportation equipment210 99 
Buildings and improvements138 140 
Office furniture and fixtures64 65 
Land17 18 
Construction in progress147 78 
 1,379 1,140 
Less: accumulated depreciation and amortization(532)(470)
 $847 $670 
v3.22.4
Revenues (Tables)
12 Months Ended
Dec. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregated Revenue
Disaggregated revenues by customer-type were as follows:
Year Ended December 30, 2022
Defense SolutionsCivilHealthTotal
(in millions)
DoD and U.S. Intelligence Community
$6,027 $84 $999 $7,110 
Other U.S. government agencies(1)
1,004 2,660 1,576 5,240 
Commercial and non-U.S. customers1,211 618 108 1,937 
Total$8,242 $3,362 $2,683 $14,287 
Year Ended December 31, 2021
Defense SolutionsCivilHealthTotal
(in millions)
DoD and U.S. Intelligence Community
$5,939 $54 $756 $6,749 
Other U.S. government agencies(1)
964 2,447 1,681 5,092 
Commercial and non-U.S. customers1,126 543 107 1,776 
Total$8,029 $3,044 $2,544 $13,617 
Year Ended January 1, 2021
Defense SolutionsCivilHealthTotal
(in millions)
DoD and U.S. Intelligence Community$5,407 $59 $519 $5,985 
Other U.S. government agencies(1)
995 2,418 1,329 4,742 
Commercial and non-U.S. customers937 426 107 1,470 
Total$7,339 $2,903 $1,955 $12,197 
(1) Includes federal government agencies other than the DoD and U.S. Intelligence Community, as well as state and local government agencies.
Disaggregated revenues by contract-type were as follows:
Year Ended December 30, 2022
Defense SolutionsCivilHealthTotal
(in millions)
Cost-reimbursement and fixed-price-incentive-fee
$4,620 $1,781 $712 $7,113 
Firm-fixed-price
2,642 1,077 1,683 5,402 
Time-and-materials and fixed-price-level-of-effort
980 504 288 1,772 
Total$8,242 $3,362 $2,683 $14,287 
Year Ended December 31, 2021
Defense SolutionsCivilHealthTotal
(in millions)
Cost-reimbursement and fixed-price-incentive-fee
$4,792 $1,576 $508 $6,876 
Firm-fixed-price
2,290 1,020 1,661 4,971 
Time-and-materials and fixed-price-level-of-effort
947 448 375 1,770 
Total$8,029 $3,044 $2,544 $13,617 
Year Ended January 1, 2021
Defense SolutionsCivilHealthTotal
(in millions)
Cost-reimbursement and fixed-price-incentive-fee
$4,504 $1,411 $280 $6,195 
Firm-fixed-price
2,067 1,061 1,303 4,431 
Time-and-materials and fixed-price-level-of-effort
768 431 372 1,571 
Total$7,339 $2,903 $1,955 $12,197 
Disaggregated revenues by geographic location were as follows:
Year Ended December 30, 2022
Defense SolutionsCivilHealthTotal
(in millions)
United States
$7,212 $3,203 $2,683 $13,098 
International
1,030 159  1,189 
Total$8,242 $3,362 $2,683 $14,287 
Year Ended December 31, 2021
Defense SolutionsCivilHealthTotal
(in millions)
United States
$7,045 $2,880 $2,544 $12,469 
International
984 164 — 1,148 
Total$8,029 $3,044 $2,544 $13,617 
Year Ended January 1, 2021
Defense SolutionsCivilHealthTotal
(in millions)
United States
$6,501 $2,738 $1,955 $11,194 
International
838 165 — 1,003 
Total$7,339 $2,903 $1,955 $12,197 
Schedule of Components of Contract Assets and Contract Liabilities
The components of contract assets and contract liabilities consisted of the following:
Balance sheet line itemDecember 30,
2022
December 31,
2021
(in millions)
Contract assets - current:
Unbilled receivablesReceivables, net$1,010 $1,022 
Contract liabilities - current:
Deferred revenue(1)
Accounts payable and accrued liabilities
$380 $364 
Contract liabilities - non-current:
Deferred revenue(1)
Other long-term liabilities$29 $24 
(1) Certain contracts record revenue on a net contract basis, and therefore, the respective deferred revenue balance will not fully convert to revenue.
v3.22.4
Acquisitions and Divestitures (Tables)
12 Months Ended
Dec. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination The following table summarizes the fair value of intangible assets acquired at the Purchase Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Programs12$89 
The following table summarizes the fair value of intangible assets acquired at the Closing Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Technology8$43 
Programs1037 
Backlog1
Total8$86 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The final fair values of the assets acquired and liabilities assumed at the Transaction Date were as follows (in millions):
Current assets$287 
Intangible assets355 
Other assets67 
Current liabilities(140)
Long-term liabilities(97)
Total identifiable net assets acquired472 
Goodwill574 
Purchase price$1,046 
The final fair values of the assets acquired and liabilities assumed at the Acquisition Date were as follows (in millions):
Current assets$241 
Intangible assets528 
Other assets205 
Current liabilities(79)
Long-term liabilities(24)
Total identifiable net assets acquired871 
Goodwill789 
Purchase price$1,660 
Schedule of Preliminary Fair Value of Intangible Assets Acquired at the Transaction Date and the Related Weighted Average Amortization Period The following table summarizes the preliminary fair value of intangible assets acquired at the Agreement Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Programs7$21 
Technology94
Total7$25 
The following table summarizes the final fair value of intangible assets acquired at the Transaction Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Programs13$141 
Customer relationships1049 
Technology 1073 
In-process research and development ("IPR&D")(1)
— 92 
Total11$355 
(1) IPR&D assets are indefinite-lived at the acquisition date until placed into service, at which time such assets will be reclassified to a finite-lived amortizable intangible asset.
The following table summarizes the final fair value of intangible assets acquired at the Acquisition Date and the related weighted average amortization period:
Weighted average amortization periodFair value
(in years)(in millions)
Programs13$485 
Backlog 132 
Technology 1111 
Total12$528 
Schedule of Business Acquisitions, by Acquisition The following expenses were incurred related to the acquisitions of Dynetics, the SD&A Businesses, 1901 Group, Gibbs & Cox, Cobham Special Mission and our strategic business acquisition:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Acquisition costs$ $$23 
Integration costs16 20 12 
Total acquisition and integration costs$16 $24 $35 
v3.22.4
Receivables (Tables)
12 Months Ended
Dec. 30, 2022
Receivables [Abstract]  
Schedule of Components of Receivables The components of receivables, net consisted of the following:
 December 30,
2022
December 31,
2021
 (in millions)
Billed and billable receivables$1,368 $1,194 
Unbilled receivables1,010 1,022 
Allowance for credit losses(28)(27)
$2,350 $2,189 
v3.22.4
Inventory (Tables)
12 Months Ended
Dec. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventory The components of inventory, net consisted of the following:
 December 30,
2022
December 31,
2021
 (in millions)
Raw materials$180 $154 
Work in process34 27 
Finished goods73 93 
$287 $274 
v3.22.4
Goodwill and Intangible Assets (Tables)
12 Months Ended
Dec. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Goodwill by Segment
The following table presents changes in the carrying amount of goodwill by reportable segment:
Defense SolutionsCivilHealthTotal
 (in millions)
Goodwill at January 1, 2021(1)
$3,300 $2,047 $966 $6,313 
Acquisitions of businesses425 — 430 
Divestiture of a business(1)— — (1)
Goodwill re-allocation(17)17 — — 
Foreign currency translation adjustments(26)28 — 
Goodwill at December 31, 2021(1)
3,681 2,097 966 6,744 
Acquisitions of businesses26 — — 26 
Divestiture of a business(6)— — (6)
Foreign currency translation adjustments(37)(31)— (68)
Goodwill at December 30, 2022(1)
$3,664 $2,066 $966 $6,696 
(1) Carrying amount includes accumulated impairment losses of $369 million and $117 million within the Health and Civil segments, respectively.
Schedule of Intangible Assets
Intangible assets, net consisted of the following:
 December 30, 2022December 31, 2021
 Gross
carrying
value
Accumulated
amortization
Net
carrying
value
Gross
carrying
value
Accumulated
amortization
Net
carrying
value
 (in millions)
Finite-lived intangible assets:   
Programs$1,721 $(1,016)$705 $1,722 $(830)$892 
Software and technology225 (136)89 230 (121)109 
Customer relationships87 (25)62 97 (18)79 
Backlog   38 (37)
Trade names1 (1) (1)— 
Total finite-lived intangible assets2,034 (1,178)856 2,088 (1,007)1,081 
Indefinite-lived intangible assets:      
In-process research and development (1)
92  92 92 — 92 
Trade names4  4 — 
Total indefinite-lived intangible assets96  96 96 — 96 
Total intangible assets$2,130 $(1,178)$952 $2,184 $(1,007)$1,177 
(1) IPR&D assets are indefinite-lived at the acquisition date until placed into service, at which time such assets will be reclassified to a finite-lived amortizable intangible asset.
Schedule of Estimated Annual Amortization Expense Related to Finite-Lived Intangible Assets The estimated annual amortization expense related to finite-lived intangible assets as of December 30, 2022, is as follows:
Fiscal Year Ending 
 (in millions)
2023$208 
2024153 
2025124 
202699 
202771 
2028 and thereafter201 
 $856 
v3.22.4
Property Plant and Equipment (Tables)
12 Months Ended
Dec. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment, Net Depreciation is recognized using the methods and estimated useful lives as follows:
 Depreciation methodEstimated useful lives (in years)
Computers and other equipmentStraight-line or declining-balance
2-15
Buildings Straight-line
Not to exceed 40
Building improvements and leasehold improvements
Straight-lineShorter of useful life of asset or remaining lease term
Vehicles and transportation equipmentStraight-line
2-15
Office furniture and fixturesStraight-line or declining-balance
6-9
Property, plant and equipment, net consisted of the following:
 December 30,
2022
December 31,
2021
 (in millions)
Computers and other equipment$399 $373 
Leasehold improvements404 367 
Vehicles and transportation equipment210 99 
Buildings and improvements138 140 
Office furniture and fixtures64 65 
Land17 18 
Construction in progress147 78 
 1,379 1,140 
Less: accumulated depreciation and amortization(532)(470)
 $847 $670 
v3.22.4
Leases (Tables)
12 Months Ended
Dec. 30, 2022
Leases [Abstract]  
Schedule of ROU Assets and Lease Liabilities ROU assets and lease liabilities consisted of the following:
Balance sheet line itemDecember 30,
2022
December 31,
2021
(in millions)
ROU assets:
Finance leasesProperty, plant and equipment, net$43 $51 
Operating leasesOperating lease right-of-use assets, net545 612 
$588 $663 
Current lease liabilities:
Finance leasesShort-term debt and current portion of long-term debt$6 $
Operating leasesAccounts payable and accrued liabilities130 140 
$136 $149 
Non-current lease liabilities:
Finance leasesLong-term debt, net of current portion$38 $43 
Operating leasesOperating lease liabilities570 589 
$608 $632 
Schedule of Lease Cost
Total lease cost for the periods presented consisted of the following:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Finance lease cost:
Amortization of ROU assets$9 $11 $
Interest on lease liabilities
1 — 
10 12 
Operating lease cost(1)
161 172 169 
Variable lease cost42 90 103 
Short-term lease cost3 
Less: Sublease income(6)(8)(11)
Total lease cost$210 $270 $278 
(1) Includes ROU lease expense of $134 million, $150 million and $145 million for fiscal 2022, 2021 and 2020, respectively.
Lease terms and discount rates related to leases were as follows:
December 30,
2022
December 31,
2021
January 1,
2021
Weighted-average remaining lease term (in years):
Finance leases8.28.42.9
Operating leases7.56.87.3
Weighted-average discount rate:
Finance leases2.6 %2.5 %2.7 %
Operating leases3.3 %3.2 %3.5 %
Other information related to leases was as follows:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Cash paid for amounts included in measurement of lease liabilities:
Operating cash related to finance leases$1 $$— 
Operating cash related to operating leases168 174 164 
Financing cash flows related to finance leases9 11 
ROU assets obtained in exchange for lease liabilities:
Finance lease liabilities$1 $51 $12 
Operating lease liabilities122 161 314 
Schedule of Future Minimum Lease Commitments of Operating Leases Future minimum lease commitments of our finance and operating leases on an undiscounted basis, reconciled to the respective lease liability at December 30, 2022, were as follows:
Fiscal Year EndingFinance lease commitmentsOperating lease commitments
(in millions)
2023$$152 
2024143 
2025103 
202679 
202757 
2028 and thereafter21 266 
Total undiscounted cash flows49 800 
Less: imputed interest(5)(100)
Lease liability as of December 30, 2022$44 $700 
Schedule of Future Minimum Lease Commitments of Finance Leases Future minimum lease commitments of our finance and operating leases on an undiscounted basis, reconciled to the respective lease liability at December 30, 2022, were as follows:
Fiscal Year EndingFinance lease commitmentsOperating lease commitments
(in millions)
2023$$152 
2024143 
2025103 
202679 
202757 
2028 and thereafter21 266 
Total undiscounted cash flows49 800 
Less: imputed interest(5)(100)
Lease liability as of December 30, 2022$44 $700 
Schedule of Components of Lease Income, Sale-Type Lease The components of lease income were as follows:
Year Ended
Income statement line itemDecember 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Sales-type leases:
Selling price at lease commencementRevenues$65 $80 $61 
Cost of underlying assetCost of revenues(52)(60)(47)
Operating income 13 20 14 
Interest income on lease receivablesRevenues9 
22 28 22 
Operating lease incomeRevenues35 32 31 
Total lease income$57 $60 $53 
Schedule of Components of Lease Income, Operating Lease The components of lease income were as follows:
Year Ended
Income statement line itemDecember 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Sales-type leases:
Selling price at lease commencementRevenues$65 $80 $61 
Cost of underlying assetCost of revenues(52)(60)(47)
Operating income 13 20 14 
Interest income on lease receivablesRevenues9 
22 28 22 
Operating lease incomeRevenues35 32 31 
Total lease income$57 $60 $53 
Schedule of Undiscounted Cash Flows for Operating Leases As of December 30, 2022, undiscounted cash flows for sales-type and operating leases for the next five years are as follows:
Fiscal Year EndingSales-type leasesOperating leases
(in millions)
2023$42 $26 
202431 27 
202520 29 
202611 — 
2027— 
2028 and thereafter— 
Total undiscounted cash flows$114 $82 
Present value of lease payments as lease receivables103 
Difference between undiscounted cash flows and discounted cash flows$11 
Schedule of Undiscounted Cash Flows for Sales-Type and Direct Finance Leases As of December 30, 2022, undiscounted cash flows for sales-type and operating leases for the next five years are as follows:
Fiscal Year EndingSales-type leasesOperating leases
(in millions)
2023$42 $26 
202431 27 
202520 29 
202611 — 
2027— 
2028 and thereafter— 
Total undiscounted cash flows$114 $82 
Present value of lease payments as lease receivables103 
Difference between undiscounted cash flows and discounted cash flows$11 
v3.22.4
Fair Value Measurements (Tables)
12 Months Ended
Dec. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Financial Instruments Measured on a Recurring Basis at Fair Value Financial instruments measured on a recurring basis at fair value consisted of the following:
December 30, 2022December 31, 2021
Carrying valueFair valueCarrying valueFair value
(in millions)
Financial assets:
Derivatives$20 $20 $— $— 
Financial liabilities:
Derivatives$ $ $53 $53 
v3.22.4
Derivative Instruments (Tables)
12 Months Ended
Dec. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of the Company's Interest Rate Swaps
The fair value of the interest rate swaps was as follows:
Balance sheet line itemDecember 30,
2022
December 31,
2021
(in millions)
Asset derivatives:
Cash flow interest rate swapsOther long-term assets$20 $— 
Liability derivatives:
Cash flow interest rate swapsOther long-term liabilities$ $53 
Schedule of the Effect of the Company's Cash Flow Hedges on Other Comprehensive (Loss) Income and Earnings The effect of the cash flow hedges on other comprehensive income (loss) and earnings for the periods presented was as follows:
Year Ended
December 30,
2022
December 31,
2021
January 1,
2021
(in millions)
Total interest expense, net presented in the consolidated statements of income in which the effects of cash flow hedges are recorded
$199 $184 $179 
Amount recognized in other comprehensive income (loss)59 18 (61)
Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net11 19 14 
v3.22.4
Debt (Tables)
12 Months Ended
Dec. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Company's Debt Debt consisted of the following:
 Stated
interest rate
Effective
interest rate
December 30, 2022December 31, 2021
 (in millions)
Short-term debt and current portion of long-term debt:
Senior unsecured term loans:
$380 million term loan, due May 2022
1.54 %1.64 %$ $380 
$380 million term loan, due May 2023
5.42 %5.51 %320 — 
Current portion of long-term debt672 103 
Total short-term debt and current portion of long-term debt$992 $483 
Long-term debt:
Senior unsecured term loan:
$1,925 million term loan, due January 2025
5.77 %6.09 %$1,211 $1,306 
Senior unsecured notes:    
$500 million notes, due May 2023
2.95 %3.17 %500 500 
$500 million notes, due May 2025
3.63 %3.76 %500 500 
$750 million notes, due May 2030
4.38 %4.50 %750 750 
$1,000 million notes, due February 2031
2.30 %2.38 %1,000 1,000 
$250 million notes, due July 2032
7.13 %7.43 %250 250 
$300 million notes, due July 2033
5.50 %5.88 %161 161 
$300 million notes, due December 2040
5.95 %6.03 %218 218 
Notes payable and finance leases due on various dates through fiscal 2032
1.84%-4.51%
Various44 54 
Less: unamortized debt discounts and deferred debt issuance costs(34)(43)
Total long-term debt  4,600 4,696 
Less: current portion  (672)(103)
Total long-term debt, net of current portion
  $3,928 $4,593 
Schedule of Future Minimum Payments of Debt Future minimum payments of debt are as follows:
Fiscal Year Ending
 (in millions)
2023$996 
2024197 
20251,353 
2026
2027
2028 and thereafter2,399 
Total principal payments4,954 
Less: unamortized debt discount and issuance costs(34)
Total short-term and long-term debt$4,920 
v3.22.4
Accumulated Other Comprehensive Income (Loss) (Tables)
12 Months Ended
Dec. 30, 2022
Equity [Abstract]  
Schedule of Changes in the Components of Accumulated Other Comprehensive Loss Changes in the components of Accumulated Other Comprehensive Income (Loss) ("AOCI") were as follows:
Foreign currency translation adjustmentsUnrecognized gain (loss) on derivative instrumentsPension adjustmentsTotal AOCI
(in millions)
Balance at January 3, 2020$(33)$(33)$(4)$(70)
Other comprehensive income (loss)70 (61)(3)
Taxes(7)10 
Reclassification from AOCI— 14 — 14 
Balance at January 1, 202130 (70)(6)(46)
Other comprehensive income (loss)(3)18 17 32 
Taxes(5)(8)(4)(17)
Reclassification from AOCI— 19 — 19 
Balance at December 31, 202122 (41)(12)
Other comprehensive income (loss)(108)59 (27)(76)
Taxes13 (16)
Reclassification from AOCI— 11 — 11 
Balance at December 30, 2022$(73)$13 $(13)$(73)
v3.22.4
Composition of Certain Financial Statement Captions (Tables)
12 Months Ended
Dec. 30, 2022
Disclosure Schedule Of Certain Financial Statement Captions [Abstract]  
Schedule of Composition of Certain Financial Statement Captions
 Balance Sheets
December 30,
2022
December 31,
2021
 (in millions)
Other current assets:  
Restricted cash$167 $148 
Transition costs and project assets(1)
132 110 
Other(2)
191 171 
 $490 $429 
Other long-term assets:
Transition costs and project assets(1)
$74 $121 
Equity method investments(3)
18 25 
Other(2)
296 293 
$388 $439 
Accounts payable and accrued liabilities:  
Accrued liabilities(4)
$772 $747 
Accounts payable733 692 
Deferred revenue380 364 
Other(2)(4)
369 338 
 $2,254 $2,141 
Accrued payroll and employee benefits:  
Accrued vacation$356 $351 
Salaries, bonuses and amounts withheld from employees’ compensation345 254 
 $701 $605 
(1) During the year ended December 30, 2022, and December 31, 2021, $489 million and $428 million, respectively, of amortization was recognized related to transition costs and project assets.
(2) Balance represents items that are not individually significant to disclose separately.
(3) Balances are net of $19 million and $16 million of dividends received during fiscal 2022 and fiscal 2021, respectively, that were recorded in cash flows provided by operating activities of continuing operations on the consolidated statements of cash flows.
(4) Certain accounts in accrued liabilities were reclassified in the prior year to other to conform to current year presentation.
Schedule of Condensed Income Statement

Year Ended
 Statements of Income
December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Other expense, net:
Loss on debt extinguishment$ $— $(36)
Loss on sale of businesses (3)— 
Loss on foreign currencies(3)(1)(4)
Other income, net 
$(3)$(1)$(38)
v3.22.4
Earnings Per Share ("EPS") (Tables)
12 Months Ended
Dec. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares used to Compute Basic and Diluted EPS The weighted average number of shares used to compute basic and diluted EPS attributable to Leidos stockholders were:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Basic weighted average number of shares outstanding137 141 142 
Dilutive common share equivalents—stock options and other stock awards
1 
Diluted weighted average number of shares outstanding138 143 144 
v3.22.4
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation and Related Tax Benefits Recognized Under all Plans Stock-based compensation and related tax benefits recognized under all plans were as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Total stock-based compensation expense
$73 $67 $62 
Tax benefits recognized from stock-based compensation
16 17 15 
Schedule of Monte Carlo Simulation Assumptions The weighted average grant-date fair value and assumptions used to determine fair value of stock options granted for the periods presented were as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
Weighted average grant-date fair value$24.67$20.23$19.64
Expected term (in years)4.74.64.5
Expected volatility29.5 %29.6 %25.0 %
Risk-free interest rate1.6 %0.7 %0.6 %
Dividend yield1.6 %1.3 %1.3 %
The Monte Carlo simulation assumptions used for the periods presented were as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
Expected volatility33.18 %32.86 %23.99 %
Risk free rate of return1.61 %0.29 %0.50 %
Weighted average grant date stock price$107.67 $90.85 $105.12 
Schedule of Stock Option Activity Stock option activity for each of the periods presented was as follows:
Shares of
stock under
stock options
Weighted
average
exercise price
Weighted
average
remaining
contractual
term
Aggregate
intrinsic value
 (in millions) (in years)(in millions)
Outstanding at January 3, 20202.4 $46.04 3.8$128 
Options granted0.3 106.73 
Options forfeited or expired(0.1)66.84 
Options exercised(0.4)35.94 29 
Outstanding at January 1, 20212.2 $56.01 3.5$108 
Options granted0.3 90.25 
Options forfeited or expired— 85.42 
Options exercised(0.4)38.79 27 
Outstanding at December 31, 20212.1 $65.18 3.5$54 
Options granted0.3 105.01 
Options forfeited or expired— 92.10 
Options exercised(0.6)39.26 41 
Outstanding at December 30, 20221.8 $81.45 3.9$42 
Exercisable at December 30, 20221.0 $69.70 2.8$34 
Vested and expected to vest in the future as of December 30, 2022
1.7 $81.24 3.9$42 
Schedule of Restricted Stock Units and Awards Activity Restricted stock units and awards activity for each of the periods presented was as follows:
Shares of stock
under stock
awards
Weighted
average grant-
date fair value
(in millions) 
Unvested stock awards at January 3, 20201.4 $60.91 
Awards granted0.5 106.38 
Awards forfeited(0.1)79.61 
Awards vested(0.5)56.36 
Unvested stock awards at January 1, 20211.3 $79.05 
Awards granted0.7 91.09 
Awards forfeited(0.1)89.56 
Awards vested(0.5)71.60 
Unvested stock awards at December 31, 20211.4 $88.89 
Awards granted0.5 104.78 
Awards forfeited(0.1)99.38 
Awards vested(0.5)74.20 
Unvested stock awards at December 30, 20221.3 $98.52 
Schedule of Performance-Based Stock Award Activity Performance-based stock award activity for each of the periods presented was as follows:
Expected number
of shares of stock
to be issued under
performance-based
stock awards
Weighted
average grant-
date fair value
 (in millions) 
Unvested at January 3, 20200.6 $63.66 
Awards granted0.2 103.34 
Awards forfeited(0.1)72.96 
Awards vested(0.2)58.61 
Unvested at January 1, 20210.5 $80.20 
Awards granted0.2 86.88 
Awards forfeited— 89.65 
Awards vested(0.2)65.30 
Unvested at December 31, 20210.5 $88.72 
Awards granted0.2 114.98 
Awards forfeited— 103.06 
Awards vested(0.2)67.79 
Unvested at December 30, 20220.5 $106.70 
v3.22.4
Income Taxes (Tables)
12 Months Ended
Dec. 30, 2022
Income Tax Disclosure [Abstract]  
Schedule of Provision for Income Taxes The provision for income taxes for the periods presented included the following:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Current:   
Federal$290 $156 $90 
State80 49 37 
Foreign33 29 28 
Deferred:  
Federal(169)(20)13 
State(36)(3)(11)
Foreign(5)(3)(5)
Total$193 $208 $152 
Schedule of Reconciliation of the Provision for Income Taxes to the Amount Computed by Applying the Statutory Federal Income Tax Rate to Income before Income Taxes A reconciliation of the provision for income taxes to the amount computed by applying the statutory federal income tax rate to income before income taxes for the periods presented was as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Amount computed at the statutory federal income tax rate$186 $203 $164 
State income taxes, net of federal tax benefit36 34 20 
Research and development credits(31)(23)(26)
Excess tax benefits from stock-based compensation(13)(11)(15)
Change in valuation allowance for deferred tax assets3 (5)
Impact of foreign operations2 11 
Dividends paid to employee stock ownership plan(2)(2)(2)
Change in accruals for uncertain tax positions(1)
Other13 (3)
Total$193 $208 $152 
Effective income tax rate21.8 %21.5 %19.5 %
Schedule of Deferred Tax Assets (Liabilities)
Deferred income taxes are recorded for differences in the basis of assets and liabilities for financial reporting purposes and tax reporting purposes. Deferred tax assets (liabilities) were comprised of the following:
 December 30,
2022
December 31,
2021
 (in millions)
Capitalized research and development$228 $— 
Operating lease liabilities190 187 
Accrued vacation and bonuses87 91 
Reserves40 47 
Deferred compensation32 39 
Credits and net operating losses carryovers32 26 
Vesting stock awards27 24 
Deferred revenue 16 
Accumulated other comprehensive loss2 — 
Other13 
Total deferred tax assets651 439 
Valuation allowance(24)(21)
Deferred tax assets, net of valuation allowance$627 $418 
Purchased intangible assets$(415)$(413)
Operating lease right-of-use assets(140)(158)
Property, plant and equipment(75)(63)
Accumulated other comprehensive income (1)
Deferred revenue(4)— 
Other(5)(9)
Total deferred tax liabilities(639)(644)
Net deferred tax liabilities$(12)$(226)
Summary of Income Tax Related Balance on Balance Sheet Income tax balance sheet items are included in the accompanying consolidated balance sheets as follows:
 December 30,
2022
December 31,
2021
 (in millions)
Other current assets:
Prepaid income taxes and tax refunds receivable$11 $
Other long-term assets:
Deferred tax assets$28 $13 
Accounts payable and accrued liabilities:
Income taxes payable$135 $29 
Deferred tax liabilities$40 $239 
Other long-term liabilities:
Unrecognized tax benefits$92 $
Schedule of Changes in the Unrecognized Tax Benefits The changes in the unrecognized tax benefits were as follows:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Unrecognized tax benefits at beginning of year$2 $$
Additions for tax positions related to current year91 — — 
Additions for tax positions related to prior years 
Reductions for tax positions related to prior years (2)— 
Settlements with taxing authorities (3)— 
Lapse of statute of limitations(1)(1)— 
Unrecognized tax benefits at end of year$92 $$
Unrecognized tax benefits that, if recognized, would affect the effective income tax rate
$ $$
v3.22.4
Business Segments (Tables)
12 Months Ended
Dec. 30, 2022
Segment Reporting [Abstract]  
Schedule of Business Segment Information The following table summarizes business segment information for the periods presented:
 Year Ended
 December 30,
2022
December 31,
2021
January 1,
2021
 (in millions)
Revenues:  
Defense Solutions$8,244 $8,032 $7,341 
Civil3,464 3,157 2,994 
Health2,688 2,548 1,962 
Total revenues$14,396 $13,737 $12,297 
Operating income (loss):  
Defense Solutions$541 $569 $506 
Civil234 248 280 
Health421 442 235 
Corporate(108)(107)(23)
Total operating income$1,088 $1,152 $998 
Amortization of intangible assets:  
Defense Solutions$130 $121 $92 
Civil70 73 66 
Health30 34 40 
Total amortization of intangible assets$230 $228 $198 
v3.22.4
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Guaranteed Obligation, Fiscal Year Maturity As of December 30, 2022, the future expirations of the outstanding letters of credit, surety bonds and future lease commitments were as follows:
Fiscal year ending
(in millions)
2023$60 
2024104 
202537 
202619 
202722 
2028 and thereafter
$246 
v3.22.4
Nature of Operations and Basis of Presentation (Details) - segment
12 Months Ended
Dec. 30, 2022
Jan. 26, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Number of reportable segments (in segments) 3  
Mission Support Alliance, LLC    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Ownership percentage (in percentage) 88.00%  
Mission Support Alliance, LLC | Mission Supporting Alliance    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Voting interest (in percentage)   41.00%
Hanford Mission Integration Solutions    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Ownership percentage (in percentage) 53.00%  
v3.22.4
Accounting Standards (Additional Information) (Details) - USD ($)
May 06, 2022
May 07, 2021
Term loan | Unsecured debt    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Debt instrument, face amount $ 380,000,000 $ 380,000,000
v3.22.4
Summary of Significant Accounting Policies (Schedule of Changes in Estimates on Contracts for the Periods Presented) (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Accounting Policies [Abstract]      
Favorable impact $ 146 $ 149 $ 137
Unfavorable impact (113) (102) (61)
Net favorable impact to income before income taxes $ 33 $ 47 $ 76
Impact on diluted EPS attributable to Leidos common stockholders (usd per share) $ 0.17 $ 0.25 $ 0.39
v3.22.4
Summary of Significant Accounting Policies (Additional Information) (Details)
$ in Millions
12 Months Ended
Dec. 30, 2022
USD ($)
reporting_unit
Dec. 31, 2021
USD ($)
reporting_unit
Jan. 01, 2021
USD ($)
Significant Accounting Policies [Line Items]      
Contract with customer, performance obligation satisfied in previous period $ 9 $ 26 $ 40
Internal research and development costs included in selling, general and administrative expenses 116 109 73
Accounts payable and accrued liabilities 2,254 2,141  
Less: restricted cash at end of year $ 167 $ 148 $ 163
Number of reporting units (in reporting units) | reporting_unit 7 7  
Cash and Cash Equivalents      
Significant Accounting Policies [Line Items]      
Accounts payable and accrued liabilities $ 158 $ 138  
v3.22.4
Summary of Significant Accounting Policies (Schedule of Finite-Lived Intangible Assets) (Details)
12 Months Ended
Dec. 30, 2022
Backlog  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets (in years) 1 year
Customer relationships | Minimum  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets (in years) 8 years
Customer relationships | Maximum  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets (in years) 10 years
Programs | Minimum  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets (in years) 4 years
Programs | Maximum  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets (in years) 13 years
Software and technology | Minimum  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets (in years) 3 years
Software and technology | Maximum  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets (in years) 15 years
Trade names  
Finite-Lived Intangible Assets [Line Items]  
Useful life of intangible assets (in years) 3 years
v3.22.4
Summary of Significant Accounting Policies (Schedule of Depreciation using Estimated Useful Lives) (Details)
12 Months Ended
Dec. 30, 2022
Computers and other equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 2 years
Computers and other equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 15 years
Buildings | Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 40 years
Office furniture and fixtures | Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 6 years
Office furniture and fixtures | Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 9 years
Vehicles and transportation equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 2 years
Vehicles and transportation equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 15 years
v3.22.4
Revenues - Narrative (Details) - USD ($)
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Remaining performance obligations, which are expected to be recognized as revenue $ 15,400,000,000    
Remaining performance obligations, which are expected to be recognized as revenue (as percent) 57.00%    
Revenue recognized under ASC 842 $ 109,000,000 $ 120,000,000 $ 100,000,000
Contract liability revenue recognized 270,000,000 340,000,000  
Capitalized contract cost, impairment loss $ 0 $ 0 $ 0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-12-31      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Remaining performance obligations, which are expected to be recognized as revenue, period 12 months    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-12-30      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Remaining performance obligations, which are expected to be recognized as revenue (as percent) 74.00%    
Remaining performance obligations, which are expected to be recognized as revenue, period 24 months    
v3.22.4
Revenues - Schedule of Disaggregated Revenue (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Disaggregation of Revenue [Line Items]      
Revenues $ 14,287 $ 13,617 $ 12,197
United States      
Disaggregation of Revenue [Line Items]      
Revenues 13,098 12,469 11,194
International      
Disaggregation of Revenue [Line Items]      
Revenues 1,189 1,148 1,003
Cost-reimbursement and fixed-price-incentive-fee      
Disaggregation of Revenue [Line Items]      
Revenues 7,113 6,876 6,195
Firm-fixed-price      
Disaggregation of Revenue [Line Items]      
Revenues 5,402 4,971 4,431
Time-and-materials and fixed-price-level-of-effort      
Disaggregation of Revenue [Line Items]      
Revenues 1,772 1,770 1,571
DoD and U.S. Intelligence Community      
Disaggregation of Revenue [Line Items]      
Revenues 7,110 6,749 5,985
Other U.S. government agencies      
Disaggregation of Revenue [Line Items]      
Revenues 5,240 5,092 4,742
Commercial and non-U.S. customers      
Disaggregation of Revenue [Line Items]      
Revenues 1,937 1,776 1,470
Defense Solutions      
Disaggregation of Revenue [Line Items]      
Revenues 8,242 8,029 7,339
Defense Solutions | United States      
Disaggregation of Revenue [Line Items]      
Revenues 7,212 7,045 6,501
Defense Solutions | International      
Disaggregation of Revenue [Line Items]      
Revenues 1,030 984 838
Defense Solutions | Cost-reimbursement and fixed-price-incentive-fee      
Disaggregation of Revenue [Line Items]      
Revenues 4,620 4,792 4,504
Defense Solutions | Firm-fixed-price      
Disaggregation of Revenue [Line Items]      
Revenues 2,642 2,290 2,067
Defense Solutions | Time-and-materials and fixed-price-level-of-effort      
Disaggregation of Revenue [Line Items]      
Revenues 980 947 768
Defense Solutions | DoD and U.S. Intelligence Community      
Disaggregation of Revenue [Line Items]      
Revenues 6,027 5,939 5,407
Defense Solutions | Other U.S. government agencies      
Disaggregation of Revenue [Line Items]      
Revenues 1,004 964 995
Defense Solutions | Commercial and non-U.S. customers      
Disaggregation of Revenue [Line Items]      
Revenues 1,211 1,126 937
Civil      
Disaggregation of Revenue [Line Items]      
Revenues 3,362 3,044 2,903
Civil | United States      
Disaggregation of Revenue [Line Items]      
Revenues 3,203 2,880 2,738
Civil | International      
Disaggregation of Revenue [Line Items]      
Revenues 159 164 165
Civil | Cost-reimbursement and fixed-price-incentive-fee      
Disaggregation of Revenue [Line Items]      
Revenues 1,781 1,576 1,411
Civil | Firm-fixed-price      
Disaggregation of Revenue [Line Items]      
Revenues 1,077 1,020 1,061
Civil | Time-and-materials and fixed-price-level-of-effort      
Disaggregation of Revenue [Line Items]      
Revenues 504 448 431
Civil | DoD and U.S. Intelligence Community      
Disaggregation of Revenue [Line Items]      
Revenues 84 54 59
Civil | Other U.S. government agencies      
Disaggregation of Revenue [Line Items]      
Revenues 2,660 2,447 2,418
Civil | Commercial and non-U.S. customers      
Disaggregation of Revenue [Line Items]      
Revenues 618 543 426
Health      
Disaggregation of Revenue [Line Items]      
Revenues 2,683 2,544 1,955
Health | United States      
Disaggregation of Revenue [Line Items]      
Revenues 2,683 2,544 1,955
Health | International      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Health | Cost-reimbursement and fixed-price-incentive-fee      
Disaggregation of Revenue [Line Items]      
Revenues 712 508 280
Health | Firm-fixed-price      
Disaggregation of Revenue [Line Items]      
Revenues 1,683 1,661 1,303
Health | Time-and-materials and fixed-price-level-of-effort      
Disaggregation of Revenue [Line Items]      
Revenues 288 375 372
Health | DoD and U.S. Intelligence Community      
Disaggregation of Revenue [Line Items]      
Revenues 999 756 519
Health | Other U.S. government agencies      
Disaggregation of Revenue [Line Items]      
Revenues 1,576 1,681 1,329
Health | Commercial and non-U.S. customers      
Disaggregation of Revenue [Line Items]      
Revenues $ 108 $ 107 $ 107
v3.22.4
Revenues - Schedule of Components of Contract Assets and Contract Liabilities (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Contract assets - current $ 1,010 $ 1,022
Deferred revenue 380 364
Contract liabilities - non-current $ 29 $ 24
v3.22.4
Acquisitions and Divestitures - Narrative (Details)
$ in Millions, $ in Millions
12 Months Ended
Oct. 30, 2022
USD ($)
Oct. 30, 2022
AUD ($)
Sep. 21, 2021
USD ($)
May 07, 2021
USD ($)
Jan. 14, 2021
USD ($)
May 04, 2020
USD ($)
Jan. 31, 2020
USD ($)
Dec. 30, 2022
USD ($)
Dec. 30, 2022
AUD ($)
Dec. 31, 2021
USD ($)
Jan. 01, 2021
USD ($)
Restructuring Cost and Reserve [Line Items]                      
Goodwill               $ 6,696   $ 6,744 $ 6,313
Revenues               14,287   13,617 12,197
Payments to acquire businesses, net of cash acquired               192   622 2,655
Cobham Aviation Services                      
Restructuring Cost and Reserve [Line Items]                      
Preliminary purchase consideration $ 190 $ 295             $ 310    
Cash acquired in excess of payments to acquire business   $ 10                  
Cash acquired 6                    
Goodwill 26                    
Property, plant and equipment $ 147                    
Earnings from acquiree               $ 21      
Acquired finite-lived intangible assets, weighted average useful life               7 years 7 years    
Cobham Aviation Services | Programs                      
Restructuring Cost and Reserve [Line Items]                      
Acquired finite-lived intangible assets, weighted average useful life               7 years 7 years    
Gibbs Cox                      
Restructuring Cost and Reserve [Line Items]                      
Preliminary purchase consideration       $ 375              
Cash acquired       1              
Goodwill       $ 276              
Gibbs Cox | Defense Solutions Segment                      
Restructuring Cost and Reserve [Line Items]                      
Revenues               $ 114   98  
1901 Group                      
Restructuring Cost and Reserve [Line Items]                      
Preliminary purchase consideration         $ 212            
Cash acquired         $ 2            
Goodwill               123      
Goodwill tax deductible amount               118      
Acquired finite-lived intangible assets, weighted average useful life         8 years            
1901 Group | Programs                      
Restructuring Cost and Reserve [Line Items]                      
Acquired finite-lived intangible assets, weighted average useful life         10 years            
A1901 Group and Gibbs Cox                      
Restructuring Cost and Reserve [Line Items]                      
Revenue               40   47  
September21 Acquisition                      
Restructuring Cost and Reserve [Line Items]                      
Preliminary purchase consideration     $ 36                
Goodwill     25                
September21 Acquisition | Programs                      
Restructuring Cost and Reserve [Line Items]                      
Intangible assets     $ 8                
SD&A Businesses                      
Restructuring Cost and Reserve [Line Items]                      
Preliminary purchase consideration           $ 1,019          
Cash acquired           27          
Goodwill           574          
Goodwill tax deductible amount               432      
Intangible assets           355          
Payments to acquire businesses           1,015          
Payment for contractual net working capital acquired           $ 31          
Revenues               330   291 243
Acquired finite-lived intangible assets, weighted average useful life           11 years          
SD&A Businesses | Programs                      
Restructuring Cost and Reserve [Line Items]                      
Acquired finite-lived intangible assets, weighted average useful life           13 years          
SD&A Businesses | Customer relationships                      
Restructuring Cost and Reserve [Line Items]                      
Acquired finite-lived intangible assets, weighted average useful life           10 years          
Dynetics                      
Restructuring Cost and Reserve [Line Items]                      
Goodwill             $ 789        
Intangible assets             528        
Revenues               $ 950   $ 1,065 $ 937
Payments to acquire businesses, net of cash acquired             $ 1,640        
Acquired finite-lived intangible assets, weighted average useful life             12 years        
Dynetics | Programs                      
Restructuring Cost and Reserve [Line Items]                      
Acquired finite-lived intangible assets, weighted average useful life             13 years        
v3.22.4
Acquisitions and Divestitures - Schedule of Intangible Assets Acquired (Details) - USD ($)
$ in Millions
12 Months Ended
May 07, 2021
Jan. 14, 2021
May 04, 2020
Jan. 31, 2020
Dec. 30, 2022
1901 Group          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period   8 years      
Finite-lived intangible assets   $ 86      
SD&A Businesses          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period     11 years    
Fair value     $ 355    
Dynetics          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period       12 years  
Finite-lived intangible assets       $ 528  
Fair value       $ 528  
Cobham Aviation Services          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period         7 years
Finite-lived intangible assets         $ 25
In-process research and development ("IPR&D") | SD&A Businesses          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Indefinite-lived intangible assets     $ 92    
Programs          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Finite-lived intangible assets         $ 21
Programs | Gibbs And Cox          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period 12 years        
Finite-lived intangible assets $ 89        
Programs | 1901 Group          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period   10 years      
Finite-lived intangible assets   $ 37      
Programs | SD&A Businesses          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period     13 years    
Finite-lived intangible assets     $ 141    
Programs | Dynetics          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period       13 years  
Finite-lived intangible assets       $ 485  
Programs | Cobham Aviation Services          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period         7 years
Customer relationships | SD&A Businesses          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period     10 years    
Finite-lived intangible assets     $ 49    
Technology | 1901 Group          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period   8 years      
Finite-lived intangible assets   $ 43      
Technology | SD&A Businesses          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period     10 years    
Finite-lived intangible assets     $ 73    
Technology | Dynetics          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period       11 years  
Finite-lived intangible assets       $ 11  
Technology | Cobham Aviation Services          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period         9 years
Finite-lived intangible assets         $ 4
Backlog | 1901 Group          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period   1 year      
Finite-lived intangible assets   $ 6      
Backlog | Dynetics          
Acquired Indefinite-lived Intangible Assets [Line Items]          
Weighted average amortization period       1 year  
Finite-lived intangible assets       $ 32  
v3.22.4
Acquisitions and Divestitures - Schedule of Preliminary Fair Values of the Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
May 04, 2020
Jan. 31, 2020
Business Acquisition [Line Items]          
Goodwill $ 6,696 $ 6,744 $ 6,313    
SD&A Businesses          
Business Acquisition [Line Items]          
Current assets       $ 287  
Intangible assets       355  
Other assets       67  
Current liabilities       (140)  
Long-term liabilities       (97)  
Total identifiable net assets acquired       472  
Goodwill       574  
Purchase price       $ 1,046  
Dynetics          
Business Acquisition [Line Items]          
Current assets         $ 241
Intangible assets         528
Other assets         205
Current liabilities         (79)
Long-term liabilities         (24)
Total identifiable net assets acquired         871
Goodwill         789
Purchase price         $ 1,660
v3.22.4
Acquisitions and Divestitures - Acquisition Expenses Incurred (Details) - SD&A Businesses and Dynetics - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Business Acquisition [Line Items]      
Acquisition costs $ 0 $ 4 $ 23
Integration costs 16 20 12
Total acquisition and integration costs $ 16 $ 24 $ 35
v3.22.4
Acquisitions and Divestitures - Divestitures (Details) - Disposal Group, Held-for-sale, Not Discontinued Operations - Aviation & Missile Solutions LLC
$ in Millions
Apr. 29, 2022
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Disposal group, consideration $ 15
Assets divested $ 19
v3.22.4
Receivables - Schedule of Components of Receivables (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Receivables [Abstract]    
Billed and billable receivables $ 1,368 $ 1,194
Unbilled receivables 1,010 1,022
Allowance for credit losses (28) (27)
Accounts receivable, net $ 2,350 $ 2,189
v3.22.4
Receivables (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Receivables [Abstract]      
Receivable collectible period 30 days    
Accounts receivable sold $ 209 $ 693 $ 1,866
Proceeds from sale of receivables $ 209 $ 693 $ 1,864
v3.22.4
Inventory (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 180 $ 154
Work in process 34 27
Finished goods 73 93
Inventory, net $ 287 $ 274
v3.22.4
Goodwill and Intangible Assets (Schedule of Changes in Goodwill by Segment) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Goodwill [Roll Forward]      
Beginning balance $ 6,744 $ 6,313  
Acquisitions of businesses 26 430  
Divestiture of a business (6) (1)  
Goodwill re-allocation   0  
Foreign currency translation adjustments (68) 2  
Ending balance 6,696 6,744  
Defense Solutions      
Goodwill [Roll Forward]      
Beginning balance 3,681 3,300  
Acquisitions of businesses 26 425  
Divestiture of a business (6) (1)  
Goodwill re-allocation   (17)  
Foreign currency translation adjustments (37) (26)  
Ending balance 3,664 3,681  
Civil      
Goodwill [Roll Forward]      
Beginning balance 2,097 2,047  
Acquisitions of businesses 0 5  
Divestiture of a business 0 0  
Goodwill re-allocation   17  
Foreign currency translation adjustments (31) 28  
Ending balance 2,066 2,097  
Goodwill impairment charges 117 117 $ 117
Health      
Goodwill [Roll Forward]      
Beginning balance 966 966  
Acquisitions of businesses 0 0  
Divestiture of a business 0 0  
Goodwill re-allocation   0  
Foreign currency translation adjustments 0 0  
Ending balance 966 966  
Goodwill impairment charges $ 369 $ 369 $ 369
v3.22.4
Goodwill and Intangible Assets (Narrative) (Details) - USD ($)
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Indefinite-lived Intangible Assets [Line Items]      
Goodwill $ 6,696,000,000 $ 6,744,000,000 $ 6,313,000,000
Goodwill impairments 0 0 0
Amortization of intangible assets 230,000,000 228,000,000 198,000,000
Impairment of intangible assets, 0    
Security Products      
Indefinite-lived Intangible Assets [Line Items]      
Goodwill $ 899,000,000    
Reporting unit, percentage of fair value in excess of carrying amount 13.00%    
Defense Solutions      
Indefinite-lived Intangible Assets [Line Items]      
Goodwill $ 3,664,000,000 3,681,000,000 3,300,000,000
Amortization of intangible assets 130,000,000 121,000,000 92,000,000
Civil      
Indefinite-lived Intangible Assets [Line Items]      
Goodwill 2,066,000,000 2,097,000,000 2,047,000,000
Amortization of intangible assets $ 70,000,000 73,000,000 $ 66,000,000
Civil | Security Products      
Indefinite-lived Intangible Assets [Line Items]      
Goodwill   $ 926,000,000  
v3.22.4
Goodwill and Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying value $ 2,034 $ 2,088
Accumulated amortization (1,178) (1,007)
Net carrying value 856 1,081
Indefinite-lived intangible assets 96 96
Total intangible assets, Gross carrying value 2,130 2,184
Total intangible assets, Net carrying value 952 1,177
In-process research and development ("IPR&D")    
Acquired Finite-Lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 92 92
Trade names    
Acquired Finite-Lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 4 4
Programs    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying value 1,721 1,722
Accumulated amortization (1,016) (830)
Net carrying value 705 892
Software and technology    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying value 225 230
Accumulated amortization (136) (121)
Net carrying value 89 109
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying value 87 97
Accumulated amortization (25) (18)
Net carrying value 62 79
Backlog    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying value 0 38
Accumulated amortization 0 (37)
Net carrying value 0 1
Trade names    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying value 1 1
Accumulated amortization (1) (1)
Net carrying value $ 0 $ 0
v3.22.4
Goodwill and Intangible Assets (Schedule of Estimated Annual Amortization Expense) (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Estimated Annual Intangible Amortization Expense    
2023 $ 208  
2024 153  
2025 124  
2026 99  
2027 71  
2028 and thereafter 201  
Net carrying value $ 856 $ 1,081
v3.22.4
Property Plant and Equipment (Schedule of Property, Plant and Equipment) (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross, including finance lease ROU assets $ 1,379 $ 1,140
Less: accumulated depreciation and amortization (532) (470)
Property, plant and equipment, net, including finance lease ROU assets 847 670
Computers and other equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross, including finance lease ROU assets 399 373
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross, including finance lease ROU assets 404 367
Vehicles and transportation equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross, including finance lease ROU assets 210 99
Buildings and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross, including finance lease ROU assets 138 140
Office furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross, including finance lease ROU assets 64 65
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross, including finance lease ROU assets 17 18
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross, including finance lease ROU assets $ 147 $ 78
v3.22.4
Property, Plant, and Equipment (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Property, Plant and Equipment [Abstract]      
Depreciation $ 103 $ 97 $ 84
v3.22.4
Leases (Schedule of ROU Assets and Lease Liabilities) (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
ROU assets:    
Finance leases $ 43 $ 51
Operating leases 545 612
Non-current ROU assets $ 588 $ 663
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Property, plant and equipment, net Property, plant and equipment, net
Current lease liabilities:    
Finance leases $ 6 $ 9
Operating leases 130 140
Current lease liabilities $ 136 $ 149
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Debt, Current Debt, Current
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Non-current lease liabilities:    
Finance leases $ 38 $ 43
Operating leases 570 589
Non-current lease liabilities $ 608 $ 632
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Long-term debt, net of current portion Long-term debt, net of current portion
v3.22.4
Leases (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Operating Leased Assets [Line Items]      
Impairment charge $ 40 $ 4 $ 12
Lease payment receivables 103 $ 93  
Facility rationalization effort      
Operating Leased Assets [Line Items]      
Impairment charge $ 37    
Health      
Operating Leased Assets [Line Items]      
Impairment charge     $ 11
v3.22.4
Leases (Schedule of Lease Cost) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Leases [Abstract]      
Amortization of ROU assets $ 9 $ 11 $ 9
Interest on lease liabilities 1 1 0
Finance lease cost 10 12 9
Operating lease cost 161 172 169
Variable lease cost 42 90 103
Short-term lease cost 3 4 8
Less: Sublease income (6) (8) (11)
Total lease cost 210 270 278
ROU lease expense $ 134 $ 150 $ 145
v3.22.4
Leases (Schedule of Other Information Related to Leases) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Weighted-average remaining lease term (in years):      
Finance leases 8 years 2 months 12 days 8 years 4 months 24 days 2 years 10 months 24 days
Operating leases 7 years 6 months 6 years 9 months 18 days 7 years 3 months 18 days
Weighted-average discount rate:      
Finance leases 2.60% 2.50% 2.70%
Operating leases 3.30% 3.20% 3.50%
Cash paid for amounts included in measurement of lease liabilities:      
Operating cash related to finance leases $ 1 $ 1 $ 0
Operating cash related to operating leases 168 174 164
Financing cash flows related to finance leases 9 11 9
ROU assets obtained in exchange for lease liabilities:      
Finance lease liabilities 1 51 12
Operating lease liabilities $ 122 $ 161 $ 314
v3.22.4
Leases (Schedule of Future Minimum Lease Commitments) (Details)
$ in Millions
Dec. 30, 2022
USD ($)
Finance lease commitments  
2023 $ 8
2024 5
2025 5
2026 5
2027 5
2028 and thereafter 21
Total undiscounted cash flows 49
Less: imputed interest (5)
Lease liability as of December 30, 2022 44
Operating lease commitments  
2023 152
2024 143
2025 103
2026 79
2027 57
2028 and thereafter 266
Total undiscounted cash flows 800
Less: imputed interest (100)
Lease liability as of December 30, 2022 $ 700
v3.22.4
Leases (Schedule of Components of Lease Income) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Sales-type leases:      
Selling price at lease commencement $ 65 $ 80 $ 61
Cost of underlying asset (52) (60) (47)
Operating income 13 20 14
Interest income on lease receivables $ 9 $ 8 $ 8
Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration] Revenues Revenues Revenues
Sales-type lease, lease income $ 22 $ 28 $ 22
Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration] Revenues Revenues Revenues
Operating lease      
Operating lease income $ 35 $ 32 $ 31
Total lease income $ 57 $ 60 $ 53
v3.22.4
Leases (Schedule of Undiscounted Cash Flows for Sales-Type and Operating Leases) (Details)
$ in Millions
Dec. 30, 2022
USD ($)
Sales-type leases  
2023 $ 42
2024 31
2025 20
2026 11
2027 6
2028 and thereafter 4
Total undiscounted cash flows 114
Present value of lease payments as lease receivables 103
Difference between undiscounted cash flows and discounted cash flows 11
Operating leases  
2023 26
2024 27
2025 29
2026 0
2027 0
2028 and thereafter 0
Total undiscounted cash flows $ 82
v3.22.4
Fair Value Measures (Financial Instruments Measured at Fair Value on Recurring Basis) (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other long-term assets  
Derivative Liability, Statement of Financial Position [Extensible Enumeration]   Other long-term liabilities
Carrying value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative asset $ 20 $ 0
Derivative liability 0 53
Fair value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative asset 20 0
Derivative liability $ 0 $ 53
v3.22.4
Fair Value Measurements (Narrative) (Details) - USD ($)
Dec. 30, 2022
Dec. 31, 2021
Carrying value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Notes receivable, fair value disclosure $ 12,000,000 $ 15,000,000
Fair value of notes payable and long-term debt 4,900,000,000 5,100,000,000
Fair value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of notes payable and long-term debt 4,600,000,000 $ 5,400,000,000
Designated as Hedging Instrument | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Hedged instrument, face amount $ 1,000,000,000  
v3.22.4
Derivative Instruments (Interest Rate Swaps) (Details) - Cash flow hedging - Interest rate swaps - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Other long-term assets    
Derivatives, Fair Value [Line Items]    
Asset derivatives $ 20 $ 0
Other long-term liabilities    
Derivatives, Fair Value [Line Items]    
Liability derivatives $ 0 $ 53
v3.22.4
Derivative Instruments (Narrative) (Details)
$ in Millions
12 Months Ended
Oct. 30, 2022
AUD ($)
Oct. 30, 2022
USD ($)
Dec. 30, 2022
AUD ($)
Dec. 30, 2022
USD ($)
Derivative [Line Items]        
Foreign currency transaction gain (loss), before tax       $ (18,000,000)
Income expected to be reclassified in the next 12 months       14,000,000
Cobham Aviation Services        
Derivative [Line Items]        
Preliminary purchase consideration $ 295 $ 190,000,000 $ 310  
Designated as Hedging Instrument | Interest rate swaps        
Derivative [Line Items]        
Hedged instrument, face amount       $ 1,000,000,000
Designated as Hedging Instrument | Unsecured debt | Interest Rate Swap, Maturity Date August 2025        
Derivative [Line Items]        
Stated interest rate (in percentage)       3.00%
v3.22.4
Derivative Instruments (Effect of Cash Flow Hedge ) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Derivatives, Fair Value [Line Items]      
Total interest expense, net presented in the consolidated statements of income in which the effects of cash flow hedges are recorded $ 199 $ 184 $ 179
Amount recognized in other comprehensive income (loss) 59 18 (61)
Interest Expense      
Derivatives, Fair Value [Line Items]      
Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net $ 11 $ 19 $ 14
v3.22.4
Debt (Schedule of Debt) (Details) - USD ($)
Dec. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Current portion of long-term debt $ 672,000,000 $ 103,000,000
Total short-term debt and current portion of long-term debt 992,000,000 483,000,000
Less: unamortized debt discounts and deferred debt issuance costs (34,000,000) (43,000,000)
Total long-term debt 4,600,000,000 4,696,000,000
Less: current portion (672,000,000) (103,000,000)
Total long-term debt, net of current portion 3,928,000,000 4,593,000,000
Unsecured debt | $1,925 million term loan, due January 2025    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 1,925,000,000  
Stated interest rate 5.77%  
Effective interest rate 6.09%  
Senior unsecured notes $ 1,211,000,000 1,306,000,000
Unsecured debt | $500 million notes, due May 2023    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 500,000,000  
Stated interest rate 2.95%  
Effective interest rate 3.17%  
Senior unsecured notes $ 500,000,000 500,000,000
Unsecured debt | $500 million notes, due May 2025    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 500,000,000  
Stated interest rate 3.63%  
Effective interest rate 3.76%  
Senior unsecured notes $ 500,000,000 500,000,000
Unsecured debt | $750 million notes, due May 2030    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 750,000,000  
Stated interest rate 4.38%  
Effective interest rate 4.50%  
Senior unsecured notes $ 750,000,000 750,000,000
Unsecured debt | $1,000 million notes, due February 2031    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 1,000,000,000  
Stated interest rate 2.30%  
Effective interest rate 2.38%  
Senior unsecured notes $ 1,000,000,000 1,000,000,000
Unsecured debt | $250 million notes, due July 2032    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 250,000,000  
Stated interest rate 7.13%  
Effective interest rate 7.43%  
Senior unsecured notes $ 250,000,000 250,000,000
Unsecured debt | $300 million notes, due July 2033    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 300,000,000  
Stated interest rate 5.50%  
Effective interest rate 5.88%  
Senior unsecured notes $ 161,000,000 161,000,000
Unsecured debt | $300 million notes, due December 2040    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 300,000,000  
Stated interest rate 5.95%  
Effective interest rate 6.03%  
Senior unsecured notes $ 218,000,000 218,000,000
Unsecured debt | Notes payable and finance leases due on various dates through fiscal 2032    
Debt Instrument [Line Items]    
Senior unsecured notes $ 44,000,000 54,000,000
Unsecured debt | Notes payable and finance leases due on various dates through fiscal 2032 | Minimum    
Debt Instrument [Line Items]    
Stated interest rate 1.84%  
Unsecured debt | Notes payable and finance leases due on various dates through fiscal 2032 | Maximum    
Debt Instrument [Line Items]    
Stated interest rate 4.51%  
Unsecured debt | $380 million term loan, due May 2022    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 380,000,000  
Stated interest rate 1.54%  
Effective interest rate 1.64%  
Senior unsecured notes $ 0 380,000,000
Unsecured debt | $380 million term loan, due May 2023    
Debt Instrument [Line Items]    
Debt instrument, face amount $ 380,000,000  
Stated interest rate 5.42%  
Effective interest rate 5.51%  
Senior unsecured notes $ 320,000,000 $ 0
v3.22.4
Debt (Narrative) (Details)
12 Months Ended
May 06, 2022
USD ($)
Jul. 12, 2021
USD ($)
May 07, 2021
USD ($)
Dec. 30, 2022
USD ($)
increase
extension
Dec. 31, 2021
USD ($)
Jan. 01, 2021
USD ($)
Debt Instrument [Line Items]            
Payments of long-term debt       $ 545,000,000 $ 106,000,000 $ 5,456,000,000
Repayments of term loan           4,925,000,000
Amortization of debt issuance costs and discounts       11,000,000 11,000,000 16,000,000
Commercial Paper            
Debt Instrument [Line Items]            
Term of debt instrument (in years)   397 days        
Commercial paper   $ 750,000,000        
Minimum denominations of commercial paper   $ 250,000        
Unsecured debt            
Debt Instrument [Line Items]            
Repayment of debt principal       $ 476,000,000 96,000,000 72,000,000
Term loan            
Debt Instrument [Line Items]            
Covenant, adjusted consolidated total debt to consolidated EBITDA ratio       3.75    
Covenant, leverage ratio, maximum, potential increase following material acquisition       4.50    
Covenant, consolidated EBITDA to interest expense ratio       3.50    
Term loan | Unsecured debt            
Debt Instrument [Line Items]            
Term of debt instrument (in years) 364 days   364 days      
Debt instrument, face amount $ 380,000,000   $ 380,000,000      
Repayments of term loan     $ 380,000,000      
Term loan | Unsecured debt | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate            
Debt Instrument [Line Items]            
Variable interest rate (in percentage) 1.10%          
The Credit Agreement            
Debt Instrument [Line Items]            
Covenant, adjusted consolidated total debt to consolidated EBITDA ratio       3.75    
Covenant, leverage ratio, maximum, potential increase following material acquisition       4.50    
Covenant, consolidated EBITDA to interest expense ratio       3.50    
Number of additional extensions | extension       2    
Debt instrument, extension term (in years)       1 year    
Number of potential leverage ratio increases | increase       2    
The Credit Agreement | LIBOR            
Debt Instrument [Line Items]            
Variable interest rate (in percentage)       1.38%    
The Credit Agreement | LIBOR | Minimum            
Debt Instrument [Line Items]            
Variable interest rate (in percentage)       1.13%    
The Credit Agreement | LIBOR | Maximum            
Debt Instrument [Line Items]            
Variable interest rate (in percentage)       1.75%    
The Credit Agreement | Unsecured debt | Term loan            
Debt Instrument [Line Items]            
Debt instrument, face amount       $ 1,900,000,000    
The Credit Agreement | Line of Credit | Revolving Credit Facility            
Debt Instrument [Line Items]            
Line of credit facility, maximum borrowing capacity       750,000,000    
Long-term line of credit       $ 0 $ 0  
Unsecured debt | Notes Which Mature On December Two Thousand Twenty            
Debt Instrument [Line Items]            
Repayments of term loan           450,000,000
Debt Payments Refinanced Debt            
Debt Instrument [Line Items]            
Payments of long-term debt           $ 731,000,000
v3.22.4
Debt (Schedule of Maturities of Notes Payable and Long-Term Debt) (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
2023 $ 996  
2024 197  
2025 1,353  
2026 4  
2027 5  
2028 and thereafter 2,399  
Total principal payments 4,954  
Less: unamortized debt discount and issuance costs (34) $ (43)
Total short-term and long-term debt $ 4,920  
v3.22.4
Accumulated Other Comprehensive Income (Loss) - Schedule of Changes in the Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]      
Beginning balance $ 4,344 $ 3,871 $ 3,417
Other comprehensive income (loss) (76) 32 6
Taxes 4 (17) 4
Reclassification from AOCI 11 19 14
Ending balance 4,353 4,344 3,871
Total AOCI      
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]      
Beginning balance (12) (46) (70)
Ending balance (73) (12) (46)
Foreign currency translation adjustments      
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]      
Beginning balance 22 30 (33)
Other comprehensive income (loss) (108) (3) 70
Taxes 13 (5) (7)
Reclassification from AOCI 0 0 0
Ending balance (73) 22 30
Unrecognized gain (loss) on derivative instruments      
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]      
Beginning balance (41) (70) (33)
Other comprehensive income (loss) 59 18 (61)
Taxes (16) (8) 10
Reclassification from AOCI 11 19 14
Ending balance 13 (41) (70)
Pension adjustments      
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]      
Beginning balance 7 (6) (4)
Other comprehensive income (loss) (27) 17 (3)
Taxes 7 (4) 1
Reclassification from AOCI 0 0 0
Ending balance $ (13) $ 7 $ (6)
v3.22.4
Accumulated Other Comprehensive Income (Loss) - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Compensation Related Costs [Abstract]    
Other comprehensive income (loss) on pending buy-out transaction $ 20  
Net assets $ 101 $ 189
v3.22.4
Composition of Certain Financial Statement Captions (Schedule of Certain Financial Statement Captions) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Other current assets:    
Restricted cash $ 167 $ 148
Transition costs and project assets 132 110
Other 191 171
Other current assets 490 429
Other long-term assets:    
Transition costs and project assets 74 121
Equity method investments 18 25
Other 296 293
Other assets 388 439
Accounts payable and accrued liabilities:    
Accrued liabilities 772 747
Accounts payable 733 692
Deferred revenue 380 364
Other 369 338
Total accounts payable and accrued liabilities 2,254 2,141
Accrued payroll and employee benefits:    
Accrued vacation 356 351
Salaries, bonuses and amounts withheld from employees’ compensation 345 254
Total accrued payroll and employee benefits 701 605
Amortization of transition costs and project assets 489 428
Dividends received from equity method investments $ 19 $ 16
v3.22.4
Composition of Certain Financial Statement Captions (Condensed Income Statement) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Other expense, net:      
Loss on debt extinguishment $ 0 $ 0 $ (36)
Loss on sale of businesses 0 (3) 0
Loss on foreign currencies (3) (1) (4)
Other income, net 0 3 2
Other expense, net $ (3) $ (1) $ (38)
v3.22.4
Earnings Per Share ("EPS") (Reconciliation of Weighted Average Number of Shares Outstanding) (Details) - shares
shares in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Earnings Per Share [Abstract]      
Basic weighted average number of shares outstanding (in shares) 137 141 142
Dilutive common share equivalents—stock options and other stock awards (in shares) 1 2 2
Diluted weighted average number of shares outstanding (in shares) 138 143 144
v3.22.4
Earnings Per Share ("EPS") (Narrative) (Details) - USD ($)
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Equity, Class of Treasury Stock [Line Items]      
Antidilutive securities (in shares) 1,000,000 1,000,000 0
Payments for repurchase of common stock $ 0 $ 237,000,000 $ 67,000,000
Accelerated Share Repurchase      
Equity, Class of Treasury Stock [Line Items]      
Payments for repurchase of common stock $ 500,000,000    
Number of shares repurchased and retired (in shares) 4,800,000    
v3.22.4
Stock-Based Compensation (Additional Information) (Details) - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Employee Stock Purchase Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares available for future issuance (in shares) 2.9    
Purchase price of common stock, percent 10.00% 10.00% 10.00%
Amount received for issuance of stock $ 45 $ 39 $ 32
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 4 years    
Maximum | Employee Stock Purchase Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Purchase price of common stock, percent 15.00%    
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 3 years    
2006 and 2017 Incentive Plans      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares available for future issuance (in shares) 3.5    
2006 and 2017 Incentive Plans | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 4 years    
2006 and 2017 Incentive Plans | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 3 years    
2006 and 2017 Incentive Plans | Tranche One      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Award vesting percentage 25.00%    
2006 and 2017 Incentive Plans | Tranche Two      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Award vesting percentage 25.00%    
2006 and 2017 Incentive Plans | Tranche Three      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Award vesting percentage 25.00%    
2006 and 2017 Incentive Plans | Tranche Four      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Award vesting percentage 25.00%    
v3.22.4
Stock-Based Compensation (Schedule of Stock-Based Compensation and Related Tax Benefits Recognized) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Share-Based Payment Arrangement [Abstract]      
Total stock-based compensation expense $ 73 $ 67 $ 62
Tax benefits recognized from stock-based compensation $ 16 $ 17 $ 15
v3.22.4
Stock-Based Compensation (Stock options) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation cost, net of estimated forfeitures $ 6    
Tax benefits from stock options exercised $ 9 $ 6 $ 7
2006 and 2017 Incentive Plans | Outside Directors      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 1 year    
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 4 years    
Maximum | 2006 and 2017 Incentive Plans      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 4 years    
Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 4 years 8 months 12 days 4 years 7 months 6 days 4 years 6 months
Expected weighted-average period of recognition, years 2 years 1 month 6 days    
Stock Options | 2006 and 2017 Incentive Plans      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 7 years    
Vesting period (in years) 4 years    
Stock Options | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 10 years    
v3.22.4
Stock-Based Compensation (Schedule of Weighted Average Grant-Date Fair Value and Assumptions Used) (Details) - Stock Options - $ / shares
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average grant-date fair value (usd per share) $ 24.67 $ 20.23 $ 19.64
Expected term (in years) 4 years 8 months 12 days 4 years 7 months 6 days 4 years 6 months
Expected volatility 29.50% 29.60% 25.00%
Risk-free interest rate 1.60% 0.70% 0.60%
Dividend yield 1.60% 1.30% 1.30%
v3.22.4
Stock-Based Compensation (Schedule of Stock Option Activity) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Jan. 03, 2020
Shares of stock under stock options        
Outstanding, beginning balance (in shares) 2.1 2.2 2.4  
Options granted (in shares) 0.3 0.3 0.3  
Options forfeited or expired (in shares) 0.0 0.0 (0.1)  
Options exercised (in shares) (0.6) (0.4) (0.4)  
Outstanding, ending balance (in shares) 1.8 2.1 2.2 2.4
Exercisable at year end (in shares) 1.0      
Vested and expected to vest in the future as of year end (in shares) 1.7      
Weighted average exercise price        
Outstanding, beginning balance (usd per share) $ 65.18 $ 56.01 $ 46.04  
Options granted (usd per share) 105.01 90.25 106.73  
Options forfeited or expired (usd per share) 92.10 85.42 66.84  
Options exercised (usd per share) 39.26 38.79 35.94  
Outstanding, ending balance (usd per share) 81.45 $ 65.18 $ 56.01 $ 46.04
Exercisable at year end (usd per share) 69.70      
Vested and expected to vest in the future as of year end (usd per share) $ 81.24      
Weighted average remaining contractual term        
Outstanding, beginning balance (in years) 3 years 10 months 24 days 3 years 6 months 3 years 6 months 3 years 9 months 18 days
Exercisable at year end (in years) 2 years 9 months 18 days      
Vested and expected to vest in the future as of year end (in years) 3 years 10 months 24 days      
Aggregate intrinsic value        
Outstanding, beginning balance $ 54 $ 108 $ 128  
Options exercised 41 27 29  
Outstanding, ending balance 42 $ 54 $ 108 $ 128
Exercisable at year end 34      
Vested and expected to vest in the future as of year end $ 42      
v3.22.4
Stock-Based Compensation (Schedule of RSU and Awards Activity) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 3 years    
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 4 years    
Restricted Stock Units (RSUs)      
Shares of stock under stock awards      
Unvested beginning balance (in shares) 1.4 1.3 1.4
Awards granted (in shares) 0.5 0.7 0.5
Awards forfeited (in shares) (0.1) (0.1) (0.1)
Awards vested (in shares) (0.5) (0.5) (0.5)
Unvested ending balance (in shares) 1.3 1.4 1.3
Weighted average grant- date fair value      
Unvested beginning balance (usd per share) $ 88.89 $ 79.05 $ 60.91
Awards granted (usd per share) 104.78 91.09 106.38
Awards forfeited (usd per share) 99.38 89.56 79.61
Awards vested (usd per share) 74.20 71.60 56.36
Unvested ending balance (usd per share) $ 98.52 $ 88.89 $ 79.05
Unrecognized compensation cost, net of estimated forfeitures $ 52    
Expected weighted-average period of recognition, years 2 years    
Fair value of vesting awards that vested $ 52 $ 48 $ 58
Performance Shares      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 3 years    
Shares of stock under stock awards      
Unvested beginning balance (in shares) 0.5 0.5 0.6
Awards granted (in shares) 0.2 0.2 0.2
Awards forfeited (in shares) 0.0 0.0 (0.1)
Awards vested (in shares) (0.2) (0.2) (0.2)
Unvested ending balance (in shares) 0.5 0.5 0.5
Weighted average grant- date fair value      
Unvested beginning balance (usd per share) $ 88.72 $ 80.20 $ 63.66
Awards granted (usd per share) 114.98 86.88 103.34
Awards forfeited (usd per share) 103.06 89.65 72.96
Awards vested (usd per share) 67.79 65.30 58.61
Unvested ending balance (usd per share) $ 106.70 $ 88.72 $ 80.20
Unrecognized compensation cost, net of estimated forfeitures $ 21    
Expected weighted-average period of recognition, years 1 year 8 months 12 days    
Fair value of vesting awards that vested $ 17 $ 19 $ 25
v3.22.4
Stock-Based Compensation (Schedule of Performance-Based Stock Award Activity) (Details) - Performance Shares - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Performance period (in years) 3 years    
Maximum percentage that will ultimately vest for shares provided under long term performance based incentive equity awards based on target amount stated in agreement 150.00%    
Cycle performance period 3 years    
Weighted average grant date fair value of the awards granted, excluding dividend equivalents (usd per share) $ 105.07 $ 89.26 $ 106.80
Weighted average grant date fair value, market conditions (usd per share) $ 129.42 $ 88.21 $ 127.92
Expected volatility 33.18% 32.86% 23.99%
Risk-free interest rate 1.61% 0.29% 0.50%
Weighted average grant-date fair value, Awards granted (in dollars per share) $ 107.67 $ 90.85 $ 105.12
Unrecognized compensation cost, net of estimated forfeitures $ 21    
Expected weighted-average period of recognition, years 1 year 8 months 12 days    
Fair value of vesting awards that vested $ 17 $ 19 $ 25
v3.22.4
Income Taxes (Schedule of Provision for Income Taxes) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Current:      
Federal $ 290 $ 156 $ 90
State 80 49 37
Foreign 33 29 28
Deferred:      
Federal (169) (20) 13
State (36) (3) (11)
Foreign (5) (3) (5)
Total $ 193 $ 208 $ 152
v3.22.4
Income Taxes (Schedule of Reconciliation of Provision for Income Taxes) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Income Tax Disclosure [Abstract]      
Amount computed at the statutory federal income tax rate $ 186 $ 203 $ 164
State income taxes, net of federal tax benefit 36 34 20
Research and development credits (31) (23) (26)
Excess tax benefits from stock-based compensation (13) (11) (15)
Change in valuation allowance for deferred tax assets 3 5 (5)
Impact of foreign operations 2 4 11
Dividends paid to employee stock ownership plan (2) (2) (2)
Change in accruals for uncertain tax positions (1) 1 1
Other 13 (3) 4
Total $ 193 $ 208 $ 152
Effective income tax rate 21.80% 21.50% 19.50%
v3.22.4
Income Taxes (Schedule of Deferred Tax Assets (Liabilities) (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Capitalized research and development $ 228 $ 0
Operating lease liabilities 190 187
Accrued vacation and bonuses 87 91
Reserves 40 47
Deferred compensation 32 39
Credits and net operating losses carryovers 32 26
Vesting stock awards 27 24
Deferred revenue 0 16
Accumulated other comprehensive loss 2 0
Other 13 9
Total deferred tax assets 651 439
Valuation allowance (24) (21)
Deferred tax assets, net of valuation allowance 627 418
Purchased intangible assets (415) (413)
Operating lease right-of-use assets (140) (158)
Property, plant and equipment (75) (63)
Accumulated other comprehensive income 0 (1)
Deferred revenue (4) 0
Other (5) (9)
Total deferred tax liabilities (639) (644)
Net deferred tax liabilities $ (12) $ (226)
v3.22.4
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Income Tax Contingency [Line Items]      
Valuation allowance $ 24 $ 21  
Liabilities for uncertain tax positions 92 $ 2 $ 6
Liabilities for uncertain tax positions, long-term     $ 4
Increase (decrease) in deferred income taxes 130    
Increase (decrease) in income taxes payable 130    
Unrecognized tax benefits, period increase (decrease) 91    
Unrecognized tax benefits, expected future period decrease 20    
State      
Income Tax Contingency [Line Items]      
Net operating loss carryforwards 62    
Tax credit carryforwards 2    
Operating loss carryforwards, expected to utilize 45    
Tax credit carryforwards, expected to utilize 2    
Foreign      
Income Tax Contingency [Line Items]      
Net operating loss carryforwards 35    
Operating loss carryforwards, expected to utilize 2    
Foreign tax credits 18    
Foreign tax credits, expected to be utilized $ 7    
v3.22.4
Income Taxes (Schedule of Balance Sheet) (Details) - USD ($)
$ in Millions
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Jan. 03, 2020
Accounts payable and accrued liabilities:        
Deferred tax liabilities $ 40 $ 239    
Other long-term liabilities:        
Unrecognized tax benefits 92 2 $ 6 $ 5
Other Current Assets        
Other current assets:        
Prepaid income taxes and tax refunds receivable 11 6    
Other long-term assets        
Other long-term assets:        
Deferred tax assets 28 13    
Accounts Payable and Accrued Liabilities        
Accounts payable and accrued liabilities:        
Income taxes payable 135 29    
Other long-term liabilities        
Other long-term liabilities:        
Unrecognized tax benefits $ 92 $ 2    
v3.22.4
Income Taxes (Schedule of Changes in Unrecognized Tax Benefits) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Unrecognized tax benefits at beginning of year $ 2 $ 6 $ 5
Additions for tax positions related to current year 91 0 0
Additions for tax positions related to prior years 0 2 1
Reductions for tax positions related to prior years 0 (2) 0
Settlements with taxing authorities 0 (3) 0
Lapse of statute of limitations (1) (1) 0
Unrecognized tax benefits at end of year 92 2 6
Unrecognized tax benefits that, if recognized, would affect the effective income tax rate $ 0 $ 2 $ 5
v3.22.4
Retirement Plans (Details)
$ in Millions
12 Months Ended
Dec. 30, 2022
USD ($)
plan
Dec. 31, 2021
USD ($)
Jan. 01, 2021
USD ($)
Defined Benefit Plan Disclosure [Line Items]      
Compensation expense $ 145 $ 131 $ 120
Number of deferred compensation plans (in plans) | plan 3    
Number of defined benefit pension plans (in plans) | plan 2    
Other comprehensive income (loss) on pending buy-out transaction $ 20    
Net assets 7    
Defined benefit plan, plan assets, amount 101 189  
Projected benefit obligation 101 160  
Uk Plan      
Defined Benefit Plan Disclosure [Line Items]      
Funded status of plan - overfunded (underfunded) 7 37  
Gibbs & Cox, Inc.      
Defined Benefit Plan Disclosure [Line Items]      
Funded status of plan - overfunded (underfunded) $ (7) $ (8)  
v3.22.4
Business Segments (Additional Information) (Details)
12 Months Ended
Dec. 30, 2022
segment
Segment Reporting [Abstract]  
Number of reportable segments (in segments) 3
v3.22.4
Business Segments (Schedule of Segment Reporting Information by Segment) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Segment Reporting Information [Line Items]      
Revenues $ 14,396 $ 13,737 $ 12,297
Operating income (loss) 1,088 1,152 998
Amortization of intangible assets 230 228 198
Defense Solutions      
Segment Reporting Information [Line Items]      
Revenues 8,244 8,032 7,341
Amortization of intangible assets 130 121 92
Civil      
Segment Reporting Information [Line Items]      
Revenues 3,464 3,157 2,994
Amortization of intangible assets 70 73 66
Health      
Segment Reporting Information [Line Items]      
Revenues 2,688 2,548 1,962
Amortization of intangible assets 30 34 40
Operating Segments | Defense Solutions      
Segment Reporting Information [Line Items]      
Operating income (loss) 541 569 506
Operating Segments | Civil      
Segment Reporting Information [Line Items]      
Operating income (loss) 234 248 280
Operating Segments | Health      
Segment Reporting Information [Line Items]      
Operating income (loss) 421 442 235
Corporate      
Segment Reporting Information [Line Items]      
Operating income (loss) $ (108) $ (107) $ (23)
v3.22.4
Business Segments (Schedule of Total Revenue Percentages Contributable to Specific Government Agencies) (Details) - Total Revenues
12 Months Ended
Dec. 30, 2022
Dec. 31, 2021
Jan. 01, 2021
Government Contracts Concentration Risk | US Government      
Segment Reporting Information [Line Items]      
Percentage of sales 86.00% 87.00% 87.00%
Government Contracts Concentration Risk | DoD and U.S. Intelligence Community      
Segment Reporting Information [Line Items]      
Percentage of sales 44.00% 44.00% 49.00%
Geographic Concentration Risk | International      
Segment Reporting Information [Line Items]      
Percentage of sales 8.00%    
v3.22.4
Commitments and Contingencies (Narrative) (Details)
1 Months Ended 12 Months Ended
Oct. 30, 2020
USD ($)
Aug. 30, 2018
USD ($)
Apr. 10, 2018
USD ($)
Jan. 31, 2021
USD ($)
Dec. 30, 2022
USD ($)
patent
Loss Contingencies [Line Items]          
Lessee, operating lease, liability, payments, due         $ 800,000,000
Aircraft          
Loss Contingencies [Line Items]          
Lessee, operating lease, liability, payments, due         74,000,000
Standby Letters of Credit          
Loss Contingencies [Line Items]          
Amount outstanding         72,000,000
Performance Guarantee          
Loss Contingencies [Line Items]          
Surety bonds notional amount         $ 100,000,000
Leidos          
Loss Contingencies [Line Items]          
Litigation settlement, percentage of total (percentage)         25.00%
Virnet X Inc          
Loss Contingencies [Line Items]          
Awarded from other party $ 503,000,000 $ 595,000,000 $ 502,000,000    
Royalty rate awarded (per device) $ 0.84       $ 1.20
Awarded to the other party, interest and legal fees   $ 93,000,000      
Number of infringed patents (in patents) | patent         2
Number of infringed other patents (in patents) | patent         2
Additional costs and interest       $ 75,000,000  
v3.22.4
Commitments and Contingencies - Future Expirations Maturity Table (Details) - Standby Letters of Credit, Surety Bonds and Future Lease Commitments
$ in Millions
Dec. 30, 2022
USD ($)
Guaranteed Obligation, Type [Line Items]  
2023 $ 60
2024 104
2025 37
2026 19
2027 22
2028 and thereafter 4
Guaranteed obligation $ 246